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e.g.   exempli gratia 
ECM   extracellular matrix 
EDTA   ethylenediaminetetraacetic acid 
EGF   epidermal growth factor 
EGFP   enhanced green fluorescent protein 
EGFR   epidermal growth factor receptor 
Eph   erythropoietin-producing hepatocellular carcinoma cell  
ephrin  Eph receptor interacting protein 
ER   endoplasmatic reticulum  
Fc   human Fc-antibody fragment 
FGFR   Fibroblast growth factor receptor 
Fig.   figure 
FL   fluorescence 
FNIII   type-III fibronectin protein 
FP   fluorescent protein 
FRET   Förster resonance energy transfer 
GFP   green fluorescent protein 
GPI   glycosylphosphatidylinositol 
GRIP   glutamate receptor interacting protein 
HEK   human embryonic kidney 
HEPES  N-2-hydroxyethylpiperanzine-N’-2-ethanesulfonic acid 
hr(s)   hour(s) 
i.e.   id est 
IC50   half maximal inhibitory concentration 
ICD   Intracellular domain 
IP   immunoprecipitation 
JM   juxtamembrane 
JMS   juxtamembrane segment 
kd   kinase-dead/deficient 
KD   Kinase domain 
l   liter 
LB0   lysogeny broth  
LBD   ligand binding domain 
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MCF-7  Michigan cancer foundation-7 
MDCK  Madin-darby canine kidney cells 
min   minute(s) 
ml   milliliter 
NGF   Nerve growth factor 
n.s.   not significantly different 
N/A   numerical aperture 
ns   nanosecond(s) 
N-terminus  amino terminus 
PAGE   poly-acrylamide gel electrophoresis 
PBM   PDZ-binding motif 
PDZ   PSD95/Dlg/ZO1 
pH   potentium hydrogenii 
PM   plasma membrane 
PTB   phospho-tyrosine binding 
PTP   phosophotyrosine phosphatases 
PTP1B  protein tyrosine phosphatases 1B 
pTyr   phosphotyrosine 
RBD   receptor binding domain 
RE   recycling endosome 
RT   room temperature 
RTK(s)  receptor tyrosine kinase(s) 
s   second(s) 
SAM   sterile-α-motif 
SEM   standard error of mean 
SH2   src homology 2 
SPIM   single plane illumination microscopy 
TM   transmembrane 
Tris   Tris[hydroxymethyl]aminomethane 
TyrK   Tyrosine kinases 
VEGF   vascular endothelial growth factor 
WT   wild type 
 
Units were abbreviated using the International System of Units (SI). The triple and 
single letter codes were used for abbreviations of amino acids. Chemicals are 
abbreviated according to guidelines by the International Union of Pure and 
Applied Chemistry. 
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ABSTRACT
 
 Eph receptors (Ephs) and their membrane bound ephrin ligands constitute 
one of the major guidance cues that control developmental and pathological cell 
positioning. As in other receptor tyrosine kinases (RTKs), ligand binding induces 
oligomerization of Ephs at the plasma membrane (PM), activation of their intrinsic 
autocatalytic activity and phosphorylation of key tyrosine residues in their 
intracellular domain. In this thesis, we asked how the autocatalytic activity of Eph 
is dynamically controlled inside cells to prevent spurious self-activation yet allow 
for robust activation upon exposure to ligand.  
 The current view in Eph signaling is that ligand-driven oligomerization of 
Ephs converts inactive monomers to active oligomers. However, in this thesis we 
show that the mechanism of receptor clustering is not that simple. Using an FKBP-
based dimerizing system, we investigated the effect of cluster size composition on 
EphB2 cellular output. We found that small-sized EphB2 clusters produce a 
functional response, whose strength is determined by the abundance of multimers 
over dimers within a cluster population. In addition, we identified a positive 
regulatory effect on EphB2 clustering by GRIP1 protein and a negative regulatory 
effect on ephrin-induced clustering by C-terminal domains of EphB2. Together 
these results showed how the cell’s pre-established molecular context could 
determine the response of Ephs to ephrins, which is then translated into clusters 
with different size, composition and/or stability. 
 The autocatalytic activity of Eph receptors is regulated by reversible 
autophosphorylation and dephosphorylation cycles that are spatially and 
temporally partitioned within cells due to the interactions with protein tyrosine 
phosphatases (PTPs). Using quantitative cellular imaging approaches, we found 
that the endoplasmic reticulum (ER)-anchored PTP1B comes in close proximity to 
regions of cell-cell contact rich in Eph receptors and identified EphA2 as a new 
substrate for PTP1B specifically at those regions. These results highlighted ER-PM 
interactions as an emerging new paradigm in cellular signaling. 
 To investigate how Eph conformational dynamics as well as its spatial 
organization within cells can affect its inherent autocatalytic activity, we designed a 
genetically encoded biosensor that monitors EphA2 conformation, termed Linker 
optimized Intramolecular-FRET based sensor for EphA2 (LIFEA2). By 
measurements of LIFEA2 conformational dynamics, we could describe EphA2 
	   IX	  
activation with precise spatial temporal resolution. In addition, by correlating the 
cell-to-cell variance in LIFEA2 expression level to its activity state, we 
demonstrated the propensity of this autocatalytic system to self-activate in the 
absence of ligand. Finally, we described two levels of regulation for EphA2 
activation, a cis-inhibitory dynamic interaction between the kinase domain and the 
juxtamembrane segment, and a novel PM-recycling mediated mechanism. The 
continuous recycling of EphA2 to the PM acts as a safeguard mechanism by 
maintaining a low steady-state level of receptor at the PM and by trafficking the 
receptor through peri-nuclear areas with high PTP1B activity that 
dephosphorylates spuriously autoactivated receptors.  
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ZUSAMMENFASSUNG 	  
 Eph-Rezeptoren (Ephs) und ihre membrangebundenen Ephrin-Liganden 
bilden eine der wichtigsten Orientierungsmarken, für die Kontrolle der 
Zellpositionierung im Rahmen ontogenetischer und pathologischer Prozesse. Wie 
bei anderen Rezeptortyrosinkinasen (RTKs) induziert die Ligandenbindung die 
Oligomerisierung der Ephs an der Plasmamembran (PM), die Aktivierung der 
autokatalytischen Aktivität und die Phosphorylierung wichtiger Tyrosinreste in 
der intrazellulären Domäne. In dieser Arbeit wird der Frage nachgegangen, wie 
die autokatalytische Aktivität von Eph innerhalb der Zelle dynamisch derart 
kontrolliert wird, dass einerseits spontane Autoaktivierung verhindert und 
andererseits eine robuste Aktivierung des Rezeptors nach Ligandenbindung erzielt 
wird.  
Nach dem derzeit geläufigen Modell für Eph konvertiert die Liganden 
induzierte Oligomerisierung des Ephs inaktive Monomere in aktive Oligomere. In 
dieser Arbeit wird jedoch gezeigt, dass der Mechanismus des Clustering der 
Rezeptoren komplexer ist. Mithilfe eines FKBP-basierten Dimersierungssystems 
wurde der Effekt der Clustergröße auf die EphB2 vermittelte Zellantwort 
untersucht. Dabei zeigte sich, dass kleine EphB2 Cluster eine funktionelle 
Zellantwort induzieren, deren Stärke vom Verhältnis der Multimere zu Dimeren 
innerhalb der Clusterpopulation bestimmt wird. Desweiteren wurde ein positiver 
regulatorischer Effekt des GRIP1 Proteins auf EphB2 und ein inhibierender Effekt 
C-terminaler Domänen des EphB2 auf die Ephrin-induzierte Oligomerisierung 
identifiziert. Zusammen zeigen diese Ergebnisse, wie der vorhandene molekulare 
Kontext der Zelle die Antwort von Ephs auf Ephrine bestimmen  und wie sich dies 
in in Bezug auf die Clustergröße, -Zusammensetzung und/oder -Stabilität von Eph 
auswirken kann.  
Die autokatalytische Aktivität des Eph wird in Zellen durch Zyklen 
reversibler Autophosphorylierung und Dephosphorylierung reguliert, die durch 
Interaktion mit Proteintyrosinphosphatasen (PTPs) räumlich und zeitlich separiert 
sind. Mit quantitativen, mikroskopischen Verfahren konnten wir zeigen, dass am 
Endoplasmatischen Retikulum (ER) verankertes PTP1B in unmittelbare Nähe zu 
Zell-Zell-Kontakten kommt, die reich an Ephs sind, und konnten EphA2 als neues 
Substrat für PTP1B in genau diesen Regionen identifizieren. Diese Ergebnisse 
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untermauern das derzeit aufkeimende Modell der Bedeutung von ER-PM 
Interaktionen für die zelluläre Signalregulation. 
Um zu untersuchen, wie die Dynamik der Konformationsänderungen von Eph 
sowie seine räumliche Organisation in Zellen die autokatalytische Aktivität 
beeinflussen, entwickelten wir einen genetisch-kodierten Biosensor namens 
„Linker optimized Intramolecular-FRET based sensor for EphA2” (LIFEA2), der 
die Konformation von EphA2 anzeigt. Durch Messung der 
Konformationsdynamik von LIFEA2 konnten wir die EphA2 Aktivierung mit 
hoher räumlicher und zeitlicher Auflösung beschreiben. Weiterhin konnten wir 
durch Korrelation der Zell-zu-Zell-Varianz in LIFEA2-Expressionsleveln zum 
LIFEA2-Aktivitätszustand auch die Neigung des autokatalytischen Systems zur 
Selbstaktivierung in Abwesenheit des Liganden aufzeigen. Abschließend 
beschreiben wir zwei Regulationsebenen für die EphA2 Aktivierung – eine cis-
inhibitorische, dynamische Interaktion zwischen der Kinasedomäne und dem 
Juxtamembran-Segment sowie einen neuen Recycling-Mechanismus zur PM. Das 
kontinuierliche Recycling des EphA2 zur PM dient als Schutzmaßnahme, indem es 
niedrige Gleichgewichtslevel des Rezeptors an der PM aufrechterhält und durch 
das Schleusen des Rezeptors durch den peri-nukleären Bereich mit hoher PTP1B-
Aktivität spontan autoaktivierte Rezeptoren dephosphoryliert.  
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1. INTRODUCTION 
 
Despite the successes achieved by reductionist research of the twentieth-
century in identifying and describing the molecular components of cellular 
signaling pathways, little is known about how these multicomponent pathways 
process extracellular signals to generate a defined cellular response. To understand 
signal processing, it is no longer sufficient to depend on linear reaction schemes 
that consider an active state of a given protein. Rather, one needs to consider how 
external and internal stimuli are dynamically processed by a given 
multicomponent signaling system1. Dynamically here refers to the spatial 
organization of signaling, which does not only include the topology of a given 
simple network but also the initial concentration of each protein state over space 
and time. Dynamic biological systems are kept in-check by operating under 
constant opposing tendencies, favoring one or the other depending on the context. 
Amplification and attenuation or robustness and adaptability of signaling systems 
are examples of opposing tendencies underlying every level of organization 2. Even 
on a molecular level, such duality can be seen between individual proteins, 
allowing local sources to affect global patterns. The emerging patterns will in 
return affect the interactions of individual proteins at local sources, in a negative or 
positive manner.   
The function of a subfamily of receptor tyrosine kinases (RTKs) called Eph 
(from erythropoietin-producing hepatocellular carcinoma cell) family is an 
excellent example of such duality in signaling. Like other RTK family members, the 
signaling capacity of Eph is mediated by autophosphorylation of intracellular 
tyrosine residues that can serve as docking sites for downstream effectors. 
Interactions of Ephs with their cognate membrane-bound ephrin ligands can either 
prolong cell-cell adhesion and communication or promote cell-cell repulsion. Upon 
ligand binding, activated Ephs form expansive clusters that need to be terminated 
for cell-cell repulsion to take place. Promotion versus termination of signaling is 
therefore the balance that Eph RTKs must maintain at every level of organization. 
Local factors influencing this balance include, gradients of interacting 
Eph/ephrins, duration of their contact, clustering capacity of Ephs and the cell’s 
own clustering history, spatial organization of the phosphorylation-
dephosphorylation cycle and recycling versus termination of signaling.   
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In this thesis, my main aim is to study the spatial organization of Eph signaling 
while focusing on local factors contributing to such organization. Factors such as 
regulation by the ER-anchored PTP1B, Eph trafficking, Eph clustering and Eph 
conformational dynamics are analyzed and their link to Eph regulation in space 
and time is assessed.  These questions required a method, capable of measuring 
Eph clustering and/or Eph activation in living cells. For the former, fluorescence 
anisotropy coupled to a dimerizer controlled clustering system of Ephs was used 
to measure cluster sizes of fluorescently labeled EphB2. For the latter, high-
resolution fluorescence microscopy and a genetically encoded sensor monitoring 
EphA2 active conformation was designed and used.  
This thesis is divided into (4) major parts. Chapter 1 summarizes the current 
structural, biochemical and cell biological knowledge of the Eph/ephrin system as 
well as describing the basis of FLIM and Anisotropy. Chapter 2 gives a detailed 
description of the experimental procedures and reagents used in this thesis. 
Chapter 3 presents experimental results that study the spatial organization the ER-
anchored phosphatase (PTP1B) towards points of cell-cell contact, with the aim of 
addressing the regulation of signaling at these points by PTP1B.  Furthermore, the 
role of clustering in Eph signaling is presented, to test the hypothesis that 
clustering can allow Ephs to modulate the signaling capacity in a graded fashion 
when exposed to ephrin gradients during cellular patterning. Moreover, local 
factors affecting Eph active conformation will be presented while following the 
activity of Eph with a linker optimized intra-molecular FRET based sensor for 
EphA2 (LIFEA2). A discussion of the experimental results is given in chapter 4.  	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1.1 Cell signaling by receptor tyrosine kinases 
In order to understand Eph signaling in space and time, one has to start with 
the parental cellular communication system, i.e. phosphotyrosine signaling by 
receptor tyrosine kinases (RTKs). Phosphotyrosine (pTyr)-based signaling is 
mediated by three distinct functional components: tyrosine kinases (TyrK) that 
phosphorylate specific tyrosine residues on proteins, Src Homlogy 2 (SH2) and 
phospho-tyrosine binding (PTB) domains that identify the tyrosine modification 
and phosophotyrosine phosphatases (PTP) that remove the phosphates.  Together, 
these components play a pivotal role in many cell-to-cell communication 
pathways, including differentiation, proliferation, adhesion, immune defense and 
hormone responses (Figure 1.1) 3,4. Since the cloning of the first cell surface RTK, 
the Epidermal Growth Factor Receptor (EGFR) more than two decades ago, RTKs 
have dwelled in the spotlight as key players of critical cellular responses.  
Unraveling the RTK signaling networks that connect extracellular signals with key 
cellular processes, such as differentiation and proliferation, cell migration and cell 
cycle control, cell survival and metabolism has now evolved into the well-
established field of signal transduction 5,6. TyrK can be divided into either 
nonreceptor or receptor tyrosine kinases (RTKs). There are 58 known RTKs in 
humans, with similar molecular topology, yet divided into twenty subfamilies (Fig 
1.2).  
  
 
 
Fig 1.1 The three-part toolkit of 
phosphotyrosine signaling  
In phosphor-Tyrosine (pTyr) signaling, 
the tyrosine kinase (TyrK), Src 
Homology 2(SH2), phosphor tyrosine-
binding domain (PTB) and 
phosphotyrosine phosphatase (PTP) 
domains form a highly interdependent 
signaling platform. Adapted from 4. 
 
 
All RTKs have their ligand-binding domain (LBD) on the extracellular side of 
the membrane, a single-pass transmembrane (TM) helix, followed by an 
intracellular domain (ICD) that contains the protein tyrosine kinase (TK) catalytic 
region, plus additional regulatory domains in the juxtamembrane (JM) and 
carboxy (C-) terminus region of the molecule 7.  
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Fig 1.2 Receptor tyrosine kinase families 
In human, there are 58 receptor tyrosine kinases (RTKs) that fall in 20 subfamilies, shown 
here schematically with the family members listed below each receptor. Structural 
domains in the extracellular regions identified by structure determination or sequence 
analysis, are marked according to the key.  The intracellular domains are shown as red 
rectangles.  Adapted from 7. 
 
1.1.1 Receptor activation through Ligand-induced dimerization of RTKs 
Growth factor binding generally leads to RTK activation by inducing receptor 
dimerization. There is however, a subset of RTKs that exist in an oligomeric form 
even before ligand activation.  Ligand-induced activation of RTK whether the 
“inactive” state is a monomer or an oligomer, will still require the bound ligand to 
stabilize the “active” form of RTK, be it dimeric or oligomeric 5. Early work on 
“ligand mediated” RTK dimerization suggested that a divalent ligand interacts 
with and thereby cross-links two receptor molecules, forming a 2:2, ligand: 
receptor complex.  This model was supported by various crystal structures 
including, vascular endothelial growth factor (VEGF) receptor 8,9, nerve growth 
factor (NGF)/neurotrophin receptor TrkA 10, stem cell factor receptor KIT1 11 and 
Eph receptors 12.   Recent structural studies of full extracellular regions of RTKs, 
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has replaced the generic “ligand-mediated” mode of receptor dimerization, with a 
range of mechanisms (Fig 1.3).  At one end, the ligand holds the sole responsibility 
for inducing receptor dimerization, and the two receptors do not directly contact, 
as for the NGF/TrkA, ligand/receptor interaction 10,13 (Fig 1.3A). At the other end, 
receptors mediate dimerization and ligands do not contribute to the dimer 
interface, as for the EGFR/ErbB family 14,15 (Fig 1.3D). Dimerization can also 
involve both receptor and ligand-mediated components (Fig 1.3B and 1.3C). 
  
 
Fig 1.3 Receptor tyrosine kinase 
dimerization 
RTKs associate into dimers when ligand 
(red) binds to their extracellular domains.  
The bound ligand activates the receptors 
by stabilizing a certain relationship 
between two separate receptor molecules. 
(A) Nerve growth factor dimers (red) cross-
links two TrkA molecules without any 
direct contact between the two receptors 13. 
(B) Stem cell factor dimer (red) cross-links 
two KIT molecules, accompanied by 
interaction of the two Ig-like domains (D4 
and D5) across the dimer interface 16. (C) 
Two fibroblast growth factor receptors 
(FGFRs) as well the necessary molecule 
heparin (white) contact one another 
through the Ig-like domain D2. In addition 
the fibroblast growth factor (FGF) ligand 
(red) contacts Ig-like domain D2 and D3 of 
both FGFRs 17. (D) Dimerization of ErbB 
receptors is mediated entirely by the 
receptor.  When the ligand binds to the two 
sites (DI and DIII) it drives the exposure of 
the dimerization interface in Domain II.  
 
1.1.2 Activation of tyrosine kinase domain 
The central question in RTK signaling is how the ligand-induced 
dimerization of the extracellular domain gets translated into kinase domain (KD) 
activation on the intracellular side of the membrane.  All tyrosine KDs consist of an 
N-lobe and a C-lobe (Fig 1.4), and exhibit a similar structure when crystallized in 
an active form 18. Crucial regulatory elements such as the αC helix in the kinase N-
lobe and the activation loop (AL) adopt a specific structure in the active KD form 
that is essential for phosphotransfer 19. Structures of the inactive tyrosine KDs are 
on the other hand quite versatile between the different receptor, depending on the 
set of intramolecular inhibitory interactions that are receptor specific.    
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Fig 1.4 Receptor tyrosine kinase (RTK) 
activation upon extracellular dimerization 
Intracellular tyrosine kinase domains 
(TKDs), contain a C-lobe (light purple), N-
lobe (dark purple or yellow). Many 
receptors are inhibited by a set of 
intramolecular (or cis) interactions: (A) 
Activation loop inhibition. In FGFR, insulin 
receptor and IGF1 receptor, the activation 
loop interacts directly with the kinase active 
site thereby blocking access to protein 
substrates or both ATP and protein 
substrates.  Phosphorylation of key 
tyrosines releases this inhibition allowing 
the kinase a “relaxed” active state. 
Juxtamembrane (JM) inhibition. In KIT, 
PDGFR and Eph receptors, the JM region 
(red) interacts with and disrupts the kinase 
domain.  Phophorylation of key tyrosines in 
the JM region destabilizes these 
autoinhibitory cis interactions and allows 
the kinase domain to attain an active 
conformation. C-terminal tail inhibition. In 
Tie1 and Tie2, the C-terminus tail interacts 
with the kinase active site to stabilize an 
inactive conformation20. (B) EGFR kinase 
domain is activated allosterically by direct 
contacts between C-lobe of one kinase, the 
“Activator” and the N-lobe of another 
kinase, “Receiver” 21.  
 
1.1.2.1 Inhibition of the kinase domain by the activation loop 
Activation loop autoinhibition was first demonstrated by the structure of the 
insulin receptor KD.  An essential tyrosine residue in the activation loop (Y1162) 
blocks access of ATP and protein substrates to the active site (“activation loop 
inhibition” in Fig 1.4A). Upon insulin binding, trans-phosphorylation of Y1162 
disrupts its cis-autoinhibitory effect, allowing the kinase domain to adopt the 
generic RTK active state (Fig1.4A) 22. The KD of Fibroblast Growth Factor 
Receptor1 (FGFR1) is also cis-autoinhibited by the activation loop, but through a 
different set of activation loop interactions that stabilize an inactive conformation.  
Ligand-induced dimerization, again releases this cis-autoinhibition through trans-
phosporylation of activation loop tyrosines 23. 
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1.1.2.2 Inhibition of the kinase domain by the juxtamembrane 
In addition to cis-autoinhibition by the KD itself, many RTKs are inhibited by 
elements outside of the KD, best example of which is the juxtamembrane segment 
(JMS), as seen in KIT 24 and Eph family RTKs 25. Through extensive contacts with 
the KD, that involve key tyrosines in the JM region, the inactive autoinhibied KD 
conformation is stabilized (“JM inhibition” in Fig. 1.4A).  Ligand-induced 
dimerization promotes trans-phosphorylation of those JM-tyrosines, thereby 
disrupting cis-autoinhibitory interactions of JM and promoting KD activation 22.   
1.1.2.3 Inhibition of the kinase domain by C-terminal sequences 
Despite the fact that the activation loop of Tie2 kinase domain exists in an 
active-like conformation prior to phosphorylation, its nucleotide-binding loop 
adopts an inactive configuration 20.  The tyrosine-containing C-terminal tail of Tie2 
is involved in cis-autoinhibition of KD by blocking substrate access to the kinase 
active site (“C-terminus inhibition in Fig. 1.4A).  Autophosphorylation of the C-
terminal located tyrosines, may lead to the disruption of this autoinhibitory 
interaction and thereby activate Tie2 26.  
1.1.2.4 Allosteric activation of kinase domain 
Most RTKs follow the general dogma of trans-phosphorylation alleviating 
KD cis-autoinbibition and thereby leading to kinase activation.  The EGFR/ErbB 
family of proteins and Ret stand as exception to this rule, since they do not require 
trans-phosphorylation for activation 21,27. The kinase domain of EGFR forms an 
asymmetric dimer (Fig 1.4B) where the C-lobe of one KD “Activator” is in contact 
with the N-lobe of the second KD “Receiver”.  This interaction allows the receiver-
kinase to adopt an active conformation without phosphorylation of activation loop. 
1.1.2.5 Conformational coupling across the plasma membrane  
Recent work done on the EGF receptor, uncovered the involvement of the 
transmembrane (TM) helices in intracellular kinase domain (KD) activation. 
Activation requires an N-terminal interaction between the TM helices that 
facilitates antiplarallel interaction between JM domains and release of inhibition by 
the membrane. Ligand binding would release steric constrains in the extracellular 
domain and translate that across the TM to an activation of intracellular KD 28,29. 	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1.2 Eph receptors and ephrin ligands 
Eph receptors constitute the largest subfamily of RTKs. Together with their 
membrane-associated ephrin ligands, they function as principal guidance cues 
during developmental tissuegenesis, normal tissue homeostasis and tumorigenesis 
30,31. The ability of Ephs to alter cell positioning is achieved principally by 
modulating the adhesion or repulsion between receptor and ligand expressing 
cells upon their contact 32. Interaction of Ephs and ephrins in trans leads to typical 
RTK forward signaling in receptor expressing cells and unique reverse signaling in 
ligand expressing cells, which is a distinguishing feature of the Eph/ephrin system 
known as bidirectional signaling 30. Bidirectionality arises because Ephs are unique 
among other RTKs in their dependency on membrane-anchored ephrin ligand for 
activation 33. Contrary to other RTKs, which are activated by dimerization, Ephs 
form higher-ordered oligomers with ephrins for proper biological response 34. 
1.2.1 Nomenclature of Ephs and ephrins 
The acronym EPH comes from the cell line from which the first family 
member (EphA1) was isolated, namely an Erythropoietin-Producing 
Hepatocellular carcinoma cell line 35. Based on sequence conservation and their 
affinities towards ephrins, Ephs are divided into two subclasses, A and B. EphA 
subtype, consists of nine members in mammals (EphA1-EphA8 and EphA10) that 
bind promiscuously to six glycosylphosphatidylinositol (GPI)-anchored ephrinsAs 
(ephrin-A1-A6). EphB subtype, consists of five members (EphB1-EphB4 and 
EphB6) that interact with three transmembrane ephrinBs (ephrin-B1-B3) 36. Inter-
subclaass interactions between Eph and ephrin has been reported, for example 
EphA4 binds both ephrin A- and B-type 37,38, and ephrinA5 can bind and thereby 
activateEphB2 39.   
1.2.2 Eph/ephrin domains 
The general domain topology of Ephs is conserved throughout the animal 
kingdom (Fig. 1.5) 40. Eph extracellular region starts with an N-terminal globular 
ligand-binding domain (LBD), a cysteine-rich domain composed of a sushi domain 
and an EGF-like domain and two fibronectin type-III repeats (FNIIIa and b). In 
addition to ligand binding, the Eph globular domain, together with the cysteine-
rich domain, contribute to ephrin-independent receptor dimerization and 
clustering 41-43. Smilar to other RTKs, Eph receptors contain a single-pass 
transmembrane (TM) α-helical domain. Eph intracellular region consists of a 
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juxtamembrane (JM) segment containing two conserved regulatory tyrosine 
residues, the catalytic tyrosine kinase domain, a sterile-α-motif (SAM) protein 
interaction domain and a PDZ-binding motif (PBM) 31,44.  
 
 
 
Fig 1.5 Domain structure of Eph receptors and ephrin ligands 
Eph receptors contain an extracellular region with a globular ligand-binding domain 
(LBD), followed by cysteine-rich (Cys-rich) and fibronection type III repeats (FNIIIa and 
FNIIIb). Similar to other type 1 RTKs, the receptor contains a single-pass trans-membrane 
(TM) domain. The intracellular region contains a juxtamembrane (JM) domain, the kinase 
catalytic domain, sterile-alpha-motif (SAM) and PSD95/Dlg/Zo1 (PDZ)-binding motif 
(PBM). Ligand binding promotes clustering and phosphorylation at key tyrosines 
indicated by (Y). The transmembrane ephrin-Bs also become phosphorylated on tyrosine 
residues by Src family kinases, which are probably also promoting signaling by the GPI-
anchored ephrin-As.   RBD, receptor-binding domain; LBD, ligand-binding domain; GPI, 
glycosylphosphatidylinositol-anchor. 
 
EphrinAs are membrane anchored via a glycosylphosphatidylinositol (GPI), 
while ephrinBs contain a single-pass TM domain and a short cytoplasmic tail with 
five conserved tyrosines followed by a PDZ-binding motif (PBM) (Fig 1.5). Both 
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ephrin subclasses posses an extracellular globular receptor-binding domain (RBD), 
and both lack intrinsic catalytic activity 31,45.   
1.2.3 Signaling clusters of Ephs/ephrins  
Contrary to ligands of other RTK subfamilies, only artificially clustered 
ephrins or naturally occurring membrane-bound ligand can trigger receptor 
signaling 33. It has even been shown that the soluble non-clustered form of the 
ligand acts as an antagonist 46-48. Prior to ligand contact, Ephs are scarcely 
distributed within the plasma membrane, and showing an expression level-
dependent basal kinase activity 49-51. The initiator step in Eph-ephrin signaling is a 
1:1 high-affinity heterodimer between the Eph globular LBD and the conserved 
RBD of ephrins 52.  It has been shown for EphB2/ephrinB2, that additional 
interactions tether the formed heterodimers so that each ephrin now binds two 
Ephs and vice versa, to form a ring-like tetramer with distinct dimerization and 
tetramerization interfaces 41 (Fig. 1.6 a). Using a mutagenesis screen to study the 
molecular determinants of EphA3/ephrin-A5 binding, three extracellular receptor 
surface areas were defined as essential for the receptor/ligand interaction 53.  Two 
of those areas map to the previously identified dimerization and tetramerization 
interfaces in the EphB2/ephrinB2 complex, while the third interface lies outside 
the structurally characterized interaction domains (Fig. 1.6 b).  A cluster of 10 
residues on eprhinA5 was later on identified to be responsible for the formation of 
the third surface required for oligomerization and activation of EphA3 signaling 54. 
Moving from this so-called Eph/ephrin nucleus to higher-order oligomers could 
be explained if one takes into account the aforementioned third interaction 
interface, as well as Eph-Eph homotypic ectodomain interactions 42,43,55 (Fig. 1.6 c), 
all of which can help propagate Eph signaling laterally independent of ephrin 
contact 56. It is, however, important to mention that structures of other Eph/ephrin 
complexes 39,57,58 have not shown the previously described heterotetramer, and 
therefore nucleation via tetramerization, cannot be taken as a general mechanism 
of Eph/ephrin clustering. A recent study on the formation of expansive 
Eph/ephrin signaling clusters coined the term “extracellular steric seeding 
mechanism” 42. The study confirmed the aforementioned “lateral propagation” 
concept 56, and suggested a “nucleation mechanism” whereby few EphA2-
ephrinA5 interactions would “seed” an arrangement of receptors that can 
propagate into expansive signaling arrays.  Further studies on EphBs/ephrinBs are 
needed to confirm or refute the existence of such a steric-seeding mechanism. In 
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addition to Eph extracellular domain, Eph TM segment 59, and Eph SAM domain 60-
63 have also been implicated in receptor clustering, however, their functional role is 
yet to be confirmed. 
 
 Fig 1.6 Eph/ephrin clustering 
(a) Crystal arrangement of EphB2 (blue) and ephrinB2 (red) molecules shows four ligand 
and four receptor molecules 41. Two possible tetramers are indicated with green and 
purple lines; ligand-lignad crystal packing (red arrow) and receptor-receptor crystal 
packing (blue arrow) are shown.  First tetramer (green box): ligand molecules in red and 
orange, and the receptors in blue and green. Tetramer is generated by two receptor-ligand 
dimers joined together. Black arrows show receptor-ligand dimerization interfaces. Second 
tetramer (purple box): two EphB2 molecules joined through receptor-receptor interfaces, 
and each EphB2 is bound to a single ligand molecule. (b) Model of ephrin-induced Eph 
clustering.  Monomeric ephrinA5 (red) and EphA3 (blue) combine into high affinity 
Eph/ephrin dimers 52; those then assemble via a lower affinity interface into Eph/ephrin 
heterotetramers 41. A cluster of 10 residues on the eprhinA5 were later on identified to be 
responsible for the formation of the third surface required for oligomerization and 
activation of EphA3 signaling 53,54. (c) Moving from this Eph/ephrin nucleus to higher-
order oligomers could be explained if one takes into account the aforementioned third 
interaction interface, as well as Eph-Eph homotypic ectodomain interactions 42,43.  
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1.2.4 Eph/Eph clustering 
The contribution of various domains to Eph clustering, and in particular the 
involvement of intracellular, ligand-independent domains, raises the possibility of 
intra- and inter-subclass cross talk. The concept of RTK hetero-oligomerization, 
although common for receptors of other RTK subfamilies 64, was yet to be 
confirmed and investigated for the Eph subfamily. Given the promiscuity of Eph-
ephrin interactions intra-subclass, co-expression of same subclass Ephs will likely 
lead to their interaction with the same ephrin. In fact, EphB1 and EphB4 were 
shown to form functional hetero-oligomeric complexes when co-expressed with 
kinase dead EphB6, resulting in its transphosphorylation 65,66. Evidence for cross-
class trans-phosphorylation has been accumulated from many studies, for 
example, the capability of EphA4 to phosphorylate the JM tyrosines of EphB2 and 
EphA2 in vitro 67, the capability of ephrinB1 to simulate phosphorylation of 
EphA2/A3/A7 in addition to EphB4/B2 and EphB3 68, and the capability of 
ephrinB1-expressing cells to modulate phosphorylation of various EphAs in 
EphB2-expressing HEK293 cells 69. In addition to cross-class transphorphorylation, 
cross clustering has also been observed. Activation of EphA3 with a selective 
monoclonal antibody, managed to co-cluster and activate the co-expressed EphB2 
in HEK293T cells 70, as well as endogenous EphA and EphB receptors in tumour 
cells 71.  Taken together, this would mean that upon cell-cell contact, the resulting 
cell behavior will not be limited to those Ephs able to directly bind the activating 
ephrin, but will depend on the overall abundance of Ephs inside the cell.   
1.2.5 Eph activation 
Similar to other RTKs, activation of Ephs follows a general framework, 
beginning with ligand binding, receptor reorientation or oligomerization, and 
consequent trans-phosphorylation by the tyrosine kinase domain. Tyrosine 
phosphorylation affects the signaling properties of RTKs in at least two ways. First, 
autophosphorylation of a key tyrosine residue within the kinase activation loop 
(AL), known as TyrACT changes the local structure of the receptor and stabilizes the 
active conformation of the kinase domain (Fig. 1.7). In the inactive state, TyrACT 
blocks ATP binding by protruding into the active site.  Auto-phosphorylation of 
TyrACT and adjacent residues reposition the AL into a catalytically competent 
conformation, thereby freeing the active site to interact with substrates 72,73. Second, 
phosphorylation of neighboring noncatalytic sites creates docking sites for the Src 
Homology 2 (SH2) and/or phosphotyrosine binding (PTB) domain necessary for 
	   13	  
downstream effectors 74-77. All tyrosine KDs consist of an N-lobe, that assists in the 
binding and coordination of ATP, and a C-lobe, that orients the substrate for 
productive transfer of γ-phosphate (Fig 1.7), and a similar structure when 
crystallized in an active form 18. Crucial regulatory elements such as the αC helix in 
the kinase N-lobe and the AL adopt a specific structure in the active KD form that 
is essential for phosphotransfer 19. Owing to an inherent interlobe flexibility that 
allows for both, open and closed conformations, protein kinases are capable of 
adopting a range of conformations. However, the catalytically competent 
conformation is the one in which the two lobes clamp together to form an 
interfacial nucleotide binding site and catalytic cleft, i.e. it is superficially a closed 
structure 25.  
 
 
Fig 1.7 Phosphorylated, active tyrosine kinase domain of RTK represented by EphA4 
Ribbon diagram of phosphorylated, and therefore active form of murine EphA4. First, the 
αC –helix of the kinase N-lobe is in the ATP proximal position allowing the formation of 
the conserved Lys653-Glu670 salt bridge, which coordinates the alpha and beta phosphate 
groups of ATP. Second, the activation loop (AL) is disorganized and adopts the so-called 
“DFG-in” conformation with the side-chain of Phe765 pointing towards the interior of the 
molecule. N-terminal lobe (pink) and consists of five-stranded anti-parallel β-sheet and 
one α-helix (αC). The C-terminal lobe (grey), is mainly α-helical. The p-loop (orange), hinge 
region (green), the catalytic loop (blue) and the activation loop (red). PDB accession 
number 2Y6M 78.  
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1.2.5.1 Mechanism of Eph cis-inhibition by JMS 
In addition to serving as docking sites, phosphorylation of non-catalytic 
tyrosines in the JM region of Ephs regulates catalytic activity. More specifically, 
activation of Ephs correlates with auto-phosphorylation of two conserved 
tyrosines (Tyr604 and Tyr610, for murine EphB2; Tyr587 and Tyr593, for EphA2) 
embedded in a highly conserved ~10-amino acid motif within the JM segment 
(JMS), in addition to phosphorylation of the aforementioned TyrACT (Tyr788 for 
murine EphB2; Tyr 771 in the case of EphA2)79. It has been shown that mutation of 
the conserved JM tyrosines to phenylalanine impairs kinase activity, while 
glutamic acid substitution preserves kinase activity 80,81. In-vitro kinetic analysis of 
EphA4 showed a decreased affinity for peptide substrate when AL or JM tyrosines 
are substituted, and suggested a two step inhibitory mechanism, released by 
autophosphorylation of TyrACT and JM tyrosines 79. In the crystal structure of 
murine EphB2, the JMS in its non-phosphorylated form, adopts an ordered α-
helical conformation that interacts with several elements in the kinase domain, and 
prevents it from adopting an ordered, active structure (Fig. 1.8 a). As a whole, the 
autoinhibited EphB2 kinase domain adopts a closed conformation that 
superficially resembles an active state. From a closer perspective, JM-mediated 
autoinhibition mainly arises from contacts with the N-lobe of the kinase. One way 
the JMS was thought to represses kinase activity, is by distorting the key αC helix 
in the kinase N-lobe 25. However, subsequent crystal structures of EphA2 and 
EphA4 lacking JMS exhibited a similar kink in the αC helix 78,82 (Fig 1.8 c). In 
addition, contact with the C-lobe of the kinase prevents the activation segment 
from adopting an ordered productive conformation, and restricts inter-lobe 
flexibility through bridging of N- and C-lobes 25. Whether the observed 
autoinhibited structure would be oriented in a certain fashion with respect to the 
inner surface of the membrane is impossible to extrapolate considering the lengthy 
sequence between the plasma membrane and the start of strand Ex1 83 (Fig 1.8 a). 
Subsequent NMR studies done on autoinhibited and activated EphB2 and EphA4, 
suggested that increased interlobe flexibility and the dynamic sampling of 
catalytically competent conformations for helix αC and the AL, rather than a 
transition to a static active conformation is the basis for Eph RTK activation 84. In 
contrast to EphA4, kinase activation mutations (Tyr742A) in a double EphA3 YYFF 
background did not lead to the dissociation of the JMS, suggesting an alternative 
activation mechanism 85. Crystal structures of dephosphorylated, fully 
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phosphorylated or partially phosphorylated wild type EphA3, revealed the 
relationship between the JM and AL (Fig. 1.8 d). At the crystallographic level, the 
extent to which the AL after the conserved DFG segment is structured is 
commonly correlated with the phosphorylation state of the protein and the absence 
of the JMS from the crystal’s electrons density. However, some EphA3 structures 
indicate that the relationship between the AL and JMS regions and kinase activity 
is not binary (Fig 1.8 d cyan structure). Other conserved tyrosine residues (660, 
744, 750 and 939) have been identified as in vivo phosphorylation site in EphB2 and 
EphB5 receptors 86,87. However, their role in regulating Eph receptor activation and 
their contribution, if any, in attaining an active conformation is sill unknown.  
Using a semisynthetic EphA4 receptor, activation of Ephs upon ephrin binding 
was proposed to follow a sequential and ordered autophosphorylation process, 
where TyrJM2 is phosphorylated first, followed by TyrJM1, and finally by TyrACT 88. It 
remains to be established how subtle, sequential phosphorylation events can affect 
the activity and conformation of Ephs in vivo. 
 
Fig 1.8 Mechanisms of Eph Activation, inferred from crystallographic studies 
(a) Ribbon diagram of murine EphB2 in complex with AMP-PNP (black). N-terminal lobe 
(pink), C-terminal lobe (grey), p-loop (orange), hinge region (green), and the 
juxtamembrane segment (JMS) in (cyan) with the phophoregulatory residues Tyr/Phe604 
and Tyr/Phe610 depicted in sticks, the catalytic loop (blue) and the activation loop (AL) in 
red. Protein Data Bank accession number 1JPA 25. (b) Schematic diagram comparing the 
autoinhibited (upper) and active states (lower) of Eph receptor. The autoinhibited scheme 
is based on crystal structure of 2YF-Ephb2 (1JPA) 25, and the active configuration is based 
on the crystal structure of active Insulin receptor kinase (IRK) (Accession no. 1IR3) 73. 
Dashed lines indicate regions of activation segment disorder. Numbering scheme 
corresponds to murine EphB2. (c) Comparison of EphA2 crystal structure (1MQB 82, green) 
with the kinase domain of other Ephs. Superimposition of phosphorylated murine EphA4-
kinase domain (2Y6M 78, grey), Y596/602F, Y742A EphA4-kinase domain + JM (however 
JM is disordered and cannot be seen here) (2HEL 84, red). Crystal structure of the EphB2 
active state, comprising a D754A activating mutation in the activation loop (2HEN 84, 
blue), and the autoinhibited EphB2-kinase domain + JMS, comprising Y604/610P (1JPA 25, 
yellow). (d) Structures of wild type EphA3 kinase showing relationship between AL and 
JMS. In summary, differences between the wild type structures presented occur mainly in 
the N-terminal region of the AL and the N-terminal region of the JMS. The AL tyrosine, 
Tyr779, is autophosphorylated, however the conformational consequence of this 
phosphorylation event is unclear, as the electron density in this region is always 
interpretable (magenta dashed line). Except for the segment surrounding the second JM 
tyrosine (Tyr602), which is disordered (grey dashed line), the conformation of the wile 
type JMS of CIP treated EphA3-apo (PDB: 2QO2, green) and basal (partially 
phosphorylated) EphA3-AMP-PNP (PDB: 2QOQ, yellow) matches closely with that of the 
dominant negative Y604/608F double mutant of EphB2 (PDB: 1JPA). Basal JMS-EphA3 
kinase-apo structure (PDB: 2GSF, cyan) is considered intermediate low activity 
conformation. CIP treated JMS-EphA3 kinase-AMP PNP (PDB: 2QO7, red) and ATP 
treated JMS-EphA3 kinase-AMP PNP (PDB: 2QO9, blue) 85. 
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1.3 Biological roles of Eph/ephrin signaling 
Originally identified as axon guidance molecules, the role of Ephs/ephrins in 
the developing vascular system is their next best-studied function. Their 
expression and function in adult tissues is now well established during tumor 
invasion, neoangiogenesis and metastasis. Upon cell-cell contact, interactions 
between Ephs and ephrins initiate bi-directional signaling in both, receptor-
expressing and ligand-expressing cells. Signaling cascades are propagated laterally 
and/or vertically with the help of various adaptors, mediators, and effector 
proteins. Several reviews sum up the current knowledge about Eph/ephrin 
biological roles 31,32,89. Some of those Eph-mediated functions will be detailed here.  
1.3.1 Eph as the central integrator of cell positioning 
During embryogenesis, Eph receptors position motile cells and cell layers 
within their surrounding tissues. They can do that, by affecting the assembly 
and/or disassembly of cell-cell contacts, thereby controlling the direction of 
motion and the choice of interacting cells. This coupled with the spatially and 
temporally restricted pattern of expression in developing tissues and organs, can 
eventually affect tissue patterning 89. Due to the dependency of Eph signaling on 
cell-cell contact, the final cell position will depend on many factors including; 
slope, shape, composition and orientation of Eph/ephrin gradients, abundance of 
interacting Ephs and ephrins, and crosstalk with other signaling systems 90-92 
1.3.2 Cell sorting and boundary formation 
The ability of Eph/ephrin signaling system to modulate cell positioning 
during development, has endowed them with the ability to mediate cell-cell 
segregation necessary for boundary formation. One of the earliest studied Eph-
mediated boundary formation processes during development, is zebrafish 
rhombomeres. Complementary expression of Ephs and ephrins in the different 
segments, coupled with their unique bi-directional signaling maintains 
rhombomeres boundaries 93. This biological concept has been replicated in various 
other models including recently, mammalian cell co-cultures of Eph- and ephrin-
expressing cells 69. Eph-mediated pathways involved in cell-cell segregation 
include, MAPK activation downstream of EphB2 94, inhibition of gap junction 
communication 95, and Wnt pathway-dependent RhoA activation 96.  
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1.3.3 Vasculogenesis and angiogenesis 
Class-B Ephs and ephrins, especially interactions between EphB2/B4 and 
ephrin-B2, play crucial roles during the development of the embryonic 
cardiovascular system 97,98. Studies have shown that ephrin-B2 is prominently 
expressed on embryonic arteries, while its cognate receptor EphB4 on veins. This, 
together with lethal vascular defects in knock-out mice, have promoted the idea 
that reciprocal signaling at arterial-venous boundaries prevents arterial and 
venous endothelial cell intermingling 99. Class-A Ephs and ephrins on the other 
hand, have limited roles during cardiovascular development, mostly attributed to 
the expression of EphA3 and ephrin-A1 during embryogenesis on major blood 
vessels and heart valves 100,101. In contrast to embryonic vasculature, recent 
evidence suggested important roles for Eph/ephrin type-A, especially EphA2 and 
ephrin-A1, in post-natal angiogenesis and pathological neo-angiogenesis 102,103. Not 
surprisingly, and owing to a common role of Eph/ephrin- and VEGFR-signaling in 
blood vessel assembly, growth and differentiation, interactions of the two 
signaling pathways have recently been reported. Ephrin-B2 was shown to regulate 
VEGFR2 internalization and thus its function in developmental and tumor 
angiogenesis. In addition, ephrin-B2 was able to directly activate VEGFR2, while 
ephrin-B2 PDZ signaling-deficient mice with abrogated VEGFR2 regulation 
showed reduced multi-tissue vascularization 104,105.   
1.3.4 Eph signaling in cancer 
Considering the fact that most Eph family members were first identified in 
tumor cell lines, it is not surprising to see the volumes of data documenting their 
roles in various epithelial and mesenchymal tumors. The aforementioned crucial 
role of Ephs in defining cell position during tissue and organ development now re-
emerges in adult tissues in a deregulated fashion, affecting cell-cell, cell-matrix 
attachment and survival during invasion, metastasis and neoangiogenesis 106-108. 
Eph overexpression often marks invasive, metastatic tumors and poor prognosis 
109. The expression of EphA2 for example, is more elevated in distant metastases 
than primary melanomas 110. Also expression of EphA2 in MCF10A, which are non-
transformed mammary epithelial cells, increases invasiveness in matrigel, induces 
anchorage-independent growth and induces tumor formation in nude mice 111. In 
addition to breast cancer and melanoma, elevated expression of Ephs has been 
documented in various other cancers, including, lung, kidney, colon, prostate and 
ovarian cancers 106. Neovascularisation is another aspect of cancer Ephs and 
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ephrins play a role in. EphA2 and ephrinA1, as well as EphB4 and ephrinB2 are 
elevated in tumor vasculature, where the ligand is usually marking endothelial 
cells 102,112. Depending on the context, Ephs can act as tumor suppressors rather 
than tumor promoters. Compared to its aforementioned roles in tumor 
progression, EphA2 knockout mice are more susceptible to skin tumors induced by 
carcinogen 113. EphB4 can also either promote or suppress tumor growth 114,115. This 
opposing effect can be explained by stage-dependent changes of Eph expression, 
which increases in initial stages of cancer progression, then it is either subjected to 
epigenetic silencing or modulation of function at later stages of tumor progression 
107. Another explanation for this dichotomy is the activity of Eph system in 
question. Treating EphB4+ve mouse xenografts with ephrinB2 inhibits tumor 
progression, which suggests that EphB4 promotes tumor progression in a ligand-
independent manner or in the presence of low ligand levels, but at high kinase 
activity shifts to inhibition of tumor progression 115. Overexpressing kinase-dead 
(kd) EphB4 in breast cancer cells enhanced tumor vascularization by promoting 
recruitment and proliferation of ephrinB2+ve endothelial cells 116.  
1.4 Tipping the balance at points of cell-cell contact 
Eph-ephrin interactions at points of cell-cell contact usually lead to, cell 
retraction, contraction and segregation. However, depending on the context, Eph-
ephrin signaling can also lead to enhanced cell adhesion within the same cell type. 
The output of a given Eph/ephrin complex depends on various aspects, including 
composition of signaling clusters, Eph and ephrin cell surface densities, 
termination and internalization of formed Eph/ephrin clusters, regulation by 
phosphatases and cross-talk with other signaling systems 117. The specifics of some 
of those factors will be outlined here.  
1.4.1 Signaling capacity of interacting Ephs/ephrins 
Eph kinase activity and the strength of bidirectional signaling are important 
factors governing the switch between repulsion and adhesion at points of cell-cell 
contact. Co-expression of a cytoplasmic-truncated form of EphA7 decreased 
phosphorylation of wild type full-length receptor and switched cellular response 
upon exposure to ephrinA5 from cell-cell segregation to adhesion 118, confirming 
the crucial role of Eph-kinase in determining the fate of cell-cell contact site.  Mice 
carrying mutations that disrupt bidirectional signaling between B-subclass Ephs 
and ephrins on the developing urethra, developed with incomplete fusion events 
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that tabularize the urethra, indicating the importance of intact Eph-ephrin 
bidirectional signaling for midline cell-cell adhesion and fusion events 119. It has 
been shown earlier that ephrinB1 can cause EphB1-expressing HEK293 cells to 
retract above a certain concentration, below which the same ephrin can promote 
integrin-mediated extracellular matrix (ECM) attachment 120. Such a graded 
dependency on ephrin concentration has also been reported for retinal axons 121, 
and HEK293T cells expressing the kinase-deficient EphB6 receptor. Despite kinase 
deficiency of EphB6, higher ephrin-B2 concentrations inhibited migration and 
shifted response to retraction through the EphB6-associated Src family kinase Fyn 
122. The aforementioned examples suggest a model where kinase activation with 
sufficient concentration of ligand is needed for retraction at points of cell-cell 
contact 123.  
1.4.2 Protein tyrosine phosphatases (PTPs) 
Similar to other RTKs, one cannot account for the signaling capacity of a 
given Eph-ephrin system inside the cell without taking into consideration the 
competing and coordinated roles played by protein tyrosine phosphatases (PTPs). 
Consistent with this idea, elevated PTP activity in EphA3-positivie leukaemia cells 
provokes adhesion to an ephrin-A5 surface, while its inhibition reverses the 
adhesive response to a repulsive one 124.  EphA4 is negatively regulated by PTP 
receptor type O 125, while EphB2 activation is regulated by the leukocyte common 
antigen related receptor tyrosine phosphatase (LAR-1) 94. In addition, insulin 
secretion, triggered by glucose-induced increase in PTP activity, reduces EphA5 
forward and enhances ephrinA reverse signaling 126. Furthermore, changing 
expression of the endoplasmic reticulum (ER)-anchored PTP1B can modulate 
duration and amplitude of EphA3 phosphorylation and biological function 127. The 
ability of ER-anchored PTP1B to interact with and affect a PM receptor in a spatial-
temporal manner is a conceptual dilemma that has been extensively investigated. 
Recent studies support a dynamic interplay between PTP1B and its PM substrates, 
in space and time, whereby dephosphorylation by PTP1B takes place when 
endocytosed RTK transit past the ER 128,129. Other studies suggest a direct on-site 
contact between PTP1B and its PM and/or adhesion sites localized substrates 130,131, 
a microtubule (MT)-dependent positioning of ER-bound PTP1B to the periphery of 
growth cones 132, or a possible recruitment of PTP1B to the cell surface upon Eph-
ephrin cell-cell contact 133. We recently found that the ER network is in close 
proximity to the PM at regions of cell-cell contact, thereby allowing the ER-
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anchored PTP1B to interact with substrates at those sites. Inhibition of PTP1B 
causes increased tyrosine phosphorylation of EphA2 specifically at sites of cell-cell 
contact, thereby identifying those sites as important target regions for regulation 
by PTP1B 134. Inactivation of PTPs by thiol-reactive compounds like pervanadate, 
causes ligand-independent phosphorylation of RTKs, indicating a functional role 
of PTPs in maintaining a dephosphorylated receptor prior to stimulation 135,136. 
Ligand-dependent activation of RTKs on the other hand, may also be coupled to 
transient PTP inactivation in order to enhance signal efficiency. This happens 
through increased production of H2O2 upon activation of the NADPH oxidase 
complex and the subsequent inactivation of PTPs 137-141. These data suggest that a 
gradient of PTP activity counterbalanced by a gradient of active Eph-dependent 
H2O2 inside the cells can comprise a reaction cycle that may be required for the 
establishment of a signaling threshold close to the PM and points of cell-cell 
contact (see Results and Discussion). 
1.4.3 Termination of Eph-ephrin complexes shifts adhesion to repulsion 
Upon cell-cell contact, large Eph-ephrin complexes, which physically tether 
receptor-and ligand-expressing cells, form and need to be disrupted to allow for 
cell-cell repulsion. The transmembrane metalloprotease ADAM10 (a disintegrin 
and a metalloprotease 10) plays a much-investigated role in termination of 
Eph/ephrin class-A complexes. The Eph receptor associated ADAM10 cleaves 
ephrin ligand in trans following receptor activation 142,143. Association of ADAM10 
with EphAs depends on ephrin-induced Eph clustering 144, while ligand cleavage 
relies on a conformational change in the activated Eph cytoplasmic domain that 
relieves inhibitory JM/KD interactions, and allows productive association with 
ADAM10 145. In regulating Eph/ephrin signaling, ADAMs seem to be shed from 
both receptors and ligands, but under different conditions. In addition to the 
aforementioned ligand mediated cleavage, ADAM facilitates EphB2 extracellular 
domain shedding in the absence of ligand and in the presence of calcium influx, 
leaving behind a fragment that γ–secretase further cleaves 146. The concept of 
sequential cleavage applies also to ephrin-B1 and ephrin-B2, where possible 
extracellular domain shedding by ADAM13 147 is followed by γ–secretase cleavage 
of the remaining intracellular domain 148. The contribution of other proteases to the 
termination of Eph/ephrin complexes has also been described, including cleavage 
of ligand-activated EphB2 by matrix metalloproteases MMP-2/MMP-8 149, and TM 
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cleavage of ephrin-Bs by rhomboid serine protease RHBDL2 150. Termination of 
Eph/ephrin complexes can also occur in a protease-independent manner, namely 
through “transendocytosis” of the entire complex. Interactions between 
EphB/ephrinB-expressing cells result in normal endocytosis of activated, 
phosphorylated EphB mainly into receptor-expressing cells, and unique 
transendocytosis of ephrinB also into receptor expressing cells. Transendocytosis 
depends on Rac and cytoskeletal signaling and an intact cytoplasmic domain of 
both receptor and ligand 151,152. With the presence of different mechanisms to 
terminate Eph/ephrin complexes, the common theme is the dependence on 
intracellular, kinase signaling controlling endocytosis, to achieve cytoskeletal 
reorganization and cell retraction. 
1.5 Recycling versus processing 
The amplitude and kinetics of RTK activation; Eph included; upon ligand 
binding are influenced by a highly regulated endocytic process. The decision 
between sorting activated receptors for lysosomal processing or recycling back to 
the plasma membrane is another level of spatial organization of RTK activity 153. 
All organelles on the exocytic and endocytic pathways, be it plasma membrane, 
endoplasmic reticulum or lysosomes are connected by rapid, bidirectional 
membrane traffic mediated by vesicular transport. Several members of the Ras 
superfamily of small guanosine triphosphatases (GTPases) play essential roles in 
regulating vesicular transport. Here, we will focus on the branch of Rab GTPases, 
which control all aspects of vesicular trafficking. This includes, the formation of 
vesicles or tubular intermediates, their active transport along cytoskeletal 
elements, their tethering to acceptor membranes and the regulation of their fusion 
with target compartment 154. 
1.5.1 RAB	  proteins	  as	  membrane	  organizers	  
Rab proteins comprise the largest family of monomeric small GTPases, with 
11 Rab proteins in yeast Saccharomyces cerevisiae and over 60 members in humans. 
Rab proteins are organized on different intracellular compartments and involved 
in the regulation of transport between organelles 154-156. Like other GTPases, the 
minimal regulatory cycle of Rabs involves their capacity to switch between an 
active GTP-bound and an inactive GDP-bound conformation. Exchange of GDP 
with GTP is catalyzed by guanine nucleotide exchange factors (GEFs), while 
conversion from GTP-bound to GDP-bound state is catalyzed by GTPase-
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activating proteins (GAPs) 157. GTP-bound Rab recruits several effectors, including 
kinases, phosphatases, motors, sorting adaptors and tethering factors. Newly 
synthesized, GDP-bound Rab is recognized by a Rab escort protein (REP), which 
presents Rab-GDP to geranylgeranyl transferase (GGT). Rab GDP dissociation 
inhibitor (GDI) can chaperon the geranylgeranylated form of Rab GTPases in the 
cytosol, mediates their delivery to target membranes and recycles them back into 
the cytosol. Targeting of Rab GTPases to their cognate membranes is partly 
attributed to the membrane-bound GDI displacement factors (GDFs), which 
displaces GDI from Rab-GDI complexes, thereby facilitating the association of 
geranylgeranylated Rab GTPase with its cognate membrane (Fig 1.9) 158.  
 
 
  
Fig 1.9 The Rab switch and its cycle 
Conversion of GDP-bound Rab (red) to GTP-bound Rab (blue) is catalyzed by a guanine 
nucleotide exchange factor (GEF). The GTP-bound “active” conformation can be converted 
back to the GDP-bound “inactive” form through hydrolysis of GTP and release of 
inorganic phosphate, a reaction catalyzed by GTP-ase activating protein (GAP). The GTP-
bound conformation is recognized by various effectors (blue), which further propagate the 
signal of active Rab. Newly synthesized GDP-bound Rab is captured by a Rab escort 
protein (REP) (purple) and introduced to a geranylgeranyl transferase (GGT). GDP-bound, 
geranygeranylated Rab is recognized by Rab GDP dissociation inhibitor (GDI) (orange), 
which captures the geranylgeranylated form in the cytosol, mediates its delivery to the 
respective membrane and recycles it back to the cytosol. Membrane-bound GDI 
displacement factor (GDF) (green) recognizes specific Rab-GFI complexes, promotes GFI 
release and thereby aids in the association of geranylgeranylated Rab GTPase with the 
cognate membrane. Adapted from 159 and 157. 	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1.5.2 RAB	  proteins	  in	  membrane	  traffic	  
In the early endocytic pathway, homotypic fusion of the initial endocytic 
vesicles and their fusion to the early endosome require Rab5.  Rapid recycling of 
early endosomal vesicles to the cell surface requires Rab4. Transformation of the 
early endosome (EE) to a late endosome (LE) requires Rab7 and transport of 
material from the recycling endosome (RE) back to the cell surface requires Rab11 
154 . Early endosomes contain Rab4 and Rab11, in addition to the aforementioned 
Rab5. However, these Rabs form their own subdomains on EE membranes (Fig 
1.10) 160. Similarly, the LE contains Rab9 in addition to Rab7, each of which has its 
own subdomains 161.  
 
 
Fig 1.10 Rab domains on endosomes 
Early endosomes has distinct domains 
enriched in Rab5 (blue), which is 
involved in vesicle endosome fusion 
and Rab4 (red), which is involved in 
endocytic recycling. The recycling 
endosome has distinct domains 
enriched in Rab5 and Rab11 (green), 
which is involved in vesicle trafficking 
to the plasma membrane. Late 
endosomes has distinct domains 
enriched in Rab7 (orange), which 
mediates trafficking to lysosomes and 
Rab9 (magenta), which mediates 
trafficking to the trans-Golgi network 
(TGN). Adapted from 157. 	  
1.5.3 RAB	  proteins	  and	  receptor	  signaling	  	  
There is a tight correlation between receptor signaling and membrane 
trafficking Membrane trafficking can affect many cellular processes by regulating 
the number of functional receptors available at the cell surface 156. Activation of 
several growth factor receptors leads to their internalization and subsequent 
sorting along the endosomal pathway. Rabs, being the main players in the 
endocytic pathway are involved in facilitating receptor trafficking, transmitting 
receptor signals for cytoskeletal regulation, modulating the amplitude and 
duration of signaling based on receptor sorting and even taking direct part in 
signaling pathways downstream of RTKS through their effector proteins. For 
detailed review, refer to 155,157.  
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1.5.4 Eph	  trafficking	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
The contribution of the early, recycling and late endosome to the regulation 
of basal receptor activity and ligand-induced activation is still poorly understood. 
However, the immediate outcome of regulated endocytosis is to reduce the 
number of cell-surface receptors, thereby attenuating cellular responsiveness to 
extracellular ligands (Fig 1.11) 156. Little is yet known about Eph trafficking prior to 
ligand-induced activation and clustering. Eph receptors and ephrin ligands can 
traffic through both caveolin- and clathrin-mediated endocytic routes, activating 
small GTPases involved in membrane trafficking and actin remodeling 162. In 
support of clathrin-mediated endocytosis, EphrinA5-Fc mediated endocytosis of 
EphA8 co-localized with clathrin, transferrin and EEA1 163, and EphA4 was 
detected in clathrin-coated vesicles in vivo 164. In support of caveolin-mediated 
endocytosis, ephrinB1 and EphB1 co-localized with caveolin, and EphA2 bound 
caveolin1 in response to ephrinA1-Fc stimulation 165,166. Upon ligand induced 
EphA4 activation, the Rab5-GEF, Rin1 (Ras/Rab interactor 1), which targets 
phosphorylated receptors to Rab5+ early endosomes, bound EphA4 via its SH2 
domain 167. Similar to other RTKs, the final fate of an activated Eph receptor is 
speculated to be lysosomal degradation. Ligand stimulation induces Cbl 
phosphorylation and Cbl-dependent ubiquitinylation and downregulation of Eph-
A and –B receptors through the lysosomal pathway 168-170. However, how consistent 
these findings are among other Eph family members and how efficient they can 
reflect the physiological membrane-bound ligand response is still not clear.  	  
	  
Fig 1.11 Regulation of signaling by 
endocytosis 
Regulated endocytosis via clathrin-
independent or –dependent pathways 
removes receptors (EGFR and GPCR as 
examples) from the cell-surface, linked via 
scaffold proteins such as Grb2 or a 
heterotrimeric G protein. This contributes to 
“desensitization” of cell signaling (violet 
arrows). Recycling back to the plasma 
membrane via the recycling endosome (RE) 
can reverse this effect (blue arrow). Sorting of 
internalized receptors into multivesicular 
bodies (MVB) and their fusion with 
lysosomes results in receptor 
“downregulation” (orange arrows)156.
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1.6 Fluorescence-based methods for studying protein states 
The use of fluorescence technology has expanded over the years, making it a 
primary research tool in most disciplines. In the field of molecular biology, 
fluorescence-based imaging techniques offer a superior resolution for detecting 
protein localization and function, sometimes even up to a single-molecule 
detection level. The introduction of genetically encoded fluorophores (FPs) 
combined with advanced fluorescence microscopy techniques, allow precise 
quantifications of protein functionality in space and time 171. The work presented in 
this thesis is based on fluorescence microscopy techniques, therefore proper 
introduction into the phenomena of fluorescence will be provided. 
1.6.1 Photophysics of fluorescence   
Fluorescence (FL) is the emission of a photon from an electron in an excited 
singlet state, as it relaxes to a spin-allowed, paired ground state. FL emission rates 
are rapid, and lay typically in the range of nanoseconds. The Jablonski diagram 
(Fig. 1.12) is often used to describe the processes occurring between absorption and 
emission of light.  172. Following light absorption, an electron in the ground state S0 
is often excited to some higher vibrational level of either S1 or S2. The excited singlet 
state can either relax back to the ground state radiatively through the emission of a 
photon (fluorescence-kF), or nonradiatively to the lowest vibrational level of S1 
(internal conversion-kIC). The excited singlet state in S1 can alternatively undergo a 
spin conversion to the first triplet state T1 (inter-system crossing-kIST), radiative 
emission from which is dubbed phosphorescence (kP), and is several orders of 
magnitude longer than FL172. The rate of singlet state radiative emission (kF) cannot 
be measured indirectly from the fluorescence lifetime (τ). Fluorescence lifetime is 
defined as the average time the molecule spends in the excited state prior to return 
to the ground state and is given by: 
 τ   = !!!  !  !!"  !  !!"#         (1)  
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Fig 1.12 Jablonski diagram 
Following light absorption (blue arrows), electrons from the singlet ground state (SO) can 
be excited to some higher vibrational level of the first two excited singlet states (S1, S2). 
Molecules rapidly relax to the lowest vibrational level of S1 in a process termed internal 
conversion (ex. dashed magenta arrow from S2 to S1). Molecules in S1 or S2 can also 
undergo a spin conversion to the triplet state (T1, T2) in a process termed intersystem 
crossing (red arrows). Electrons loose their energy and return to ground state through 
radiative (green and orange arrows) or non-radiative (dashed magenta arrows) decay. 
Radiative decay from excited singlet states is termed fluorescence (green arrows), while 
radiative decay from excited triplet states is termed phosphorescence (orange arrows). 
 
1.6.2 Fluorescence anisotropy 
Anisotropy measurement is one application of Fluorescence that is commonly 
used to provide information on size and/or amount of proteins in a cluster, 
fluidity of membranes, proteins-protein interactions and for biochemical assays of 
numerous substances. Anisotropy measurements are based on the concept of 
photoselective excitation of FPs by polarized light. In an isotropic solution, the FPs 
are randomly oriented and upon excitation will emit unpolarized light. However, 
if polarized light was used, excitation will only occur to a subset of FPs whose 
absorption transition dipole is parallel to the electric vector of the excitation light 
(Fig 1.13). Selective excitation results in a partially polarized fluorescence emission 
and a partially oriented subset of FPs (photoselection). The extent of emitted light 
polarization is described by fluorescence anisotropy (r) and defined by: 
 ! =   !∥  !  !!!∥  !!!!          (2) 
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Fig 1.13 Effects of polarized excitation and rotational diffusion on anisotropy 172. 
 
Several factors can decrease the measured anisotropy through depolarization of 
the light emitted by FPs. The most common factor being rotational diffusion of the 
FP, (Fig.1.10), which takes place during the lifetime of the excited state and 
randomizes the polarization of the emission dipole. When the FP lifetime is much 
shorter than rotational diffusion time scale, Förster resonance energy transfer 
becomes the dominating factor in the depolarization of emitted light 172. 
Anisotropy measurements allow the detection of FRET between identical FPs 
(Homo-FRET), thereby providing a straightforward technique for measuring 
oligomerization and homo-dimerization of proteins 173,174.   
1.6.3 Förster Resonance Energy Transfer (FRET) 
Förster resonance energy transfer (FRET) is another process that takes place 
in the excited state. FRET occurs when the emission spectrum of an excited FP, 
called the donor (D), overlaps with the absorption spectrum of another FP, called 
the acceptor (A) (Fig. 1.14). FRET is a non-radiative process that occurs in the 
nanometer range and for which the acceptor does not need to be fluorescent to 
occur 175,176. The donor and acceptor molecules are coupled via dipole-dipole 
interactions and the rate of energy transfer (kT) between them is given by: 
 !! =    !!!    !!! 6         (3) 
 
where (r) is the distance between donor and acceptor molecules, (τD) is the 
fluorescence lifetime of the donor and (R0) is the Förster distance between donor 
and acceptor at which the transfer efficiency drops to 50% (Fig.1.14).  
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The efficiency of energy transfer (E) is also distance dependent and is defined by: ! =    !!!!!!  !  !!           (4) 
 
 
 
Fig 1.14 Factors affecting FRET 
(Left) Förster radius (Ro) is the distance at which 50% of the energy transfer is taking place 
between to molecules. (Right) The overlap integral (J(λ)) depends on the overlap area 
between donor emission spectrum and acceptor absorbance spectrum (grey area) 177.  
  
R0 is dependent on the photophysical properties of the FP pair and for most 
biologically relevant FRET pairs, falls around the value of 5 nm 178, which is well 
below the resolution limit of light microscopy and compares to typical globular 
protein radii. R0 is defined by: 
 !! =    [κ!  ×  ! λ   ×  !!!×  Q]!/!  ×  9.7  ×  10!      (5) 
 
Factors affecting R0 include: (κ!), which is the relative orientation of the transition 
dipoles of the FPs, (! λ ; cm6.mol-1) the overlap integral, which depends on the 
extent of spectral overlap between donor emission and acceptor absorbance 
(Fig.1.11), (n) the refractive index of the intervening medium and (Q) the quantum 
yield of the donor 177. FRET reduces the excited state lifetime of the donor FP by 
providing an additional pathway for depopulating the excited state (compare to 
Equation 1): 
 τ   = !!!  !  !!"  !  !!"#  !  !!"#$        (6)  
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FRET efficiency can be measured experimentally by monitoring the drop in donor 
intensity (I) or lifetime (!) in the presence of acceptor:  
 ! = 1 −    !!"!!   = 1 − !!"!!         (7)  
Imaging techniques designed to detect FRET therefore monitor the photophysical 
changes occurring to the excited donor FP in the presence of an acceptor FP. 
Intensity-based and fluorescence lifetime measurements are both used to detect 
FRET between different donor/acceptor molecules (Hetero-FRET). Donor lifetime 
measurement is independent of FP concentration, is less prone to errors arising 
from intensity fluctuations, allows precise quantification of donor fraction 
undergoing FRET and is therefore superior to intensity-based FRET 
measurements. In this thesis only lifetime measurement of FRET will be further 
discussed. For extensive review of intensity-based FRET measurements, please 
refer to 172,177,179. 
1.6.4 Fluorescence Lifetime Imaging Microscopy (FLIM) 
Fluorescence lifetime ( ! ) is an inherent property of each FP that is 
independent of probe concentration and light path length, but depends on 
processes affecting depolarization of FP excited state, such as FRET 177. In 
combination with advanced microscopy techniques, lifetime-measurement allows 
superior spatial-temporal resolution of protein dynamics. As discussed earlier in 
(Equation 7), FRET efficiency (E) for a certain donor/acceptor pair, can be 
calculated from donor lifetime ( ! ), in presence or absence of acceptor. 
Measurement of donor lifetime (!) can be done in the frequency or time domain, 
but for the purpose of work done in this thesis, only time-domain FLIM will be 
discussed in details. For extensive review of frequency-domain FLIM, please refer 
to 180,181. 
1.6.4.1 Time-domain FLIM 
In time-domain FLIM measurements, the sample is excited with a pulsed 
light source, whose width is made as short as possible to be discernable from the 
decay time (!) of the sample.  Following the excitation pulse, time-dependent 
emission fluorescence intensity is measured. The decay time (!) is calculated from 
the slope of a plot of time versus log I (t) (decay profile), but more commonly from 
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fitting the data to presumed decay models. Intensity decay curves are often 
measured with a polarizer inclined at 54.7° from the vertical z-axis, thereby 
avoiding effects by anisotropy and/or rotational diffusion on decay curves 172. This 
relates to lifetime (!), because when a fluorophore (FP) is excited with an infinitely 
sharp (δ-function) pulse of light, a population of FP molecules (n0) is initially 
excited, to further decay exponentially with a rate:  
 !" !!" = Γ+   !!"   !!  !"#(−!/!)       (8)  
where n(t) represents the number of excited FP molecules at time t, Γ is the 
emissive rate, knr is the non-radiative decay rate. Fluorescence-based experiments, 
are not based on counting the number of excited molecules, but rather on 
fluorescence intensity, which is relative to n(t). If we now substitute (Eq.8) with 
time-dependent intensity changes I(t) we get single exponential decay expression: 
 !(!) = !!  !"#(−!/!)         (9) 
 
where I0 is the intensity at time 0. The lifetime ! is the inverse of the total decay 
rate, τ = (Γ + knr)-1 and can be seen as the average length of time a FP remains in the 
excited state following excitation. Excited FP molecules emit randomly throughout 
their decay, therefore lifetime is considered a statistical average. The distribution of 
emitted photons across time is the intensity decay 172. Time-domain FLIM is mostly 
done using time-correlated single-photon counting (TCSPC). Instrumentation of 
TCSPC use high repetition rate picosecond (ps) or femtosecond (fs) lasers, coupled 
to very sensitive and extremely fast detection systems. Detectors used for TCSPC 
are either micro-channel plates (MCPs), photomultiplier tubes (PMTs) or single 
photon avalanche diodes (SPADs) 172. In principle, the sample is excited with a 
pulse of light (Fig 1.15 upper panel “green”) with a frequency allowing good 
resolution of fluorescence lifetime in question. For fluorescence lifetime within the 
range of 2.5-4 ns, the pulse rate is typically 25MHz. In TCSPC, the detection rate is 
normally set to less than one photon per pulse. For each observed photon, the time 
difference between detection and excitation pulse is noted and stored in a 
histogram (Fig 1.15 lower panel), in which the x-axis represents time-difference 
and the y-axis the number of photons per a given time-difference. So far in TCSPC, 
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only the first photon is detected, therefore one has to adjust count rate in order to 
avoid bias to early (short-lifetime) photons 172. 
 
 
Fig 1.15 Principles of TCSPC 
(Upper) Sample is excited with a pulse of 
light, resulting in the waveform observed 
(red), instrument response function is 
shown in green. (Middle) The pulses 
represent the output from a constant 
fraction discriminator. The x-axis is the 
time difference (in ns) and the y-axis is 
the number of photons detected for the 
time difference. (Lower) Shows a 
histogram-representing fraction of 
photons detected at a certain time 
difference. 
 
In case of FRET, the measured decay profile in each pixel becomes the sum of the 
different decay profiles scaled by their respective populations. The analysis in this 
case will require a multi-exponential decay model for fitting. Multi-exponential 
model assumes that intensity decays as the sum of individual single exponential 
decays 172: 
 !(!) = !!!!!! !"#(−!/!!)+ !       (10) 
 
where (B) is the background, (n) is the number of decay times present, (!! ) 
represents the amplitudes of the components at t = 0, and (!!) are the fluorescence 
decay times.  If we assume that the free donor molecules have a single lifetime (!!) 
and that the acceptor molecules exist in a single spatial configuration with respect 
to the donor in the complex (i.e. a single reduced lifetime of the donor (!!), then 
the decay profile in each pixel becomes the sum of these two populations, plus an 
additional background term (B) that accounts for the dark noise of the detector 182: 
 ! !,!, ! =   !!(!,!)  !"#(−!/!!)+   !!(!,!)  !"#(−!/!!)+ !   (11) 
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molecules in close proximity to acceptor molecules (!) can be calculated on pixel 
basis as follows: 
 ! !, ! =   !!(!,!)  !! !,! !    !!(!,!)       (12) 
 
It is often useful to determine average lifetime (! ), when using the multi-
exponential decay law. The average lifetimes is given by: 
 ! =    !!  !!!    !    !!  !!!!!  !!!    !    !!  !!!           (13)  
The connotation of (α  and τ ) depends on the context of the system under 
investigation. For a fluorophore displaying a complex decay, (α!) values represent 
the fraction of molecules in each conformation at t = 0, which is the ground-state 
equilibrium 172. Following acquisition of enough photons, TCSPC data are analyzed 
by fitting fluorescence decay histograms according to any given model that 
accounts for or excludes the instrument response function (IRF). In this thesis, most 
of the data are analyzed with precision FLIM (pFLIM), which uses a specific 
parameterized IRF model to account for the true IRF 183. In the time-domain, a 
minimum number of photons are required to distinguish two lifetimes, which 
sometimes limits the quantitative analysis of the data. This can be overcome if 
time-domain data is analyzed in the Fourier space by applying global analysis 184.  	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1.7 Outline of thesis   
Within each level of organization, dynamic biological systems are kept in-
check by operating under constant opposing tendencies. Even on a molecular level, 
such duality can be seen between individual proteins, allowing local sources to 
affect global patterns. The emerging patterns will in return affect the interactions of 
individual proteins at local sources, in a negative or positive feedback manner 2. 
There is no better signaling system defining the link between local opposing 
tendencies and global pattern formation than the Eph subfamily of RTKs. The 
same receptor-ligand pair can enhance adhesion or repulsion between two cells 
upon their contact. How local factors affecting the signaling output of the system 
can lead to such a switch at points of cell-cell contact is of utmost interest. Local 
factors influencing this balance include, clustering capacity of Ephs and the cell’s 
own clustering history, spatial organization of the phosphorylation-
dephosphorylation cycle and recycling versus termination of signaling (Fig 1.16). 
In this thesis my main aim is to understand how the activity Eph RTKs, with 
inherent autocatalytic properties and intrinsic structural features that promote 
dimerization and clustering is spatially organized (Fig 1.16). To accomplish this, 
the following specific questions were addressed:  
1. The formation of higher-order clusters is a unique and essential feature of 
Eph/ephrin family among other RTKs 12. Is there a link between 
composition of Eph clusters and cellular output? Does the cell’s historical 
context determine the response to incoming ephrin? How important is 
clustering for robust kinase activity? Is it a prerequisite or a consequence?  
2. The effect of the ER-anchored PTP1B on amplitude and duration of EphA3 
signaling was highlighted before 133. Whether the ER is polarized actively or 
passively towards cell contact points and whether it contributes to spatial 
organization of Eph signaling at these points is still poorly understood. If 
PTP1B actively contributes to regulation of Eph signaling at points of cell-
cell contact, then the question is how the balance shifts between dominating 
Eph activity and dominating PTP1B activity at these points? 
3. In addition to serving as docking sites, the two tyrosines in the Eph JM 
domain regulate catalytic activity 79-81. Does the molecule exist in either an 
autoinhibited or a catalytically active conformation or is the process of 
activation more dynamic allowing the kinase to “breath” and sample many 
conformations?  
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4. The immediate outcome of regulated endocytosis is to reduce the number of 
cell-surface receptors, thereby attenuating responsiveness to ligand 156, but is 
the endocytosed Eph receptor still active and what is the contribution of the 
early, recycling and late endosome to the spatial organization of Eph 
activity? Finally, how does the cell differentiate between an active monomer 
and a ligand clustered active receptor in terms of different trafficking routes 
and thereby fate of signaling?  
 
 
 
  
Fig 1.16 Model depicting possible determinants of Eph activity spatial organization 
(1) The formation of higher-order clusters, (2) spatial organization of phosphorylation-
dephosphorylation cycles, (3) autoregulation of Eph kinase activity by its juxtamembrane 
segment, (4) the effect of different trafficking routes on the output of Eph signaling.  
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2. MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 Chemicals 
 
Acetic acid         Sigma-Aldrich® 
Adenosin-5’-triphosphate (ATP)      Sigma-Aldrich® 
Ammonium persulfate (APS)      SERVA Electrophoresis GmbH 
Ampicillin sodium salt       SERVA Electrophoresis GmbH 
Bromophenolblue         Sigma-Aldrich® 
Dasatinib (10mM stock)       kind gift from Dr. Ralf Schneider 
Dasatinib #9052        Cell Signaling Technology ® 
2’-deoxyadenosine-5’-triphosphate (dATP)    InvitrogenTM Life Technologies 
2’-deoxythymidine-5’-triphosphate (dTTP)    InvitrogenTM Life Technologies 
2’-deoxycytidine-5’-triphosphate (dCTP)      InvitrogenTM Life Technologies 
2’-deoxyguanosine-5’-triphosphate (dGTP)    InvitrogenTM Life Technologies 
Dimethyl sulfoxide (DMSO)      SERVA Electrophoresis GmbH 
Disodium hydrogen phosphate (Na2HPO4)    Merck KG 
Dithiothreitol (DTT)       Fluka® Analytical 
Ethanol         J.T.Baker 
Ethidium bromide (EtBr) (10 mg/ml)     Fisher Scientific 
Ethylenediaminetetracetic acid (EDTA)     Fluka® Analytical 
Fluorescein isothiocyanate #F245-6     EGA-Chemie 
Glycerol         GERBU Biotechnik GmbH 
N-(2-Hydroxyethyl)Piperazine-N’-ethane- 
2-sufonic acid (HEPES)       GERBU Biotechnik GmbH 
Isopropanol         J.T.Baker 
Isopropyl β–D-thiogalactopyranoside (IPTG)    AppliChem GmbH 
Kanamycin sulfate        GERBU Biotechnik GmbH 
Magnesium chloride (MgCl2)       Merck KG/J.T.Baker 
Methanol         AppliChem GmbH 
2-Mercapto-ethanol        SERVA Electrophoresis GmbH 
Monopotassium phosphate (KH2PO4)     J.T. Baker 
Nocodazole         Sigma-Aldrich® 
Phosphatase Inhibitor Cocktail 1      Sigma-Aldrich® 
Phosphatase Inhibitor Cocktail 2      Sigma-Aldrich® 
Sodium chloride (NaCl)       Fluka® Analytical 
Sodium dodecyl sulfate (SDS)      SERVA Electrophoresis GmbH 
N,N,N’,N’-Tetramethylene-diamine (TEMED)    Sigma-Aldrich® 
Tris-base            Carl Roth GmbH 
Tris-HCl            J.T.Baker 
Tritox X-100            SERVA Electrophoresis GmbH 
Tween 20            SERVA Electrophoresis GmbH 
UltraPureTM Agarose       InvitrogenTM Life Technologies 
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2.1.2 Enzymes, Proteins and Antibodies 
 
AccuPrimeTM Pfx DNA polymerase        InvitrogenTM Life Technologies 
Age I-HF (10,000 U/ml)       New England Biolabs Inc. 
BamHI (20,000 U/ml)       New England Biolabs Inc. 
BsrGI (10,000 U/ml)       New England Biolabs Inc. 
Calf Intestinal Phosphatase (10,000 U/ml)    New England Biolabs Inc. 
DpnI          New England Biolabs Inc. 
EcoRI-HF         New England Biolabs Inc. 
EphA2 rabbit polyclonal AB (C-20) #sc-924    Santa Cruz ® Biotechnology 
mEphrin A1/Fc Chimera #602-A1     R & D Systems ® 
mEphrin B2/Fc Chimera #496-EB         R & D Systems ® 
Enolase (rabbit muscle) #E0379      Sigma-Aldrich® 
HindIII (20,000 U/ml)       New England Biolabs Inc. 
IRDye® 680 donkey anti-mouse IgG     LI-COR® Biosciences 
IRDye® 800 donkey anti-goat IgG     LI-COR® Biosciences 
IRDye® 680 donkey anti-rabbit IgG     LI-COR® Biosciences 
IRDye® 800 donkey anti-mouse IgG     LI-COR® Biosciences 
Living colors® GFP rabbit polyclonal AB    Clontech 
Living colors® GFP mouse monoclonal AB    Clontech 
NotI          New England Biolabs Inc. 
Paq5000 DNA polymerase       Agilent Technologies 
PfuUltra High-Fidelity DNA polymerase AD    Stratagene 
Phusion High-Fidelity DNA Polymerase     FINNZYMES 
Platinum® Pfx DNA polymerase      InvitrogenTM Life Technologies 
PTB1B allosteric inhibitor #539741     Calbiochem 
Purified mouse anti- phosphotyrosine (P172.1)    InVivo Biotech Services GMBH Purified	  mouse	  anti-­‐PTP1B	   (Ab-­‐1)	  #PH01	   	  	  	  Calbiochem	  Purified	  mouse	  anti-­‐ α-­‐tubulin	   	   	   	  	  	  Sigma-Aldrich® 
Purified mouse anti β-Catenin #610153     BD Transduction LaboratoriesTM  
Purified mouse anti-human Rab11 #610656     BD Transduction LaboratoriesTM 
Purified goat anti-human EphA2 #AF3035    R & D Systems ® 
Purified rabbit anti-EphA2 +A3+A4  
(phospho Y588+596) #ab62256          Abcam 
Purified mouse anti-humanIgG Fc #411455    Calbiochem  
RNaseA (100 mg/ml)       QIAGEN 
SalI            New England Biolabs Inc. 
SpeI (10,000 U/ml)        New England Biolabs Inc. 
XhoI (20,000 U/ml)        New England Biolabs Inc. 
XmaI (10,000 U/ml)        New England Biolabs Inc. 
 
2.1.3 Oligonucleotides 
All oligonucleotides were purchased from Sigma-Aldrich Chemie GmbH in salt-
free or HPLC purified form. All primer sequences are found in APPENDIX I 
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2.1.4 Plasmids 
mCherry-N1   Clontech Laboratories Inc. 
mCitrine-N1   Clontech Laboratories Inc. 
mEGFP-N1   Clontech Laboratories Inc. 
mTFP-N1   Clontech Laboratories Inc. 
mTagBFP-N1  Evrogen Laboratories Inc. 
PTP1B (D/A)-RFP-TK generated by inserting cDNA encoding catalytic 
domain of human PTP1B (D/A) (residues 1-407) 
flanked by AgeI restriction sites into pRFP-tkB-C1 
vector  (gift from Dr. M. Lackmann). 
mCherry-Rab7  kind gift by Dr. Yaowen Wu (MPI, Dortmund) 
mTagBFP-Rab11 generated by inserting cDNA encoding human Rab11 
into mTagBFP-C1 vector. 
mTagBFP-PTP1B generated by inserting cDNA encoding human PTP1B 
into mTagBFP-C1 vector. 
dSH2-cherry dimer SH2 domain from pp60src labeled with mCherry, 
generated by swapping YFP from the original dSH2-
YFP 185, (cloned by Rabea Stockert). 
2.1.5 Buffers and Solutions 
LB agar plates add 15 g agar per litre LB medium, pour plates when 
the autoclaved medium has approximately 55°C, add 
antibiotic of choice at desired concentration 
LB medium 10 g/l Bacto-Trypton, 5 g/l bacto-yeast extract, 10 g/l 
NaCl and finally autoclave 
HNTG  20 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 
0.1% Triton X100, adjust volume with ddH2O 
KRB 125 mM HEPES pH 7.5, 12.5 mM MgCl2, 20 mM MnCl2 
0.5 mM Na vanadate, 100 mM β-glycerophosphate, 
adjust volume with ddH2O 
1x PBS (pH 7.4) 137 mM NaCl, 10 nM Na2HPO4, 2.6 mM KCl, 1.8 mM 
KH2PO4 
4% PFA 4 g paraformaldehyde, 1x PBS (pH 7.4) 
RIPA lysis buffer 50mM Tris pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM 
EDTA, 1% IGEPAL, 0.25% Na deoxycholate, 2.5 mM Na 
pyrophosphate, 1 mM β-glycerophosphate, 0.1 mM 
PMSF, adjust volume with ddH2O 
5x SDS sample buffer 60 mM Tris-HCl (pH 6.8), 25 % glycerol, 2 % SDS, 14.4 
mM 2-mercapto-ethanol, 0.1 % bromo-phenolblue 
SDS running buffer 25 mM Tris-base, 192 mM glycine, 0.1 % SDS 
Separating gel buffer 1.5 M Tris-HCl (pH 8.8) 
SOC medium 20 g/l Bacto-Trypton, 5 g/l bacto-yeast extract, 0.5 g/l 
NaCl, 2.5 mM KCl, 10 mM MgCl2 (SOB medium), 
autoclave and before usage add 20 mM glucose to 
obtain SOC 
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Stacking gel buffer 0.5 M Tris-HCl (pH 6.8) 
STET 8% sucrose, 5% triton x100, 50 mM EDTA, 50 mM Tris 
pH 7.9 and adjust total volume with ddH2O 
1x TAE buffer 40 mM Tris/Acetate (pH 7.5), 20 mM NaOAc, 1 mM 
EDTA 
1x TBS 100 mM Tris-HCl (pH 7.4), 150 mM NaCl 
1x TBST 100 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1 % Tween 
20 
Transfer buffer 25 mM Tris-base, 192 mM glycine, 20 % methanol. 
 
2.1.6 Kits and Commercial Solutions 
 
For DNA work 
 
BigDye® Terminator v3.1 cycle sequencing kit Applied Biosystems 
100x BSA    New England Biolabs Inc. 
6 x DNA gel loading buffer   Novagen 
2-log DNA ladder    New England Biolabs Inc. 
100 mM dNTP mix    InvitrogenTM Life Technologies 
DyeEx® 2.0 Spin kit     QIAGEN 
GelPilot loading dye, 5x    QIAGEN 
50 mM Magnesium Sulfate    InvitrogenTM Life Technologies 
NucleoBond® Xtra Maxi EF kit   Macherey-Nagel GmbH & Co. KG. 
10x Pfu amplification buffer   InvitrogenTM Life Technologies 
QIAprep® Spin Miniprep kit   QIAGEN 
QIAquick® Gel Extraction kit   QIAGEN 
QIAquick® PCR Purification kit   QIAGEN. 
QuickChange XL Site-Directed Mutagenesis kit Stratagene 
RedSafe nucleic acid staining solution #21141 iNtRON 
10x Restriction Enzyme Buffer 1   New England Biolabs Inc. 
10x Restriction Enzyme Buffer 2   New England Biolabs Inc. 
10x Restriction Enzyme Buffer 3   New England Biolabs Inc. 
10x Restriction Enzyme Buffer 4   New England Biolabs Inc. 
T4 DNA Ligase # 15224-017   InvitrogenTM Life Technologies 
5x T4 DNA Ligation Buffer # 46300-018  InvitrogenTM Life Technologies 
Zero Blunt® TOPO® PCR cloning kit  InvitrogenTM Life Technologies 
 
For protein work 
 
30 % Acrylamide/Bis solution   Bio-Rad Laboratories, Inc. 
Bradford reagent #B6916    Sigma-Aldrich® 
10x Cell lysis buffer    Cell Signaling Technology® 
Complete Mini EDTA-free protease inhibitor 
tablets    Roche Applied Science 
Odyssey Infrared Imaging System blocking 
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buffer     Li-Cor® Biosciences 
Precision Plus ProteinTM standards  Bio-Rad Laboratories, Inc. 
Protein G Sepharose ®, fast flow #P3296  Sigma-Aldrich® 
1x TBS    Sigma-Aldrich® 
 
For cell-culture work 
 
DPBS    PANTM Biotech GmbH 
Dulbecco’s Modified Eagle’s Medium (DMEM) PANTM Biotech GmbH 
Effectene® transfection reagent   QIAGEN 
Fetal calf serum (FCS)    PANTM Biotech GmbH 
Fugene® 6 transfection reagent   Roche Applied Science 
L-Glutamine     GIBCO®/InvitrogenTM  
Lipofectamine TM 2000.    InvitrogenTM 
Trypsin/EDTA     PANTM Biotech GmbH 
 
2.1.7 Bacterial Strains 
One Shot® TOP10 Competent Cells   InvitrogenTM Life Technologies 
RosettaTM 2(DE3) SinglesTM Competent   Novagen 
XL10 Gold    Stratagene (regrown in-house) 
2.1.8 Mammalian Cell Lines  	  
Cell Line Origin Supplier Reference 
COS-7 African green monkey kidney fibroblast ATCC 186 
HEK-293 Human embryonic kidney ATCC  
HeLa Human cervical adenocarcinoma ATCC  
MCF-7 Human mammary gland adenocarcinoma ATCC  
MDA-MB468 Human mammary gland adenocarcinoma ATCC  
MDCK Madin-darby canine kidney cells ATCC  
 
2.1.9 Material and Equipment   
 
Centrifuges & Rotors 
Centrifuge 5415R     Eppendorf 
Centrifuge 5810R     Eppendorf 
Centrifuge RC 26 Plus     Sorvall® 
Rotor SH-3000     Sorvall® 
Rotor FA-45-24-11     Eppendorf 
Rotor FL 064-04053     Eppendorf 
Vacuum centrifuge     Eppendorf 
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For DNA work 
Gel Imaging Station    Bio-Rad Laboratories 
Gene PulserTM    Bio-Rad Laboratories 
PCR-Cycler    Eppendorf 
Power PacTM 1000    Bio-Rad Laboratories 
Pulse controller    Bio-Rad Laboratories 
 
For protein work 
Amicon Ultra-15 centrifugal filter unit  MilliporeTM 
1.0 mm cassettes for western blots  InvitrogenTM Life Technologies 
1.0 mm 10-well combs    InvitrogenTM Life Technologies 
Incubation box for western blots   Li-Cor® Biosciences 
Incubator Shaker Series I26   New Brunswick Scientific 
Odyssey Infrared Imager    Li-Cor® Biosciences 
PVDF membrane    Bio-Rad Laboratories, Inc. 
Sonicator needle (MS 73)    Bandelin Electronic GmbH   
Ultraschall HD 2200    Bandelin Electronic GmbH   
Test tube rotator 34528    Snijders 
Cuvettes (1 ml) Ref. 67.742    Sarstedt Aktiengesellschaft & Co.  
 
For cell-culture work 
Cell scraper    BD FalconTM 
Cryo vials 
Easy GripTM tissue culture dish (60 mm)  BD FalconTM 
75 mm filter unit    Nalge Nunc International 
Glass Pasteur pipettes (150 mm, 230 mm) Brand GmbH & Co. KG  
2-well LabTek® chambers No. 1.0  Nalge Nunc International 
4-well LabTek® chambers No. 1.0  Nalge Nunc International 
8-well LabTek® chambers No. 1.0  Nalge Nunc International 
NALGENE® Cryo 1 °C freezing container Nalge Nunc International 
35-mm MatTek petri dishes No. 1.5  MatTek Corporation 
NUAIRETM Cellgard class II biological safety Integra Biosciences 
cabinet 
T75 tissue culture flask    BD FalconTM 
Tissue culture plate (6 well)   BD FalconTM 
Vacusafe comfort    Integra Biosciences 
Vi-CellTM XR cell viability analyzer  Beckman Coulter, Inc. 
 
General Material and Equipment 
Bunsen burner LABOGAZ® 206   Campinggaz® 
Eppendorf safe lock tubes (0.5/1.5/2 ml) Eppendorf 
Falcon tubes (15/50 ml)    BD FalconTM 
Gas cartridge C 206    Campinggaz® 
Gene Pulser    Bio-Rad 
Heatable magnetic stirrer “IKMAG®RCT” IKA®Labortechnik 
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Heating block ”QBD4”    Grant Instruments 
Nanodrop® ND-1000 spectrophotometer Peqlab Biotechnologie GmbH 
Parafilm®      Pechiney Plastic Packaging 
PFE powder-free latex exam gloves (S)  Kimberly-Clark 
Pipetboy acu      Integra Biosciences 
Pulse Controller     Bio-Rad 
Safegrip® nitril gloves (S)    Süd-Laborbedarf GmbH 
Sarstedt serological pipettes (5/10/25 ml) Sarstedt Aktiengesellschaft & Co. 
Scale “Precisa 62 A”     Precisa Instruments AG 
Scale “Precisa 620 C”    Precisa Instruments AG 
Surgical disposable scalpel (No. 11, No.21) Braun Melsungen AG 
Thermomixer comfort    Eppendorf 
“Vortex Genie 1” touch mixer   Scientific Industries 
 
2.1.10 Microscopes 
Axiovert 200M: inverse FL microscope  Carl Zeiss MicroImaging GmbH 
Cell R       Olympus 
Fiber coupling unit     PicoQuant GmbH 
Fluo View FV1000     Olympus 
IU-LH75XEAPO: 75W xenon APO lamp  Olympus 
IX 81: inverse microscope    Olympus 
IX2-UCB controlling unit    Olympus 
Leica TCS SP5     Leica MICROSYSTEMS 
PR-IX2 motorised stage    Olympus 
Scan Stage      Olympus 
Sepia II      PicoQuant GmbH 
U-HSTR2: hand switch    Olympus 
UPLSAPO 40x/0.9 NA    Olympus 
UPLSAPO 60x/1.2 NA    Olympus 
U-RFL-T                 Olympus 
 
2.1.11 Software 
Adobe Illustrator     Adobe Systems Inc. 
DNASTAR Navigator v2.2.1.1   DNASTAR Inc. 
FV10-ASW Fluoview Software   Olympus 
IgorPRo v6.12     WaveMetrics 
ImageJ64 v1.44     http://rsbweb.nih.gov/   
Microsoft Excel 2011    Microsoft Corporation 
MacPyMOL      http://www.pymol.org/ 
SymPhoTime v5.12     PicoQuant GmbH  
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2.2 Methods 
2.2.1 Cloning 
2.2.1.1 Bacterial Cultures 
Unless otherwise stated, E.coli cells were grown in LB medium (+ 
appropriate antibiotic) at 37 °C and 225 rpm. Single clones (colony) grown on agar 
plates were then inoculated into cultures of 4 ml LB medium. This pre-culture was 
left to grown for 6-10 h, then used to inoculate the desired volume of main culture.   
2.2.1.2 Transformation of Chemically Competent E.coli 
Chemical transformation of foreign DNA into competent bacterial cells is a 
method of amplification for recombinant DNA and it usually has a transformation 
efficiency of 1 x 106 - 1 x 108 colonies/µg DNA. 
For each tube of chemically competent E.coli XL 10 Gold cells (100 µl), 3.25 
µl of 2.25 mM DTT was added. Aliquots of 50µl cells were used for each 
transformation reaction, and were inoculated with either ~1 µl plasmid DNA 
(50ng), or 2 – 4 µl ligation mix, then left on ice for 30 min. Tubes with 
transformation mix were then heat shocked for 60 sec at 42 °C and returned to 
settle on ice for 2-5 min. On each 50-µl tube, 250 µl of SOC medium was added and 
then tubes were left for 60 min at 37 °C, 225 rpm. In case of ligation mix, all cell 
suspension was plated on LB agar plates containing the required antibiotics and 
placed at 37 °C overnight or at RT over the weekend. In case of recombinant DNA 
amplification, 50 µl cell suspension was used for plating. 
2.2.1.3 Transformation of Electro-Competent E.coli 
For complicated or difficult cloning experiments electroporation of 
recombinant DNA was used instead of chemical competent cells, because 
electroporation has a higher transformation efficiency of up to 1 x 1010 colonies/µg 
DNA.    
On each tube of electro-competent E.coli XL 10 Gold cells (50 µl), 50 µl of 
10% glycerol and 5.0 µl recombinant DNA was added and tubes were left on ice. 
The transformation mix was later transferred to a sterile, pre-cooled 
electroporation cuvette and exposed to an electric field (1.3 V, 25 µF, 800 Ω) in the 
electroporation chamber. Time constants were monitored on the Gene Pulser 
device and were always between 6 and 8 milliseconds. Afterwards, cells were 
transferred to a 15 ml Falcon tube containing 950 µl SOC medium and then tubes 
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were left for 60 min at 37 °C, 225 rpm. In case of ligation mix, all cell suspension 
was plated on LB agar plates containing the required antibiotics and placed at 37 
°C overnight or at RT over the weekend. In case of recombinant DNA 
amplification, 50 µl cell suspension was used for plating. 
2.2.1.4 DNA Preparation Using Boiling Miniprep 
This procedure is used for quick yet dirty DNA preparations, to check the 
identity of clones before clean, large-scale DNA preps are undertaken.  It is a 
small-scale, fast and simple plasmid preparation method that works well with 
smaller plasmids (< 15 kb in size). It works with most strains of E.coli, except those 
strains that release large amounts of carbohydrates such as HB101. The procedure 
is also not recommended for endA+ strains because endonuclease A is not entirely 
inactivated during the boiling procedure. The resulting DNA can only be used for 
electrophoresis and restriction digestion.  
Bacterial cultures were grown overnight as described earlier in (2.2.1.1). 
Spin down 1.5 ml of the cell suspension for 30 sec at max speed, 4 °C. Supernatant 
was then removed leaving the pellet to dry as much as possible. The pellet was 
then resuspended in 200 µl STET by vortexing and 20 µl of 10 mg/ml fresh 
lysozyme was mixed gently before boiling the tube for 45 sec. Samples were 
centrifuged at max speed for 10 min, and clot formed was removed by toothpick 
before precipitating nucleic acids by adding 200 µl isopropanol.  Contents of the 
tube were then mixed, left for 5-10 min at RT then centrifuged at max speed for 10 
min. Supernatant was then removed with care and tubes drained on paper towel. 
Pellet was rinsed with 170 µl 70% ethanol, spun down for 2 min, left to dry 
(~30min) and afterwards resuspended in 20-50 µl TE. For restriction digestion, 2 µl 
DNA were used in a total of 20 µl digestion mix. After complete digestion, 
RNAseA (0.01 µg/ul) was added and missed with digestion mix a few sec before 
gel loading. 
 
2.2.1.5 DNA Preparation Using QIAprep® Spin Miniprep Kit 
The QIAprep® Spin Miniprep Kit is routinely used for molecular biology 
applications. It is a small-scale, fast and simple plasmid preparation method 
designed for the purification of up to 20 µg high-copy plasmid DNA. The resulting 
DNA is in sequencing quality and can be used for restriction analysis, cloning and 
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PCR. The kit is based on initial alkaline analysis of bacterial cells and the 
consequent absorption of the plasmid DNA onto a patent silica membrane in the 
presence of high-salt buffers. DNA can be eluted form the membrane with ddH2O 
or low-salt buffer.  
Plasmid DNA was prepared following the QIAprep® Miniprep Handbook. 
Bacterial cultures were grown overnight as described earlier in (2.2.1.1). Cell 
suspensions then centrifuged for 15 min at 6,800 x g, 4 °C. Plasmid DNA was 
finally eluted by adding 50 µl ddH2O to the centre of the spin column. Tubes were 
left aside for 5 min, then subsequently centrifuged for 1 min at 16,100 x g, RT. 
2.2.1.6 Endotoxin-Free Plasmid DNA Preparation Using NucleoBond® Xtra 
Maxi EF Kit 
Endotoxin-free plasmid DNA was prepared on a large-scale in order to be 
used for mammalian cells transfection. Endotoxins are amphiphilic 
lipopolysaccharides (LPS) that constitute the outer layer of a membrane enclosing 
the inner membrane of Gram-negative bacteria’s lipid bilayer membrane. During 
cell growth, endotoxins are released from cells in small amount. However, upon 
cell death and cell lysis occurring during plasmid DNA purification, large amounts 
of endotoxins are released. Free LPS induce inflammatory reactions of the 
mammalian immune system, and therefore their removal is essential to ensure 
high transfection rates and high viability of transfected cells. The amphiphilic 
nature of LPS makes it hard to separate them from DNA using common plasmid 
purification systems. NucleoBond® Xtra EF purification system is a fast and 
efficient way of reducing endotoxin level to <0.05 EU/ug plasmid DNA for up to 
1000 ug high-copy plasmid DNA. 
Endotoxin-free plasmid DNA was prepared following the NucleoBond® 
Xtra Maxi EF Kit user manual. Bacterial cultures (usually 300 ml) were inoculated 
with 4 ml pre-culture grown overnight as described earlier in (2.2.1.1). Cells were 
collected by centrifugation for 20 min at 4500 x g, 4 °C. Endotoxin-free plasmid 
DNA was finally eluted from NucleoBond® finalizers twice with the same 8000 µl 
TE-EF buffer. To increase DNA yield, the finalizer was washed once again with 200 
µl TE-EF buffer.  
2.2.1.7 Agarose Gel Electrophoresis of dsDNA 
Agarose gel electrophoresis is used to separation DNA fragments starting 
from ~50 by their size. Polymerized agarose forms pores with sizes dependent on 
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the  agarose concentration used. The distance between the DNA bands being 
separated will also depend on the percent of agarose in the gel. Because nucleic 
acids bears negative charges, DNA fragments migrate towards the anode upon 
applying an electric field. The smaller the fragment, the faster it migrates and the 
closer it is towards the anode (the lower end of the gel). 
For electrophoresis, agarose gels are prepared with 1x TAE buffer 
supplemented with RedSafe nucleic acid staining solution (5 µl/100 ml) or 
ethidium bromide (EtBr) (4 µl/100 ml). EtBr can visualize DNA owing to its ability 
to intercalate into double stranded DNA molecules and emitting orange light at 
590 nm when excited with UV light of wavelength 312 nm. RedSafe is a new and 
safer alternative to EtBr, that emits green fluorescence when bound to DNA. 
Fluorescence emission of RedSafe is centered at 537 nm and it has two fluorescence 
excitation maxima, one at 309 nm and the other at 419 nm. After leaving the gel 
aside to dry, it is transferred to an electrophoretic chamber and the chamber is 
filled up with 1x TAE buffer. Electrophoresis takes place at constant voltage of 
100V for small gels and 120 for bigger gels for about 20-30 min. For sample 
preparation, DNA samples to be resolved (volumes appropriate to comb size used 
for gel preparation) were mixed with DNA loading buffer (6 x). For proper size 
estimation of resolved DNA fragments, a DNA-marker is added in one lane of the 
gel. Agarose concentration in gels is chosen according to the size DNA molecule to 
be separated as follows: 
Agarose concentration in % (w/v) Size of DNA fragments 
2.5 <100bp 
2.0 0.1 - 1.0 kb 
1.8 0.2 – 2.0 kb 
1.5 0.3 – 3.0 kb 
1.2 0.5 – 5.0 kb 
1.0 0.5 – 7.0 kb 
0.8 0.8 – 12.0 kb 
0.5 1.0 30.0 kb 
2.2.1.8 Isolation of DNA Fragments from Agarose Gels 
The QIAquick® Gel Extraction Kit is a fast and simple procedure for gel 
extraction of up to 10 µg DNA (70 bp to 10 kb). The method is based on a simple 
and fast bind-wash-elute procedure, where DNA binds to silica-membrane-based 
columns in the presence of high salt concentrations. Contaminants are washed off 
through the column and DNA fragments can be eluted at the last step with 30-50 µl 
ddH2O. Before applying sample to the column, DNA fragments to be extracted are 
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excised from the agarose gel (up to 400 mg slices) and completely dissolved in the 
appropriate buffer at 50  °C for 10 min. Purification is then continued according to 
the manufacturer’s manual. 
2.2.1.9 Purification of DNA Fragments  
The QIAquick® PCR Purification Kit is a fast and simple procedure for 
DNA purification of up to 10 µg PCR or restriction digestion products (100 bp to 10 
kb). The method is based on a simple and fast bind-wash-elute procedure, where 
DNA binds to silica-membrane-based columns in the presence of high salt 
concentrations. Contaminants are washed off through the column and DNA 
fragments can be eluted at the last step with 30-50 µl ddH2O.  
2.2.1.10 Restriction Digestion 
Restriction endonucleases type II bind to and cleave DNA molecules at 
specific sites termed “restriction sites”, which are short sequences of bases specific 
to each enzyme.  s are washed off through the column and DNA fragments can be 
eluted at the last step with 30-50 µl ddH2O. Restriction enzymes catalyze the 
hydrolysis of 3’ -> 5’-phosphodiesterbonds in each of the DNA strands and 
thereby creates a double strand break. Restriction digestion was performed to 
create DNA fragments with sticky ends for eventual ligation and cloning of new 
recombinant DNA, for checking correct insertion of fragments and for linearization 
of vector DNA. 
For complete digestion of 1 µg DNA, appropriate reaction buffer (10x) was 
added at 1/10 of final reaction mix volume. Reaction mix was supplemented with 
BSA (10x) when indicated, excess of restriction enzyme units, ddH2O to final 
volume and incubated from 1 h up to O/N at 37 °C to achieve complete digestion.  
2.2.1.11 Dephosphorylation of 5’-Phosphorylated DNA fragments 
An essential step during cloning and before the ligation of two DNA 
fragments is the dephosphorylation of 5’-end of destination vector to prevent its 
self-ligation. Self-ligation of cut vector will prevent fragment insertion and produce 
empty vectors. For dephosphorylation, 0.5 U/µg DNA of alkaline phosphatase 
(calf intestinal phosphatase CIP) is added directly on the restriction mix (as long as 
restriction buffer was not NEB buffer 1) and reaction tubes are incubated for 1 h at 
37 °C. If the restriction reaction buffer was NEB buffer 1, it is advisable to purify 
the reaction and do the CIP treatment (0.5 U/µg DNA) in NEB reaction buffer 3 
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(10x), while adjusting final volume with ddH2O.  Once dephosphorylaiton reaction 
has reached completion (~1 h), DNA is purified using the QIAquick® PCR 
Purificaiton Kit. 
2.2.1.12 Ligation of DNA Fragments 
DNA ligation requires the action of DNA ligase, which catalyzes the 
formation of a 3’ -> 5’ phosphodiester bond between the free 5’-phosphate and the 
3’-hydroxyl groups of linearized DNA fragments, in the presence of ATP. The 
starting ligation conditions required 50 ng vector DNA and three-fold molar excess 
of insert DNA ends. The ratio of vector: insert was varied when optimization was 
needed. The required amount of insert for any given ligation reaction was 
calculated according to the following formula: 
Amount insert [in ng] = amount vector [in ng] x insert size [in bp]vector size [ in bp]  
In addition to vector DNA and the calculated amount of insert/inserts DNA, 
ligation mix is supplemented with 5 x T4 DNA ligase buffer, 1 U T4 ligase and final 
volume adjusted with ddH2O. Ligation reaction is then incubated O/N at 16 °C or 
for 1 h at RT before transformation into competent E.coli XL10 Gold. 
2.2.1.13 TOPO® - Blunt Cloning 
Zero Blunt® TOPO® PCR cloning is the easiest, fastest method for highly 
efficient insertion of blunt-end PCR products into a cloning vector. Blunt ligation 
kits include a linearized and topoisomerase I-activated (covalently bound to the 3’-
end of each DNA strand) pCR®Blunt II-TOPO® cloning vector, for fast ligations 
without ligase. The Zero Blunt® TOPO® PCR cloning kit was used when saving 
and storing hard-to-get PCR products was needed, as well as a template for some 
PCR products for sequential subcloning. 
Zero Blunt® TOPO® PCR cloning was carried out by gently mixing 4 µl 
blunt-end PCR product with 1 µl of the kit salt solution and 1 µl pCR®-Blunt 
TOPO® cloning vector. The mixture was then incubated for 5-15 min at RT and 
subsequently placed on ice. Finally 2 µl of the TOPO® cloning reaction were used 
for transformation into chemically competent E.coli One Shot® TOP10. 
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2.2.2 Polymerase Chain Reaction (PCR) 
2.2.2.1 Amplification of DNA fragments 
The polymerase chain reaction (PCR) is a method for amplifying a 
particular DNA sequence without the need for cloning into vectors. PCR utilizes 
heat-stable DNA polymerase, to synthesize DNA from single-stranded template. 
Double stranded DNA molecules are divided into single strands by heat 
denaturation. Two oligonucleotide primers direct the specificity of the reaction, 
through their hybridization to the DNA sequence of interest on opposite strands 
and acting as primers for the polymerase enzyme. Hybridization of primers to the 
single stranded DNA will occur at a temperature dependent on the primer of 
choice (usually 45-60 °C). Primers are added in excess to ensure that the formation 
of primer-template complexes takes precedence over renaturation of DNA single 
strands. Heat-stable DNA polymerase elongates bound primers as an exact copy of 
the original template, doubling the target DNA sequence for every cycle. Since 
each dsDNA molecule synthesized per cycle can serve a template for the following 
cycle, cycle repetitions leads to exponential amplification of the target sequence. 
The final specific product obtained after 25-35 cycles of denaturation, primer 
annealing and extension, can be visualized as a single band of DNA in agarose gels 
187. Special consideration for primer length, %GC in primer sequence, primer 
secondary structure and primer self-complementation was taken through checking 
designed primers in: 
(http://eu.idtdna.com/analyzer/applications/oligoanalyzer/). 
For standard PCR, AccuPrimeTM Pfx (a recombinant DNA polymerase 
isolated from Thermococcus species strain KOD), was used. AccuPrimeTM Pfx 
polymerase is a high fidelity enzyme owing to its proofreading 3’ -> 5’ exonuclease 
activity and a highly processive enzyme with a fast chain extension capability. It is 
provided in an inactive form, owing to its specific binding to an antibody that is 
inactive at ambient temperatures, but its activity is restored after the initial 
denaturation step at 94 °C in the PCR cycler. This “automatic hot start” increases 
sensitivity, specificity and yield of the PCR reaction, while allowing assembly of 
the reactants at RT. PCR reaction mixtures consisted of the equivalent of 20 ng 
template DNA, 5.0 µl 10x AccuPrimeTM Pfx reaction buffer, 1.5 µl of a 2 mM dNTP 
mix, 1.5 µl of 10mM forward primer, 1.5 µl of 10 mM reverse primer, 2.5 U 
AccuPrimeTM Pfx DNA polymerase and total volume adjusted to 50 µl with ddH2O. 
The PCR reaction started with 2 min of denaturation at 95 °C, followed by 25-35 
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cycles of amplification. Each cycle consisted of an initial denaturation at 95 °C for 
15 s, followed by primer annealing at the appropriate annealing temperature (-5°C 
from primer Tm) for 45 s, and ending with extension at 68°C for 1 min per kb. The 
last PCR cycle was followed by an additional extension step at 68°C for 15 min. 
Afterwards, the reaction was left in the PCR cycler to cool down at 4°C and PCR 
product was analyzed by agarose gel electrophoresis. PCR reaction was 
supplemented with 5% DMSO in case of GC-rich templates. Sometimes a two-step 
PCR reaction was essential to optimize primer annealing, in which case the initial 
phase was performed for 5 cycles, and the second phase for 25 cycles.  
2.2.2.2 In-Vitro Site-Directed Mutagenesis 
Stratagene’s QuickChange® In-Vitro site directed mutagenesis kit was used 
for introduced of site-specific mutation in virtually any double-stranded plasmid. 
Mutations included point mutations and/or exchange, deletion or insertion of a 
single or limited number of amino acids in a protein sequence of interest. The basic 
procedure utilizes double stranded DNA vector with an inserted protein of interest 
and two synthetic, complementary oligonucleotide primers bearing the desired 
mutation. The primers, each complementary to opposite strands of the vector 
DNA, are extended and amplified with PCR, thereby generating a mutated 
plasmid with staggered single strand nicks. Following PCR, the product is treated 
with type II endonuclease Dpn I. DNA isolated from most E.coli strains is dam-
methylated and is therefore susceptible to digestion by Dpn I. Digestion of the 
mutagenesis PCR product with DpnI would therefore ensure that clones formed 
after transforming PCR product into competent E.coli are specific to the mutated 
DNA. Transformed bacteria repairs the single strand nicks, producing a functional, 
mutated plasmid with efficiencies greater than 80%.  
The mutagenic oligonucleotide primers containing the desired mutation and 
binding to the same sequence on opposite DNA strands were designed according 
to some rules. The desired mutation was placed in the middle of the primer with 
15-25 nucleotides flanking the mutation on both sides. Primers always ended with 
one or more C- or G- bases and had a melting temperature (Tm) of ≥78 °C. Primer 
melting temperature was estimated according to the following equation: 
Tm = 81.5 + 0.41(%GC) – 675/N - %mismatch 
Where N is the primer length in bases. For mutagenesis it is important to keep 
primer concentration in excess, so 125 ng of each primer were used. To convert 
nanograms to picomoles, the following formula was used: 
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X pmol of oligo = (ng primer x 1000)/(330 x number of oligo bases) 
 
For mutagenesis PCR either Platinum® Pfx DNA polymerase, Pfu Ultra High-
Fidelity DNA polymerase or Phusion High-Fidelity DNA polymerase were used as 
suggested by the respective manufacturer. Mutaion PCR was performed as a 50 µl 
reaction including, 50 ng template DNA 5.0 µl respectice 10x reaction buffer, 2.0 µl 
of a 2mM dNTP mix, 1.0 µl mM MgSO4 (only for Platinum® Pfx DNA polymerase), 
125 ng of each primer, 2.5 U DNA polymerase, and ddH2O up to 50 µl. Cycling 
parameters consisted of an initial denaturation of template DNA and activation of 
DNA polymerase for 30 sec at 95 °C (depends on type of polymerase used). This 
was followed by 12-18 PCR amplification cycles of denaturation at the enzyme’s 
specific denaturation temperature for 30 sec, primer annealing at 55 °C for 45 sec 
and extesnsion at the appropriate temperature and rate. Final extension for 10 min 
was followed by cooling to 4 °C until gel check or DpnI treatment (1.0 µl of DpnI 
10U/ µl) for 60 min at 37 °C. Afterwards 2.5 µl of DpnI treated PCR product were 
transformed into chemically competent E.coli as described in (2.2.1.2).  
2.2.2.3 Directed Mutagenesis of dsDNA by PCR 
Mutagenesis PCR can be done with primers that bind to non-identical 
sequences inside the protein of interest. . The 3’-end of each primer encodes for 15-
25 amino base pairs of opposite strands of the original gene directly adjacent to the 
desired mutation. Their 5’-end contains one of two halves of the mutation to be 
introduced. As mentioned earlier the primers should end with one or more C- or 
G-bases. The mutagenesis oligonucleotide primers will bind to their 
complementary sequences on opposite strands, thereby amplifying the vector 
DNA with PCR. The resulting PCR produce is a linera, blunt end DNA molecule 
encoding for the entire plasmid with the mutations resting at its 3’- and 5’- ends. 
The length of the insertion was limited by the length of the oligonucleotide 
primers, than can be synthesized and used in PCR. For deletion of a specific 
nucleotide sequence, the primers used will not include the sequence to be deleted, 
and the amplified plasmid region will therefore exclude the respective amino acid 
sequence. Parental DNA is digested by DpnI, after which blunt ends were ligated 
and subsequently transformed into competent E.coli.  
For mutagenesis PCR either Platinum® Pfx DNA polymerase, Pfu Ultra 
High-Fidelity DNA polymerase or Phusion High-Fidelity DNA polymerase were 
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used as suggested by the respective manufacturer. Mutaion PCR was performed as 
a 50 µl reaction including, 50 ng template DNA 5.0 µl respectice 10x reaction buffer, 
2.0 µl of a 2mM dNTP mix, 1.0 µl mM MgSO4 (only for Platinum® Pfx DNA 
polymerase), 125 ng of each primer, 2.5 U DNA polymerase, and ddH2O up to 50 
µl. Cycling parameters consisted of an initial denaturation of template DNA and 
activation of DNA polymerase for 30 sec at 95 °C (depends on type of polymerase 
used). This was followed by 12-18 PCR amplification cycles of denaturation at the 
enzyme’s specific denaturation temperature for 30 sec, primer annealing at 55 °C 
for 45 sec and extesnsion at the appropriate temperature and rate. Final extension 
for 10 min was followed by cooling to 4 °C until gel check or DpnI treatment (1.0 µl 
of DpnI 10U/ µl) for 60 min at 37 °C. Afterwards 2.5 µl of DpnI treated PCR product 
were transformed into chemically competent E.coli as described in (2.2.1.2).  
2.2.2.4 Two-Step Fusion PCR 
When the mutant DNA molecule to be created was too long to be 
synthesized synthetically on oligonucleotide primer, then two-step fusion PCR 
reaction was used. The two fragments to be linker were amplified in separate PCR 
reactions. Both products form the initial PCR reactions were fused in a second 
standard PCR, by using amplification of both fragments in the same reaction using 
the 5’- and 3’- end primers for the N- and C- terminal parts of the final fusion 
protein, respectively. An overlapping sequence in both DNA fragments allows the 
annealing of the two separate fragments. For the second fusion PCR, fragments 
encoding C- and N-terminal parts of the final DNA were used at equimolar 
concentrations. After the amplification of the whole construct, fused DNA was 
cloned into pCR®-Blunt II-TOPO® vector for storage, sequencing and identity 
check with restriction digestion.  
2.2.2.5 DNA sequencing 
Sequencing of dsDNA was done following the dideoxy chain terminating 
method 188. This is based on using fluorescently labeled 2’,3’-dideoxy-nucleotides 
(ddNTPs) in addition to 2’-deoxynucleotides (dNTPs), that cannot form new 
phosphodiester-bonds due to the missing 3’-OH group. This leads to the 
termination of the synthesized DNA strand after insertion of ddNTP. The last 
incorporated nucleotide, which is the fluorescent ddNTP, can be detected by 
capillary gel electrophoresis. This was subsequently done in-house at our Zentrale 
Einrichtung Biotechnolgie. 
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Sequencing PCR was performed using the BigDye® Terminator v3.1 Cycle 
Sequencing Kit. In a total of 20 µl reaction adjusted with ddH2O, 150-300 ng 
plasmid DNA, 4.0 µl ready reaction premix, 2.0 µl BigDye® sequencing buffer and 
0.35 µl primer (100 pmol/ µl) were added. PCR protocol started with an initial 
denaturation cycle at 96 °C for 1 min, followed by 25 cycles of denaturation (96 °C 
for 10 sec), annealing (50 °C for 5 sec) and extension (60 °C for 4 min). Excess 
ddNTPs were removed from PCR product using the DyeEx® 2.0 Spin kit according 
to the manufacturer’s manual. Cleaned product was transferred to 0.5 ml, dried in 
a vacuum centrifuge and sent for analysis.  
2.2.3 Biochemistry 
2.2.3.1 Preparation of Whole Cell Lysates 
  Whole cell lysates for protein analysis in western blots were prepared from 
mammalian cells cultured in 35-mm and/or 100-mm Easy Grip TM tissue culture 
dishes. Cells were washed once with ice-cold PBS and then ice-cold RIPA buffer 
supplemented with 1 tablet Complete Mini EDTA-free protease inhibitor and 100 
µl phosphatase inhibitor cocktail 1 and 2 was added. Cells with lysis buffer were 
left for 15 min, then cells were scrapped with a plastic cell-scarper, and contents of 
each dish/well were transferred to pre-cooled 1.5 ml Eppendorf tubes. Samples 
were sonicated for 12 sec, cycle 3, 30% and then transferred to a bench-top 
centrifuge for 15 min, 13,000 rpm at 4 °C. Supernatant was then transferred to fresh 
pre-cooled 1.5 ml Eppendorf tubes and at this stage samples could be snap-frozen 
in liquid nitrogen if experiment was to be carried out on a different day and stored 
at -80 °C. All steps were performed on ice to avoid protein degradation.  
2.2.3.2 Determination of Protein Concentration with Bradford Assay 
For determination of protein concentrations in cell extracts the Bradford 
assay was used. Bradford assay is a colorimetric protein determination assay, 
based on the absorbance shift occurring to the Cossmassie Brilliant Blue G-250 dye 
in the presence of proteins. The binding of dye to proteins stabilizes the blue form 
of Cosomassie dye, therefore the amount of blue complex present in solution is a 
measure for protein concentration and can be estimated by reading the absorbance 
at 595 nm. The cationic unbound form of the dye is usually red, and it shifts to the 
anionic blue form when bound to proteins, seen as an increase in absorbance at 595 
nm. Bradford assay is sensitive to high levels of detergents; therefore a control 
reading is always measured for lysis buffer alone.  
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The assay was performed in UV cuvettes, one cuvette per sample. Protein 
standards were prepared by diluting a BSA standard 1 mg/ml (16 µl) in ddH2O 
and making a serial dilution out of this 1-16 µg/ µl. Each protein standard (500 µl) 
was added in a separate cuvette and mixed with 500 µl Bradford reagent. For each 
sample, 1 µl were added to 500 µl ddH2O and mixed with 500 µl Bradford reagent. 
Control sample consisted of 1 µl lysis buffer, 500 µl ddH2O mixed with 500 µl 
Bradford reagent. Absorbance values obtained at 595 nm with the 
spectrophotometer were plotted against standard protein concentration. Protein 
concentrations of the various samples were then determined by mapping their 
absorbance values at 595 nm to the standard curve.  
2.2.3.3 Denaturing Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE is used to separate proteins according to their size via an electric 
current. SDS is an anionic detergent that can bind to proteins in an amount 
proportional to their size (~ one molecule SDS per two amino acids).  SDS breaks 
hydrogen bonds and unfolds proteins creating complexes that display a similar 
charge/size ration. SDS-protein complexes carry a negative charge and therefore 
migrate towards the anode when subjected to an electric current. When an electric 
current is applied to a vertical polyacrylamide gel, smaller proteins will migrate 
faster and the distance they migrate will be proportional to the pore size formed by 
the polymerized acrylamide. The concentration of acrylamide used was 8, 10 or 
rarely 12%, depending on the molecular weight of the protein of interest. Two gels 
were prepared in sequential order, separating and stacking and both poured into 
1.0 mm western blot cassette according to the following protocol: 
 
 8 % 10 % 12 %  
Acrylamide 30% 1.7 ml Stacking gel 
1.0M Tris (pH 6.8) 1.25 ml 
10 % SDS (w/v) 100 µl 
ddH2O 6.8 ml 
10 % APS (w/v) 100 µl 
TEMED 10 µl 
Acrylamide 30% 4.0 ml 5.0 ml 6.0 ml Separating gel 
1.5M Tris (pH 8.8) 3.8 ml 3.8 ml 3.8 ml 
10 % SDS (w/v) 150 µl 150 µl 150 µl 
ddH2O 7.0 ml 5.9 ml 5.0 ml 
10 % APS (w/v) 150 µl 150 µl 150 µl 
TEMED 9 µl 6 µl 6 µl 
Total 15 ml 
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Separating gels were poured first, covered with ddH2O and left to dry for 
~15 min. After drying, water overload was removed and stacking gels poured on 
top. 10- or 15-well combs were inserted into the stacking gel immediately after 
pouring and allowed to dry to form sample pockets. Prepared gels can be stored at 
4 °C for a maximum of 1 week, if properly humidified with ddH2O and protected 
from drying by wrapping in a plastic bag or aluminum foil.  
Whole cell lysates or IP samples (20 µl) were mixed with 5 µl 5x SDS sample 
buffer and incubated for 5 min at 95 °C before loading, to heat denature proteins 
and allow their reduction by 2-mercapto-ethanol in the sample buffer. Samples 
were then centrifuged for 1 min used for loading. For electrophoresis, combs were 
removed from gels, sample pockets cleaned with ddH2O and gels were inserted 
into (BioRad…), gel chambers. Gel chambers were then assembled and filled with 
1x running buffer and samples loaded. For size determination of separated 
proteins, 4 µl () standard containing different bands of known molecular weight 
were loaded in one well. Empty pockets were loaded with sample buffer and 
electrophoresis was performed with constant voltage of 80 V until samples leave 
separating gel, followed by an increase to 150 V for roughly 90 min. 
2.2.3.4 Western Blot 
One form of immuno-blotting is western blotting.  In this technique proteins 
that were separated electrophoretically are transferred to a nitrocellulose or PVDF 
membrane to enable immunological protein detection with antibodies.  
After electrophoresis blots were assembled in () semidry bot modules 
according to the manufacturer’s manual. PVDF membranes were activated for 5 
min in methanol, then left to equilibrate in 1 x transfer buffer together with the gel 
and two pieces of (whatmann) filter paper. The blot sandwich was assembled in 
the following sequence from bottom-up: filter paper, PVDF membrane, gel and the 
second filter paper. For a mini-gel semidry transfer was done at 15 V for 25 min. 
Following semi-dry transfer, PVDF membrane was transferred to Li-Cor® 
incubation box for the remaining binding sites of the membrane blocked with 
Odyssey infrared imaging system blocking buffer (Li-Cor® Biosciences) for 1 h at 
RT on a shaker. Membranes were then incubated with primary antibodies diluted 
in 1 ml 0.1% TBST solution. PVDF membrane was sealed in a plastic bag after 
discarding air bubbles and incubated overnight at 4 °C. Next day, blots were 
transferred again to Li-Cor® incubation boxes, washed 3 times, 5 min each with 
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0.1% TBST. Blots were then incubated with the appropriate secondary antibodies 
(diluted 1:15,000) diluted in 10 ml TBS for 20 min, RT. Finally, blots were washed 3 
times, 10 min each with 0.1% TBST solution and detected with Odyssey Imaging 
System.  
2.2.3.5 Immunoprecipitation 
Cell lysis and protein quantification were performed as described in 2.2.4.1 
and 2.2.4.2. For immunoprecipitation, Protein-G Sepharose® (PG-Seph) beads were 
first pre-cleared. Purification of PG-Seph beads involved washing 5-6 times with 
ice cold PBS (~1 mL) and centrifugation at 850 g for 2 min at 4 °C after each wash. 
For lysate preclear, 25 µl of PG-Seph slurry were added to 600 µl lysate for 2 h at 4 
°C on the wheel-over-wheel-shaker. Lysates were cleared by centrifugation at 850 g 
for 2 min at 4 °C followed by transferal into new tubes and addition of anti-GFP 
antibody (living colors rabbit, #632592 at 1:200) overnight at 4 °C on the wheel-
over-wheel-shaker. Next day 40 µl of PG-Seph slurry were added to the 600 µl 
lysate for 2 h at 4 °C on the wheel-over-wheel-shaker. IP lysates were then washed 
4-5 times with lyssis buffer. The last wash was removed with a syringe and beads 
were resuspended in 20 µl lysis buffer and boiled at 95 °C for 5 min after adding 5 
µl 6X Lammeli buffer. Western blotting was undertaken according to section 
2.2.4.2. 
2.2.3.6 Immunofluorescence 
Cells were fixed with 4% paraformaldehyde in PBS for 10 min at RT, rinsed 
three times (3X) with TBS. For phosphorylation labeling of Eph receptors, cells 
were permeabilized for 5 min with 0.1 % Triton X-100 in PBS at RT, then rinsed 
again 3X with TBS at RT. Blocking was performed for 30 min at RT or overnight at 
4 °C with 4 % goat serum (v/v) (varies according to secondary antibody), 2 % BSA 
(w/v) in PBS. Primary antibodies were applied for 60 min at RT. After washing 
with PBS secondary antibodies diluted 1:200 in blocking solution were applied for 
1 hr at RT. Cells were wash 3X with PBS at RT and imaged fin PBS with the 
appropriate microscope.  
2.2.3.7 In-Vitro kinase assays 
In-vitro auto- and transphosphorylation assays were preformed as described 
earlier 79,189. COS-7 cells were transected with cDNA-encoding the construct in 
question. Cells were lysed 18-20 hr later as described in 2.2.4.1 and constructs were 
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immunoprecipitated according to section 2.2.4.5. Following IP, beads were washed 
2 times in lysis buffer and 2X in HNTG buffer. Prior to auto-phosphorylation 
kinase assay, samples were dephosphorylated using calf intestinal phosphatase 
(CIP, #M0290, 0.5 U/µg protein) for 60 min at RT.  IP lysates were then washed 2X 
with KRB buffer (1X). Last wash was removed completely with a syringe and 
beads were resuspended in 50 µl KRB. For an experiment with 5 time points, sample 
was prepared as follows: 50 µl IP beads, 20 µl 5X KRB, 10 µl 1 mM ATP (stock at 10 
mM), adjust to 100 µl with dd H2O. IP mix was left at RT until chosen time points, at 
which 20 µl were transferred to a new tube and 5 µl 6X Lammeli sample buffer were added, 
boiled with sample at 95 °C for 5 min to terminate reaction. For trans-phosphorylation 
kinase assay, acid denatured enolase was used as an external substrate. The 
equivalent of 100 µg enolase (from rabbit muscle, Sigma-Aldrich®, #E0379) was 
centrifuged at max speed for 5 min at 4 °C. Supernatant was discarded and 10 µl of 
(1 mM DTT/50 mm HEPES), pH 7.0 was added to the pellet and mixed thoroughly. This 
mixture was then incubated for 60 min on ice followed by the addition of 10 µl glycerol. 
Tubes were left on ice if the assay was to be done on the same day (otherwise stored at -80 
°C). Immediately prior to assay, 20 µl of 100 mM acetid acid were added to the enolase 
solution and mixed thoroughly. Mixture was then incubated for 5 min at a 30 °C water 
bath, then kept on ice until required (maximum 1 hour). IP lysates to be assayed were 
washed 2X with KRB buffer (1X). Last wash was removed completely with a 
syringe and beads were resuspended in 50 µl KRB. For an experiment with 5 time 
points, sample was prepared as follows: 20 µl 5X KRB, 10 µl 1 mM ATP (stock at 10 mM), 
acid denatured enolase (5 µg/reaction) and 10 µl dd H2O. Tubes were warmed for 5 min at 
30 °C then 50 µl IP lysates were added to make the final volume 100 µl. IP mix was left at 
RT until chosen time points, at which 20 µl were transferred to a new tube and 5 µl 6X 
Lammeli sample buffer were added, boiled with sample at 95 °C for 5 min to terminate 
reaction. 
2.2.4 Mammalian Cell Culture 
2.2.4.1 Subculture of Mammalian Cells 
Cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine and 1% non-
essential amino acids (NEAA), grown at 37 °C in a 90% humidified incubator with 
5% CO2. For starving, phenolred free DMEM with 0.5% FBS wss used.  
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Exponentially growing cells become confluent and reach a density where all 
available substrate of the culture dish is occupied. When this happens, cell growth 
is usually inhibited by contact inhibition and cells need to be subcultured to new 
dishes with much less density to allow for further cell growth. When cultured cells 
reached 80-90% confluency, cells were washed once with PBS, covered with 1 ml 
trypsin for a few seconds, then trypsin was removed and dishes returned for 5 min 
at 37 °C (MDCK cells required longer time ~ 20 min). Detached cells were washed 
with 10 ml complete growth media to inactivate any remaining trypsin and cell 
suspension transferred to a falcon tube and pipetted gently up and down to 
separate cells to a single cell suspension. If cell number and/or viability were to be 
determined, 50 µl of cell suspension in a total of 500 µl media were used in Vi-
CellTM XR cell viability analyzer and the desired number of cells required for 
seeding into different cell culture dishes was calculated. For maintenance of cells 
lines, cells were subcultured at a ratio of 1:10 into new culture dishes. 
2.2.4.2 Cryo-Preservation and Long-Term Storage of Cell Lines 
For long-term storage, cells were cryo-preserved by freezing at 
temperatures below -80 °C. For maximal cell viability during the process of cryo-
preservation, the use of cryo-preservative such as DMSO is essential since 
intracellular ice crystal formation and regional formation of high-concentration 
solutes can reduce cell viability drastically.  
Sub-confluent 10cm cell-culture dishes and/or T75 flasks were split as 
described above. Cells were counted and diluted to a concentration of 1.5- 2 x 106 
cells/ml in cryo-medium (90% FBS, 10% DMSO). Cells were aliquoted into cryo-
vials and transferred to a NALGENE® Cryo 1 °C freezing box. NALGENE Cryo 1 
°C boxes are filled with isopropanol and allow for controlled freezing rates of 1 °C 
per minute to avoid freezing associated cell damage. Cryo-boxes were then 
transferred to the -80 °C freezer overnight and cryo-vials were moved to the -150 
°C freezer for long-term storage.  
When frozen vials were needed, cell thawing was done as quickly as 
possible to avoid the toxic effect of DMSO on cells. Cryo-vials were thawed out in 
the 37 °C water bath and cell suspension was quickly transferred to prepared 
dishes with 10 ml complete growth media. Media was exchanged next day from 
thawed out cells with fresh 10 ml complete growth media with or without G418 
depending on type of thawed out cells.  
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2.2.4.3 Transfection with DNA 
Transfection is defined as the deliberate introduction of genetic material or 
nucleic acids into eukaryotic cells by non-viral means. Transfection can be done by 
various methods and it typically involves opening transient pores in the cell 
membrane to allow the uptake of genetic material. Transfection can be carried out 
by classical calciumphosphate co-precipitation, electroporation or by lipofection. In 
this study, all cells were transfected with plasmid DNA via lipofection, the mixing 
of a cationic lipid with the DNA to produce liposomes, which fuse with the cell 
membrane and deposit their content inside cells. The transfection reagent used was 
either Fugene® 6 or Lipofectamine TM 2000 and transfection proceeded according to 
manufacturer’s manual guidelines. Cells were either plated in 60-mm or 100-mm 
Easy GripTM tissue culture dishes, 35-mm MatTek petri dishes or 4-well LabTek® 
chambers. Cells were plated one day prior to transfection to reach 50-80% 
confluency in case of Fugene® 6 or 90% confluency in case of using Lipofectamine 
TM 2000. On the day of transfection, Fugene® 6: DNA ratios used were always 3:1 
and Lippofectamine TM 2000: DNA ratios were always 2.5:1.  
For Fugene® 6 transfection of cells in 35-mm dishes, 3.0 µl Fugene® 6 in a 
total of 100 µl serum free media was incubated for 5 min at RT. Afterwards, 1 µg 
plasmid DNA was added and mixed properly either by pipetting up and down 
several times, or by vortexing. Transfection mix was left for 15 min at RT before 
adding to cells. Fugene® 6–DNA complexes were finally added to cells drop-wise 
and culture vessels swirled gently to ensure equal distribution of transfection 
complex over the entire surface. Cells were incubated at 37 °C in a 90% humidified 
incubator with 5% CO2 until next day. For transfection of cells in other formats, 
amounts of Fugene® 6, DNA and serum free media were adjusted according to the 
following table: 
Culture vessel Surface 
area 
No. Cells Starting amount of 
Fugeme6 
DNA Medium 
96-well 
16-well Labtek 
0.3 cm2 
0.4 cm2 
0.6-1.8 x 104 0.15 µl 0.05 µg 24.85 µl 
48-well 
8-well Labtek 
1 cm2 
0.8 cm2 
1.2-3.6 x 104 0.3 µl 0.10 µg 24.7 µl 
24-well 
4-well Labtek 
2 cm2 
1.8 cm2 
2.5-7.5 x 104 0.6 µl 0.20 µg 24.4 µl 
12-well 
2-well Labtek 
4 cm2 
 
0.5-1.5 x 105 1.5 µl 0.50 µg 43.5 µl 
6-well 
35 mm dishes 
10 cm2 
9.6 cm2 
1-3 x 105 3 µl 1 µg 97 µl 
60-mm 20 cm2 1.5 - 6 x 105 6 µl 2 µg 94 µl 
10-cm 60 cm2 0.3 –1.2 x 106 18 µl 6 µg 182 µl 
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For Lipofectamine TM 2000 transfection of cells in 35-mm dishes, 10 µl 
Lipofectamine TM 2000 in a total of 250 µl serum free media was incubated for 5 min 
at RT. In another tube, dilute 4 µg plasmid DNA in 250 µl serum free media an 
leave aside till the end of the 5 min. Afterwards diluted DNA was added to diluted 
transfection reagent and mixed properly either by pipetting up and down several 
times, or by vortexing. Transfection mix was left for 20 min at RT before adding to 
cells. Lipofectamine TM 2000–DNA complexes were finally added to cells drop-wise 
and culture vessels swirled gently to ensure equal distribution of transfection 
complex over the entire surface. Cells were incubated at 37 °C in a 90% humidified 
incubator with 5% CO2 for 4-6 hours, then media exchanged with fresh complete 
growth media to minimize cell toxicity. For transfection of cells in other formats, 
amounts of Lipofectamine TM 2000, DNA and serum free media were adjusted 
according to the following table: 
Culture vessel Surface 
area 
No. Cells Starting amount of 
Lipofectamine 
DNA Medium 
96-well 
16-well Labtek 
0.3 cm2 
0.4 cm2 
1-5 x 104 0.5 µl 0.2 µg 2 x 25 µl 
48-well 
8-well Labtek 
1 cm2 
0.8 cm2 
0.25-1 x 105 1.0 µl 0.4 µg 2 x 50 µl 
24-well 
4-well Labtek 
2 cm2 
1.8 cm2 
0.5-2 x 105 2.0 µl 0.8 µg 2 x 50 µl 
12-well 
2-well Labtek 
4 cm2 
 
1-4 x 105 4.0 µl 1.6 µg 2 x 100 µl 
6-well 
35 mm dishes 
10 cm2 
9.6 cm2 
0.25-1 x 106 10 µl 4.0 µg 2 x 250  µl 
60-mm 20 cm2 0.5 - 2 x 106 20 µl 8.0 µg 2 x 500 µl 
10-cm 60 cm2 1.5 –6 x 106 60 µl 24 µg 2 x 1.5 ml 
 
2.2.5 Microscopy 
2.2.5.1 Laser Scanning Confocal Microscopy (LSCM) 
Confocal images of live and fixed cells were obtained with an Olympus FluoView 
FV1000 confocal laser-scanning microscope. TagBFP was excited with 405 nm, 
mTFP with 458 nm and EGFP and mCitrine with the 488 line of a multiline Argon 
laser. mCherry was excited with the 561 nm line of a DPSS laser. Excitation light 
was focused into the sample by a 60x/1.2 NA oil objective or a 40x/0.9 NA air 
objective using either the DM405/488/561/633 or the DM458/515 dichroic mirror. 
Detection of fluorescence was done by an acousto-optic tunable filter (AOTF) and 
SIM scanner. Blue fluorescence (Alexa 405 or TagBFP) was detected in a channel 
with bandwidth 425-478 nm and through a SDM490 emission beam splitter. Green 
and Yellow FPs were collected between 498-551 nm and through a SDM 510 
	   61	  
emission beam splitter or SDM 560 if sequential imaging with the 561 nm laser was 
used. mCherry fluorescence was detected by collecting photons within the range of 
575-675 nm. mCitrine and mCherry were separated by a SDM560 emission beam 
splitter (Fig. 2.1 a) while mTFP and mCitrine were separated by a SDM510 beam 
splitter (Fig. 2.1 b). Live cell imaging was performed in an incubation chamber 
adjusted to 37 °C, while fixed cells experiments were performed at RT (~ 25 °C). 
 
Fig 2.1 Instrumental alignment for LSCM 
Lasers (vertical black lines) and AOTF adjustments (colored, transparent rectangles) used 
for laser scanning confocal microscopy. (a) Excitation and emission spectra of mCitrine 
and mCherry are displayed with the corresponding excitation lines (488nm for mCitrine 
and 561nm for mCherry) and collection channel bandwidth (transparent green for 
mCitrine and transparent orange for mCherry). (b) Excitation and emission spectra of 
mTFP and mCitrine are displayed with the corresponding excitation lines (458nm for 
mTFP and 515nm for mCitrine) and collection channel bandwidth (transparent green for 
mCitrine and transparent blue for mTFP). Spectra from: (http://hernan.client.mpi-
dortmund.mpg.de:8080/) 
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2.2.5.2 Fluorescence Lifetime Imaging Microscopy (FLIM) 
FLIM measurements were made in a commercial setup composed of an 
Olympus FluoView FV1000 laser scanning confocal microscope equipped with an 
external unit, PicoQuant’s compact FLIM and FCS upgrade kit for laser scanning 
microscopes. Pulsed lasers are coupled to the FV1000 through an independent port 
and are controlled by a driver that can be digitally modulated (PicoHarp 300). 
Detection of photons can be directed to one or a combination of two single photon 
avalanche diodes (SPAD), which then transfer their signal to the PicoHarp 300 data 
acquisition unit. FLIM imaging was mostly done using the 60x/1.35 NA oil 
objective by Olympus. All pulsed lasers (440, 470 and 510 nm) were were 
controlled with the Sepia II software (PicoQuant GmbH) (pulse repetition every 25 
ns) and detected via the first APD. Image integration time was ~ 3 min. with an 
average total photon count of 3.0-5.0 x 106 per image. For mTFP, the 440 nm pulsed 
laser line (at 38% power) and the DM440/470 dichroic mirror were used. mTFP 
emission was detected by APDs equipped with 480/20 bandpass filter (Fig2.2 a). 
For mCitrine, the 470 nm pulsed laser line (at 37%) or the 510 nm pulsed laser (at 
64%) and the DM440/470 or the DM458/515 dichroic mirror were used. mCitrine 
fluorescence was detected by APDs equipped with 525/15 bandpass filter (Fig2.2 
b) or with the 537/26 bandpass filter (Fig2.2 c). 
 
 
Fig 2.2 Instrumental alignment for FLIM. 
Lasers (vertical black lines) and filters (colored, transparent rectangles) for FLIM. (a) 
Excitation and emission spectra of mTFP and mCitrine are displayed with the 
corresponding pulsed laser used when mTFP is the donor (440nm pulsed laser) and 
detection channel bandwidth (transparent blue for mTFP). (b) Excitation and emission 
spectra of mCitrine and mCherry are displayed with the corresponding pulsed laser used 
when mCitrine is the donor (470nm for mCitrine) and detection channel bandwidth 
(transparent green for mCitrine). (c) Excitation and emission spectra of mCitrine and 
mCherry are displayed with the another option for pulsed laser used when mCitrine is the 
donor (510nm for mCitrine) and detection channel bandwidth (transparent green for 
mCitrine). Spectra from (http://hernan.client.mpi-dortmund.mpg.de:8080/). 
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2.2.5.3 Fluorescence Loss After Photoactivation (FLAP) 
FLAP experiments were carried out at 37 °C on a Leica SP5 confocal 
microscope in imaging medium as described earlier 190. Transiently transfected 15-
24 hrs post-transfection post transfection, cells were allowed to equilibrate in the 
incubation chamber on the microscope and imaged with laser setting adjusted to 
minimize photobleaching (typically 488 and 561 lasers used at 10%). The 
fluorescence was collected via a 63x/1.4 NA oil objective, with a custom routine 
that followed through the three stps of FRAP/FLAP analysis: (1) Pre-bleach 
imaging (3 images with 488 and 561 lasers only). (2) Bleaching/Photoactivation (2 
times with the 405 laser only at 80%) in a pre-defined region of interest (ROI). (3) 
Post-bleach imaging (20 frames at 40 sec interval using the 488 and 561 lasers only). 
At the end of the experiment an image of Rab11-BFP was acquired with 5% 405-
laser power to identify the recycling compartment in a given experiment.  
After standard image processing, mean intensities of photoactivatable 
EphA2-GFP (EphA2-paGFP) in the photoactivated ROI yielded fluorescence loss 
curves, which were normalized to EphA2-cherry to account for changes in the 
structure and intensity in the ROI resulting from the dynamic nature of live cells. 
Another ROI processed and normalized in the same manner was chosen at the cell 
periphery to investigate vesicular transport form the recycling endosome to the 
plasma membrane. For measuring half time of plasma membrane gain or recycling 
endosome loss of EphA2 fluorescence in the selected ROIs, normalized 
fluorescence decay cures were averaged and average curve was then fitted to a 
single exponential function in Igor Pro. 
 ! = !! + !  !"#(−!/!) 
Where (I) is the intensity, (!)   exponential constant, (t) is time, (! ) is the 
exponential time-constant.  
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2.2.5.4 Image Manipulation and FLIM Analysis 
Quantifications done on images required their initial conversion to 32-bit in 
ImageJ, followed by background correction. When required, brightness and 
contrast of images were changed to improve signal-to-noise ratio. FLIM data were 
analyzed with precisionFLIM (pFLIM) 183 analysis code. Precision FLIM is an 
accurate, efficient code for time-domain FLIM that considers all significant 
instrumental artifacts. The analysis code uses a parameterized model to account for 
the instrument response function (IRF) (Fig.2.4). Fitting of full decay curves is done 
by conventional !2 minimization and single pixel fitting of lifetime populations is 
done with “maximum fidelity”. When fluorophores followed a single-exponential 
decay, as in the case of mCitrine donor only images, a mono-exponential decay 
model according to equation (9) was used. When more than one lifetime was to be 
expected in the sample, a double-exponential model was used for fitting according 
to the following equation 172: ! ! = !!  !"#(−!/!!) + !!  !"#(−!/!!) + !    (12) 
where B is the background, !! and !! are amplitudes, !!and !!are the fluorescent 
lifetimes. Lifetime maps analyzed by the code in IgorPro were presented as 
pseudo-colored lifetime maps. Lifetime ranges displayed were adjusted manually 
in IgorPro.    
 
Fig 2.4 Outline of precision FLIM analysis. !2 fit of a parameterized model decay function (red) to the full decay histogram (black). 
The concluded instrument response function (IRF) obtained from the fit is displayed above 
the TCSPC with the two IRF fitting components, a Gaussian and an exponential 
component. Normalized fit residuals are displayed below the TCSPC. Inset shows a 
representative fit of IRF model as compared to an IRF estimate obtained from the scattered 
excitation light of 470 nm pulsed laser at 36% power 183.  
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2.2.5.5 Fluorescence Anisotropy Microscopy  
FRET (Förster resonance energy transfer) between identical fluorophores 
(homo-FRET) can be monitored by fluorescence anisotropy 191. Fluorescence 
anisotropy was used to study protein structure 192, protein oligomerization 193,194, 
the organization of GPI-anchored proteins in submicrodomains at the cell surface 
195 and the spatial distribution of monomeric versus dimeric proteins in living cells 
196. For each measurement two images were taken, an image with the emission 
polarizer oriented parallel to the excitation polarizer (!∥) and an image with the 
emission polarizer oriented perpendicular to the excitation polarizer (!!). Steady 
state anisotropy was calculated in each pixel i by: 
 !! = !!  !∥!!  !!!!!  !∥!  !  !!!!         (13) 
The G-factors !!  were determined by acquiring the ratio of the intensities at 
perpendicular and parallel orientations for a fluorophore in solution (fluorescein) 
with a steady-state anisotropy that was close to zero: 
 ! = !!!  !∥!            (14) 
For reference measurement, fluorescein solution in water was placed in a 
glass bottomed tissue culture dish (MaTek, Ashland, MA, USA) and imaged as 
mentioned before. Average values of G images measured for 20x air objective was 
used for equation (13). As mentioned in the introduction, excitation with polarized 
light results in photoselective excitation of a subset of fluorophores (FPs) whose 
absorption transition dipole is parallel to the electric vector of the excitation light. 
The lifetime of the fluorophores we use (EGFP and Citrine) in anisotropy 
experiments is much shorter than rotational diffusion time scale. Therefore, förster 
resonance energy transfer (homo-FRET) becomes the dominating factor in the 
depolarization of emitted light 172.  
Steady-state anisotropy of EGFP and Citrine was measured using Olympus 
MT-20 150W mercury arc burner as described before by Squire et al. 197using an 
Olympus IX81 inverted microscope (Olympus, Hamburg, Germany). Three high 
extinction linear dichroic polarizers (Meadowlark optics, Frederick, Colorado) 
were used for anisotropy measurements; one was placed in the illumination path 
of the microscope, and the other two, parallel and perpendicular oriented 
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polarizers with respect to the polarization of the excitation light, placed in the 
motorized filter wheel.  The filter block was set up with a bandpass (BP) 460-480 
HQ filter for excitation light, a 485 dichroic and a 495-540 HQ filter for emission 
light. Fluorescence was collected using a 20x 0.7 N/A air objective and images of 
perpendicular and parallel emission light were acquired sequentially with an Orca 
CCD camera (Hamamatsu Photonics, Hamamatsu City, Japan). The CellR software 
was used for data acquisition and instrumental control. Images of the same cells 
were taken prior to and 20 min post dimerization, stimulation or 1 hr post-drug 
treatment. The acquired (!∥) and (!!) images were slightly shifted with respect to 
each other, therefore they were manually aligned and vertical and horizontal shift 
values were used for all experiments done with the same settings. (!!) and (!∥) 
images were background corrected before calculating steady-state anisotropy 197. 
2.2.5.6 Quantification of cluster sizes for Anisotropy Analysis 
Image processing in ImageJ was applied to compute anisotropy from the 
periphery of the cell. Two binary masks were created, one covered the whole area 
of a given cell and the other covered an eroded version of the cell same cell (10-15 
pixels removed from the 8-bit binary mask).  Subtraction of the second mask from 
the first created a new binary mask that represents the periphery of the cell that 
was multiplied with the original anisotropy image. The distribution of anisotropy 
values for a given FKBP construct as obtained from multiple samples incubated 
with the AP20187 dimerizer was then plotted (histograms represents binned 
images, bins size =50). The average molecular brightness of each state was used as 
a weighing factor in computing the relative contribution of each association state to 
the anisotropy. This intensity-weighted contribution of each association state was 
divided by their summed anisotropy, to give the cumulative relative contribution 
of each association state to a given anisotropy value. 
2.2.5.7 Total Internal Reflection Fluorescence (TIRF) microscopy 
Total internal reflection fluorescence (TIRF) microscopy (TIRFM) is based on 
the principle that when excitation light is reflected in a transparent solid at its 
boundary with liquid, then an evanescent wave with the same frequency as the 
excitation wave is produced at the solid-liquid interface. The intensity of this 
evanescent wave decays exponentially with distance from the solid surface (~100 
nm), allowing for excitation of fluorescent molecules only within a few hundred 
nanometers of the solid surface “optical section”. This thin axial region can be used 
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for the visualization of the basal plasma membrane (~7.5 nm thick) with a small 
section of the cytoplasm adjacent to the membrane 198.  
TIRFM was performed using an Olympus IX81 inverted microscope with a 
60x N/A 1.8 TIRM APOCHROMAT oil objective. The microscope is equipped with 
Argon lasers that pass through condensers that allow for the manipulation of the 
incident angle of light onto the specimen to obtain proper TIRF angle. Image 
analysis and background corrections were done later in ImageJ. 
2.2.5.8 Fluorescence Calibrated Confocal Time-Lapse Microscopy 
Fluorescence-calibrated time-lapse imaging was performed on a Zeiss LSM 
510 Meta confocal microscope equipped with a ConfoCor 3 unit and a C-
Apochromat 40x/1.2 N.A water immersion objective at 37 °C. mTFP and mCitrine 
were excited with 458 nm and 514 nm argon lasers, respectively, whereas RFP was 
excited with a 561 DPSS laser. The fluorescent light was passed through a NFT 565 
beam splitter and detected with PMT detectors through a BP 475–525 band pass 
filter for mTFP, a LP 530 long pass filter for mCitrine, and a LP 575 long pass filter 
for RFP. To minimize cross talk between individual channels, mTFP and RFP were 
recorded simultaneously, whereas mCitrine was imaged separately. Pinhole 
diameter was set to 192 µm for mTFP, 296 µm for RFP, and 1000 µm for mCitrine. 
Images were recorded at a resolution of 512x512 pixels (0.15 µm /pixel) and a bit 
depth of 12 bit. For time-lapse imaging, single-plane multi-color images were 
recorded at 1-minute intervals.  
To correlate the image intensity of mCitrine to absolute protein 
concentrations, we acquired single-channel images of cells expressing mCitrine-
PTP1B D/A CD at exactly the same settings used for the time-lapse experiments. 
Fluorescence correlation spectroscopy (FCS) measurements were performed at 
randomly chosen positions in the cytoplasm of the same cells. Background 
corrected average image intensities were determined in a 1 µm radius around the 
FCS measurement point. For FCS, mCitrine was excited with the 514 nm line of an 
argon laser, while an APD detector recorded the fluorescence through a LP 530 
long pass filter and a 70 µm pinhole. The raw intensity data were correlated using 
the microscope manufacturer’s software, and for each measurement, correlation 
curves were averaged for ten consecutive 10-second intensity recordings. 
Averaged correlation curves were fit by using a model accounting for anomalous 
diffusion and a triplet term in order to determine the average number of particles 
in the confocal observation volume, using a non-linear least squares minimization 
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algorithm implemented in Matlab (MathWorks). Confocal volume was determined 
from calibration measurements of an Alexa 546 dye solution, assuming diffusion 
coefficient of 280 µm 2/s at 25 °C that was extrapolated to 308 µm 2/s at 37 °C. 
(Data analysis was performed by Dr. Martin Bierbaum). 
2.2.6 Statistical Analysis 
Results are expressed as the mean ± SEM, unless otherwise mentioned. 
Statistical significance was estimated either by the Mann-Whitney nonparametric t-
test, one-way ANOVA or Student’s t-test. Datasets that passed the Komogorov and 
Sminov test for Gaussian distribution are indicated in the figure legend. 
Significance level of p=0.05 was used, p<0.05 (*), p<0.01 (**) and p<0.001 (***). 
2.2.7 Ephrin stimulation 
Mouse ephrinB2-Fc, mouse ephrinA1-Fc and Alexa-647 labeled ephrinA5-Fc 
(M.Lackmann laboratory) fusion proteins were used for stimulations. Clustered 
ephrin-Fc fusion proteins were prepared by incubating with goat anti-human Fc at 
a ratio of 5:1 for 30 min at room temperature. Stimulations were carried out in a 
CO2-controlled incubator at 37 °C for the indicated time.   
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3. RESULTS 
3.1 Regulation of signaling at points of cell-cell contact by PTP1B 
3.1.1 PTP1B	  substrate-­‐trapping	  mutant	  localizes	  to	  regions	  of	  cell-­‐cell	  contact	  	  
The ubiquitously expressed non-receptor protein tyrosine phosphatase 
(PTP1B) is bound to the cytosolic face of the endoplasmic reticulum (ER) through 
its C-terminal hydrophobic sequence 199,200. Despite the initial thought that their 
anchor restricts its access to key substrates, many new findings have shown that 
PTP1B not only interacts with substrates as they transit past the ER, but also 
directly at specialized regions of the plasma membrane. We investigated the ability 
of PTP1B to access and spatially-temporally regulate signaling at points of cell-cell 
contact. Expression of GFP-labeled wild type (WT) PTP1B and its “substrate 
trapping” mutant D181A (D/A) in PTP1B-null fibroblasts showed that both 
localized to the ER network (Fig. 3.1). The PTP1B (D/A) mutant which is 
catalytically impaired but retains substrate binding 233, additionally accumulated at 
regions of cell-cell contact, labeled using anti-! catenin antibodies (Fig. 3.1 white 
arrows). 
 
 
 
Fig 3.1 PTP1B localizes to regions of cell-cell contact. 
PTP1B-null fibroblasts transiently expressing PTP1B WT-GFP or PTP1B D/A-GFP fixed 
and stained for !- catenin and DAPI. Regions of cell-cell contact are highlighted with 
white arrows. Scale bars 5 µm. (reproduced from Haj, Sabet et al. 134). 	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3.1.2 The	  endoplasmic	  reticulum	  extends	  to	  regions	  of	  cell-­‐cell	  contact	  
 
To confirm that the ER can extend to regions of cell-cell contact, mCherry-
labeled PTP1B (D/A) was co-expressed in MDCK cells with YFP-labeled general 
ER marker, stress-related ER protein (SREP) (Fig. 3.2 (a)). Co-localization of SREP 
with cell-cell contact proximal PTP1B (D/A) confirmed that the ER extends out to 
the plasma membrane at regions of cell-cell contact (Fig. 3.2 (a), white arrows). 
Similar results were obtained when the rough ER marker, Sec61 was co-expressed 
with PTP1B (D/A) (Fig. 3.2 (b), white arrows). 
 
 
 
Fig 3.2 The ER is at close proximity to the PM at regions of cell-cell contact 
(a) MDCK cells coexpressing a general ER marker, stress-related ER protein (SREP-YFP) 
and PTP1B D/A-mCherry. (b) MDCK cells coexpressing a rough ER marker, (Sec61-YFP) 
and PTP1B D/A-mCherry. White arrows indicate regions of colocalization at points of 
cell-cell contact. Scale bars 10 µm.  	  
3.1.3 The	  endoplasmic	  reticulum	  is	  polarized	  towards	  regions	  of	  cell-­‐cell	  contact	  
 
To investigate the inherent tendency of the ER to polarize towards points of 
cell-cell contact, and address the possible involvement of PTP1B in this process, we 
decided to disrupt the ER network. Microtubules (MTs) play a major role in the 
formation and stabilization of the ER network 201,202, therefore we opted to disrupt 
MTs using nocodazole. Total internal reflection microscopy (TIRF) was used to 
monitor ER retraction at cell periphery and at points of cell-cell contact. COS-7 cells 
were co-transfected with mTFP-calreticulin and RFP-tagged TK-Ras as a general 
marker for plasma membrane that can account for cell shape changes and mark 
a
b
SREP PTP1B  D/A Merge Phase  Contrast
SEC61 PTP1B  D/A Merge Phase  Contrast
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points of cell-cell contact (Fig. 3.3). Consistent with previous reports, the ER 
collapsed after nocodazole treatment 203, with the peripheral tubular ER changing 
into sheet-like structures. The ER retracted from cell periphery, but persisted at 
points of cell-cell contact (Fig. 3.3 compare ROI 1 and 2). 
 
  
Fig 3.3 Polarity of the ER 
COS-7 cells co-expressing calreticulin-mTFP and RFP-tk. Cells were treated with 
ncodazole (33 µM) and imaged for 30 min using TIRF microscope. Two regions of interest (1) 
and (2) are highlighted in the merged image and magnified. ROI (1) shows a peripheral 
region of the plasma membrane to which the ER is reaching out before drug treatment 
(upper panel) and retracting from which after drug treatment (lower panel). ROI (2) 
depicts a region of cell-cell contact, where the ER network persists even after drug 
treatment (yellow arrow). Scale bars 10 µm.  
 
COS-7 cells were co-transfected with mCitrine-wt PTP1B and RFP-tagged TK-
Ras as a general marker for plasma membrane (Fig. 3.4 (A)) or mCitrine PTP1B 
(D/A) and RFP-tagged TK-Ras (Fig. 3.4 (B)). Here again the ER collapsed after 
nocodazole treatment, with the peripheral tubular ER changing into sheet-like 
structures. The ER retracted from cell periphery, but persisted at points of cell-cell 
contact (Fig. 3.4 (A) compare ROI 1 and 2). The degree of ER reorganization varied 
between experiments depending on cell shape, type and confluence. In isolated 
cells expressing the substrate trapping mutant of PTP1B, the ER retracted only 
partially after nocodazole treatment, leaving behind long stretches of tubular ER 
left attached to the plasma membrane probably at sites of cell attachment to the 
glass coverslip (focal adhesions) (Fig 3.4 (B) white arrows). 
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Fig 3.4 PTP1B and the intrinsic polarity of the ER 
(A) COS-7 cells co-expressing PTP1B WT-mCitrine and RFP-TK. Cells were treated with 
nocodazole (33 µM) and imaged for 40 min using TIRF microscope. Two regions of interest (1) 
and (2) are highlighted in the merged image and magnified. ROI (1) shows a peripheral 
region of the plasma membrane to which the ER is reaching out before drug treatment 
(upper panel) and retracting from which after drug treatment (lower panel). ROI (2) 
depicts a region of cell-cell contact, where the ER network persists even after drug 
treatment (white arrow). The PM outline is traced in white and the ER outline is traced in 
yellow, to facilitate the observation of ER retraction relative to PM. (B) COS-7 cells co-
expressing PTP1B D/A-mCitrine and RFP-tk were treated with nocodazole (33 µM) and 
imaged for 40 min using TIRF microscope. In the lower right panel, white arrows indicate the long 
stretches of ER left behind attached to sites of adhesion to the glass coverslip following drug 
treatment. This was only observed in the case of cells overexpressing PTP1B D/A. All scale bars 
10 µm. 
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3.1.4 PTP1B-­‐substrate	  interactions	  do	  not	  by	  themselves	  stabilize	  the	  polarity	  of	  ER	  to	  
regions	  of	  cell-­‐cell	  contact	  
 
The previous findings raised the possibility that the //interactions// of 
PTP1B with cell-contact based substrates might have a role in polarizing the ER 
towards these points. Competing out endogenous PTP1B from its interaction with 
substrates using an overexpressed cytosolic catalytic domain of PTP1B D/A 
(PTP1B D/A CD) should allow the ER to retract from points of cell-cell contact 
after nocodazole treatment if this was the case. MDCK cells were co-transfected 
with PTP1B D/A-CD-mCitrine, mTFP-calreticulin, RFP-TK and unlabeled EGFR. 
Following starvation, cells were stimulated with EGF (100ng/ml) for 5 minutes to 
enhance phosphorylation of EGFR and thereby recruitment of PTP1B (D/A)-CD to 
its substrates and then cells were treated with nocodazole. Similar peripheral ER 
retraction was observed, with no apparent retraction of ER from regions of cell-cell 
contact (Fig 3.5). To evaluate whether the expression of PTP1B (D/A)-CD was high 
enough at regions of point of cell-cell contact, fluorescence correlation 
spectroscopy (FCS) was used. FCS was used to correlate image intensity of 
cytoplasmic PTP1B (D/A)-CD to its absolute concentration across the cells 204. A 
linear fit to this correlation allowed for the estimation of PTP1B (D/A)-CD at 
points of cell-cell contact (by extrapolation) to be ~ 9 µM. At areas close to points of 
cell-cell contact, PTP1B (D/A)-CD concentration remained in the µM range, which 
is comparable to KD values previously calculated for PTP1B (D/A)-substrate 
interactions 205. This means that in principle, PTP1B (D/A)-CD should be able to 
compete with endogenous PTP1B for substrates at regions of cell-cell contact.   
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Fig 3.5 PTP1B substrate competition cannot destabilize the ER at of cell-cell contact 
MDCK cells co-expressing calreticulin-TFP, PTP1B D/A-CD-mCitrine and RFP-TK. Cells 
were treated with ncodazole (33 µM) and imaged for 40 min using confocal microscope. ROI (1) 
highlighted in the merged image is magnified for three time points (0, 20 and 40 min) to 
show peripheral retraction of ER post drug treatment. Lower left image shows calculated 
concentration of PTP1B (D/A)-CD at cell-contact region (yellow line) based on the 
fluorescence calibrated imaging. Lower middle graph is a correlation of the average image 
intensity of PTP1B D/A-CD measured in the cytoplasm to the absolute concentration as 
measured from FCS graphs. A linear fit (red line) returned the calibration function used 
late to calculate absolute concentrations from image intensities. Lower right graph is an 
example of an auto-correlation G (!) curve of PTP1B D/A-CD-mCitrine (black line) fit by a 
model for anomalous diffusion and triplet term (red line). All scale bars correspond to 10 
µm.  
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Being ER-anchored (2D), endogenous PTP1B has a “geometric” advantage in 
its search for substrates, thereby invalidating arguments about KD, which assumes 
3D search for substrates. To overcome the high (2D) concentration of endogenous 
PTP1B, additional competition experiments were done with a PTP1B chimera, 
which lacks its natural ER anchor, but has a C-terminal CAAX box sequence from 
KRas (TK) to anchor it to plasma membrane (PTP1B D/A-RFP-TK). The hypothesis 
was that anchoring PTP1B (D/A) to the PM should give it a similar geometric 
advantage to endogenous ER-anchored PTP1B. Expression of PTP1B D/A-RFP-TK 
with TFP-calreticulin and unlabeled EGFR followed by nocodazole treatment was 
performed as previously described. Nevertheless, the ER did not retract from 
regions of cell-cell contact post drug treatment (Fig 3.6). Taken together, these 
experiments indicate that PTP1B-substrate interactions stand-alone cannot account 
for ER polarization at points of cell-cell contact. PTP1B might not be the reason for 
intrinsic ER polarity towards these regions, but the ER polarity might still have a 
functional significance for the spatial organization of PTP1B activity.   
 
 
Fig 3.6 PTP1B D/A-RFP-TK cannot compete out endogenous PTP1B 
MDCK cells co-expressing calreticulin-TFP, PTP1B D/A-RFP-TK and unlabeled EGFR 
were treated with nocodazole (33 µM) and imaged for 40 min using confocal microscope. Two 
ROIs are highlighted in the merged image, ROI (1) shows a region of cell-cell contact and 
ROI (2) shows a peripheral region of the cell. Drug treatment increases the distance 
between peripheral plasma membrane and ER as seen in ROI (2), while the ER stays 
unchanged at regions of cell-cell contact as seen in ROI (1). All scale bars =10 µm. 	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3.1.5 Regulation	  of	  signaling	  at	  regions	  of	  cell-­‐cell	  contact	  by	  PTP1B	  
 
The above observations raised the possibility that PTP1B may play a 
significant role in the regulation of signaling at points of cell-cell contact. To test 
this hypothesis, the effect of PTP1B specific inhibition on phosphorylation of cell-
cell contact based substrates was tested. COS-7 cells were co-transfected with 
EphA2-mCherry, a closely related member to the recently described substrate of 
PTP1B, EphA3 133.  Tyrosine phosphorylation of EphA2 was monitored using YFP 
fused to SH2 domain of pp60src (dSH2-YFP) 185. Cells were treated with an allosteric 
PTP1B inhibitor 206, that show higher selectivity when compared to active site 
inhibitors, and monitored after 1 hour of incubation with drug (Fig. 3.7 a/b 
v,vi,vii). Prior to PTP1B inhibition, EphA2 showed typical membrane distribution 
of a RTK, with occasional accumulation at points of cell-cell contact (Fig 3.7 a/b, ii). 
dSH2-YFP localized to the nucleus, punctuate clusters surrounding the cell typical 
of focal adhesions (Fig.3.7 a iii) and in some instances at regions of cell-cell contact 
(Fig 3.7 b iii, yellow arrowheads). Minimal co-localization was observed between 
dSH2-YFP and EphA2-mcherry prior to inhibition, even at regions of cell-cell 
contact (Fig. 3.7 a/b iv cyan arrowheads). After 1hr of PTP1B inhibition, the extent 
of co-localization was higher, especially at points of cell-cell contact (Fig. 3.7 a/b 
vii). The enhanced tyrosine phosphorylation of EphA2 upon PTP1B inhibition 
indicates that EphA2 is a novel PTP1B substrate at points of cell-cell contact. The 
above findings show that the ER-anchored PTP1B, by virtue of the intrinsic 
polarization of ER towards points of cell-cell contact, can access and regulate its 
potential substrates at these regions, in other words, a polarized safeguard 
mechanism. 
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Fig 3.7 PTP1B access specific substrates at cell-cell contacts 
(a,b) COS-7 cells co-expressing EphA2-mCherry (ii.v) and dSH2-YFP (iii,vi) were 
incubated with PTP1B allosteric inhibitor (250µM) for 1 hr at 37 °C and imaged using confocal 
microscope. Transmission images (i) define cell confluency and help define regions of cell-
cell contact. Merge images (iv, vii) show the spatial localization of EphA2 (red) and SH2 
(green), before (iv) and after (vii) PTP1B inhibitor treatment. Notice the increased co-
localization of EphA2 and SH2 at regions of cell-cell contact after inhibitor treatment, 
indicating increased EphA2 phosphorylation. All scale bars correspond to 20 µm. 	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3.2 Clustering as the central integrator of Eph signaling 
3.2.1 Decision	  making	  at	  Eph/ephrin	  cell-­‐contact	  interfaces	  	  
Regulation of signaling at points of cell-cell contact can also be addressed from a 
kinase point of view. The Eph/ephrin signaling system is the center of this study 
and will therefore be addressed with more detail. The Eph/ephrin system 
exemplifies opposing tendencies in biology. The same receptor/ligand interaction 
can either lead to cell-cell repulsion or adhesion depending on the context. To put 
this into perspective, a co-culture assay was performed with two populations of 
cells 69,152. One cell type, (HEK293) is expressing ephrinA5 ligand, and the other cell 
type (COS-7) is expressing EphA2 receptor. COS-7 cells were transfected with 
EphA2-mCitrine (Fig. 3.8 (A) green cells), HEK293 cells were transfected with 
mCherry-ephrinA5 (Fig. 3.8 (A) purple cells).  Three regions of interest (ROIs) 
were chosen to monitor decision-making at points of Eph/ephrin contact (Fig. 3.8 
(A)).  Three points of Eph/ephrin contact were formed after adding HEK293 cells 
expressing mCherry-ephrinA5 on top of COS-7 cells expressing EphA2-mCitrine. 
In the 1st case (Fig. 3.8 (B) ROI1), Eph/ephrin clusters (white in merged RGBs “3rd 
row”), persisted over time without obvious changes. In the second case (Fig. 3.8 (B) 
ROI2), Eph/ephrin clusters were terminated over time and endocytosed into 
receptor-expressing cells. The two cells eventually underwent contact-repulsion. In 
the third case (Fig. 3.8 (B) ROI3), Eph/ephrin clusters persisted and even grew 
larger over time. Taken together, live-cell imaging of Eph/ephrin co-cultures 
displayed the concept of “opposing tendency of the system at points of cell-cell 
contact. The same receptor and ligand interactions can lead to enhanced cell-cell 
adhesion or cell-repulsion depending on the context.     
 
Fig 3.8 Formation of Eph/ephrin complexes at points of cell-cell contact 
(A) Co-culture of COS-7 cells expressing EphA2-mCitrine (green) and HEK293 cells 
expressing mCherry-ephrinA5 (magenta) imaged using confocal microscope. RBD stands for 
receptor binding domain, LBD stands for ligand binding domain. Three ROIs were 
monitored with more details during the course of the movie. (B) ROI1 in three channels, 
upper row (ephrinA5), middle row (EphA2) and lower row (merged RGB) depicts no 
changes in cell-cell contact point with time. ROI2 depicts cell-cell repulsion. ROI3 depicts 
enhanced adhesion and increased Eph/ephrin cluster formation with time. All scale bars 
correspond to 20 µm. 
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3.2.2 Generation	  of	  a	  clustering-­‐readout	  in	  living	  cells	  	  
Live cell confocal imaging of co-cultures does not offer enough spatial 
resolution to describe the composition of Eph/ephrin complexes formed at points 
of cell-cell contact. Contact between ligand- and receptor-expressing cells is 
random, non-controllable and the outcome cannot be predicted beforehand. To 
visualize clustering directly and to study its impact on Eph signaling, a dimerizer-
induced system of Eph/ephrin clustering was generated in the laboratory of 
Ruediger Klein (Max Plank Institute for Neurobiology). The approach was based 
on the ARGENT® Regulated Homo (Hetero) dimerization kit from Ariad 
Pharmaceuticals. Cloning, optimization and biochemical characterization of the 
different clones was done by Dr. Andreas Schaupp. In principle either no, 1, 2 or 3 
FKBP domains were inserted downstream of the transmembrane (TM) domain of 
murine EphB2 (Fig. 3.9). Keeping the extracellular intact meant that the chimeras 
were still sensitive to physiological ephrin stimulation, but the FKBP domains 
allowed for controlled clustering initiation with the high affinity homodimerizer 
AP20187 or the low affinity homodimerizer AP1887 when needed. 
 
Fig 3.9 Generation of a synthetic dimerizer-induced, Eph clustering system  
Schematic representation of Eph receptors showing sites of insertion of 1-3 FKBPs. 
Receptors are tagged with a fluorescent protein (in that case monomeric EGFP) in the 
cytoplasmic tail, downstream of the transmembrane (TM) domain. Model predicts 
outcome of homodimerizer-dependent receptor clustering of 1-3 FKBP chimeras. High-
affinity homodimerizer AP20187 (IC50= 1.8 nM) or low-affinity dimerizer AP1887 (IC50= 
40nM) non-covalently crosslink the different FKBP domains of adjacent Eph receptors.  
LBD: ligand binding domain. 
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3.2.3 Imaging	  EphB2	  cluster	  populations	  	  
Theoretically speaking, the more the number of FKBP domains inserted in a 
receptor, the higher-order cluster that can be formed. To test this hypothesis, 
homo-FRET was measured with fluorescence anisotropy using widefield 
microscopy. Homo-FRET involves non-radiative transfer of energy between 
similar FPs (in this case EGFP) at nanometer distances and leads to a decrease in 
the fluorophore’s steady-state anisotropy 193. Basal steady-state anisotropy values 
of all FKBP isoforms prior to dimerization was similar over different fluorescence 
intensities except at very low fluorescence signals, where anisotropy tailed off due 
to background noise (Fig 3.10 (B)). Addition of AP20187 dimerizer to cells 
decreased anisotropoy of all FKBP isoforms in a manner correlating with number 
of FKBP domain insertions due to the extended Förster energy migration within 
larger clusters of mGFP (Fig 3.10). Quantification of anisotropy was done in the 
peripheral regions of the cell, excluding central regions of the cells where signals 
would be originating from receptors residing on endo-membranes.  
 
Fig 3.10 Imaging of EphB2 cluster populations  
COS-7 cells transiently expressing kinase dead EphB2 carrying different numbers of FKBP 
domains and fused to mGFP was used for steady-state anisotropy imaging before and 
after dimerization with 250 nM AP20187. (A) Fluorescence and Anisotropy images of 
representative cells pre- and 20 min post-stimulation with AP20187 are shown. Anisotropy 
values decrease with increasing numbers of FKBP domains indicating a higher degree of 
homo-FRET/clustering. Scale bars in anisotropy panels: 10 µm. The color scale of 
anisotropy images is shown on the bottom. (B) Anisotropy plots of pre- and post-
stimulation of 0 to 3 FKBP isoforms. Data represent mean anisotropy ± SEM of n=57, 28, 22 
and 20 cells for 3FKBP, 2FKBP, 1FKBP and 0FKBP. Post-stimulation curves of 0-3FKBP are 
all significantly different from each other and controls. (0/1FKBP, 0/2FKBP, 0/3FKBP, 
1/3FKBP, 2/3FKBP: p< 0.001; 1/2FKBP: p< 0.01; Mann-Whitney nonparametric test).  
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We backed up our graded clustering response detected by anisotropy 
microscopy with blue-native polyacrylamide gel electrophoresis (Fig. 3.11 (A)). 
Following transient expression of the different FKBP-EphB2 constructs in COS-7 
cells and dimerization with AP20187, EphB2 clusters were resolved with blue-
native PAGE and blotted with anti-EphB. FKBP and FP insertions did not affect 
signaling the properties of EphB2 upon stimulation with clustered ligand as seen 
in autophosphorylation blots, cell collapse assays and internalization kinetics (data 
not shown). Blue-native PAGE gels showed that upon dimerization with AP20187, 
the 1FKBP isoform formed dimers with residual amounts of monomers. 
Dimerization of the 2FKBP isoform resulted in the formation of oligomers, 
primarily trimers, with dimers still present and no residual monomers. 
Dimerization of the 3FKBP isoform formed large oligomers with no apparent 
residual dimers or monomers (Fig. 3.11 (A)). The relative contribution of 
monomers, dimers and multimers in each FKBP isoform was determined and used 
later to determine the relative contributions of these different association states to a 
given anisotropy value. 2D histograms representing the distribution of anisotropy 
values (at the periphery of cells) for a given FKBP isoform after dimerization were 
plotted. The molecular brightness of each state was taken into consideration as a 
weighing factor in computing the relative contribution of each association state to 
the steady-state anisotropy (Fig 3.11 (B)). Three association states and their 
corresponding anisotropy were thereafter distinguished. All FKBP isoforms had a 
monomeric state prior to dimerization with an average anisotropy value of AM ± 
std. = 0.278 ± 0.009. Dimerization of the 1FKBP isoform, formed the dimeric state 
with an anisotropy value of AD ± std. = 0.237± 0.011. Finally, a mixture of 
oligomeric association states of trimers and higher-order clusters with an 
anisotropy value of AO ± std. = 0.218± 0.013 (Fig 3.11 (B)). Time-resolved 
anisotropy changes of the different FKBP isoforms showed a sigmoidal decrease in 
anisotropy after dimerization (for the 2FKBP and 3FKBP constructs), reaching 
steady-state after ~ 20 min time series (Fig 3.11 (C)). 
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Fig 3.11 Characterization of EphB2 
cluster composition  
(A) Blue-native PAGE gel showing 
different cluster populations of FKBP 
isoforms prior to and after dimerization. 
UNT: untransfected cells. FKBP 
isoforms of kinase dead EphB2 in the 
absence of dimerizer migrated as 
monomeric species. Upon dimerization 
with AP20187 (250 nm for 20 min) a 
shift in migration was observed for all 
FKBP isoforms. 1FKBP, now forms 
mostly dimers, 2FKBP and 3FKBP forms 
higher-order clusters. (B) Graph shows 
the intensity-weighted distribution of 
anisotropy values for the different FKBP 
association states. Data was extracted 
from raw eroded (10-15 pixels) 
anisotropy images in ImageJ, 0FKBP 
was used to represent monomeric state 
(purple trace), 1FKBP for the dimeric 
state (green trace), and 3FKBP for the 
multimeric state (red trace).  Summed 
anisotropy distributions (black trace) 
was later used for calculating the 
contribution of each association state to 
a given anisotropy value.	   (C) 
Representative time-lapse anisotropy 
measurements of the different FKBP 
isoforms. COS-7 cells were transiently 
transfected with the indicated FKBP-
EphB2 isoforms. Following dimerization 
with AP20187, a sigmoidal decrease in 
anisotropy could be observed for 20 
min. Fluorescence (FL) anisotropy is 
plotted as percent relative to 
predimerization condition and 
normalized to 0FKBP isoform.	   Blot	  was	  Experiments	  were	  done	  by	  Dr.	  A.	  Schaupp	  data	   analysis	   by	   O.	   Sabet	   (submitted).	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We next moved to comparing the artificially controlled cluster populations 
attained by the dimerizer to the physiological ephrin-induced oligomers. The 
calculated anisotropy values of monomers, dimers and oligomers from the 
dimerizer system, were used to estimate the complexity of EphB2 clusters formed 
at points of cell-cell contact with ephrinB2-expressing ells. COS-7 cells expressing 
kinase dead EphB2 tagged with mGFP (kdEphB2-mGFP) (Fig 3.12 (I)) were co-
cultured with HEK293 cells expressing ephrinB2 (tagged with mCherry) (Fig 3.12 
(II)). Points of cell-cell contact were identified by the colocalization of the two 
fluorophores (Fig 3.12 (III)). Homo-FRET imaging by showed areas of very low 
anisotropy indicative of higher-order EphB2 clustering (Fig 3.12 (IV)). The 
intensity-weighted distribution of anisotropy values (Fig 3.11 (B)) was used to map 
the cumulative relative contribution of each association state for a given anisotropy 
value (Fig 3.12 (V’)).  The contribution of each association state was mapped on the 
anisotropy image of co-cultures of ephrinB2+ and EphB2+ cells (Fig 3.12 (V’’, V’’’)), 
allowing for the identification of areas with multimers, dimers and monomers.  
 
Fig 3.12 Physiological clustering of kdEphB2 upon contact with ephrinB2+ cells  
COS-7 cells transfected with kdEphB2-mGFP (I) and co-cultured with HEK293 cells stably 
expressing wild type mCherry-ephrinB2 (II). Anisotropy map of clustered kdEphB2-
mGFP was determined (IV). For calibration of anisotropy values to cluster size 
distributions the cumulative relative contributions of 0FKBP (monomer), 1FKBP (dimer) 
and 3FKBP (oligomer) were plotted to the range of anisotropy values on the X-axis (V’). 
Distribution of monomers, dimers and multimers (V’’) according to the histogram in (V’’’) 
is shown. 
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3.2.4 Correlation	  between	  degree	  of	  clustering	  and	  receptor	  phosphorylation	  	  
To determine the relative contributions of the different EphB2 oligomeric 
species to receptor autophosphorylation levels, EphB2 constructs without and with 
the different FKBP insertions (1-3) were separated using blue-native PAGE (Fig 
3.13 A). Following transient expression of the different FKBP-EphB2 constructs in 
COS-7 cells and dimerization with AP20187, EphB2 clusters were resolved with 
blue-native PAGE and blotted with anti-phospho EphB2 antibodies (Fig. 3.13 (A)). 
Blots were stripped and reblotted for total EphB2 to calculate relative 
phosphorylation of each FKBP isoform ((Fig. 3.13 (B)). Quantification of relative 
phosphorylation levels showed that trimers and larger oligomers were 2-fold more 
phosphorylated as compared to dimers, with no apparent difference between the 
2FKBP and 3FKBP cluster populations. 
 
 
 
Fig 3.13 Degree of Eph clustering determines receptor activation  
 (A) Blue-native PAGE of lysates of COS-7 cells expressing different FKBP isoforms of	  
wtEphB2 and stimulated with either vehicle (-) or AP20187 (250 nM for 20 min). Western 
blot was performed with anti-phospho-EphB2 antibodies; blots were stripped and 
reblotted for total EphB2 protein, (not shown). The relative phosphorylation levels of 
single oligomeric species were measured according to example regions outlined by 
stippled boxes for monomers, dimers and species ≥ trimers. (B) Quantitative 
autophosphorylation analysis of single cluster species displayed as mean ratio ± SEM of 
phosphorylated versus total EphB2 protein from example regions in (A) from n= 4 blue-
native PAGE experiments normalized to dimer species phosphorylation level set to 1.0 (* 
p< 0.05, one-way ANOVA with post-hoc Bonferroni test).  All EphB2 monomers 
(irrespective of the number of FKBP domains present) exhibited only a small fraction of 
autophosphorylated receptors. EphB2 dimers were hypophosphorylated relative to 
trimers and species ≥trimers in the 2FKBP and 3FKBP cluster populations. Blots were done 
by Dr. Andreas Schaupp (submitted).  
A B
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3.2.5 Intracellular	  modulation	  of	  Eph	  oligomerization	  alters	  response	  to	  stimulation	  	  
After comparing the link between EphB2 clustering and the resulting signal 
output, we next asked whether clustering determinants involving the Ephb2 
intracellular domain could modulate clustering induced by extracellular ephrins. 
So we first asked if the multi PDZ domain-containing scaffolding protein GRIP1, a 
physiological adaptor protein of EphB2 207, was capable of clustering EphB2. We 
co-expressed GRIP1-mCherry and wtEphB2-mGFP in COS-7 cells and visualized 
the degree of EphB2 clustering in living cells by fluorescence anisotropy. In the 
absence of ephrinB2-Fc, the degree of EphB2 clustering was low, independently of 
the presence of GRIP1 (Fig. 3.14 (A)). Upon addition of unclustered ephrinB2-Fc, 
EphB2 clustering was induced and this effect was significantly enhanced in cells 
co-expressing GRIP1 (Fig. 3.14 (B)). When we applied the same dose of ephrinB2-
Fc to HeLa cell populations expressing wtEphB2-mGFP, we observed both a 
significantly enhanced cellular collapse response and accelerated rounding kinetics 
when GRIP1-mCherry was co-expressed (data not shown). Together these results 
indicate that GRIP1 enhances EphB2 clustering in the presence of extracellular 
ephrins and further suggest that this enhanced clustering leads to a stronger cell 
collapse response.  
 
Fig 3.14 GRIP1 enhances EphB2 clustering in response to ephrinB2  
(A) Steady-state FL anisotropy of ephrinB2-induced EphB2 clusters. COS-7 cells 
transiently expressing wtEphB2-mGFP with and without GRIP1-mCherry were stimulated 
with 0.5 µg/ml unclustered ephrinB2-Fc. Anisotropy values of representative cells pre 
(upper panels) and 20 min post-stimulation (lower panels) with ephrinB2 are shown. 
Higher-power magnifications from overlayed FL channels and the corresponding EphB2-
mGFP anisotropy panels are displayed from regions indicated with numbered boxes to the 
right. GRIP1 presence in subcellular regions leads to a decrease of FL anisotropy. Scale 
bars: 10 µM. The color-coding of anisotropy values is shown. (B) Quantification of steady-
state FL anisotropy plots from (a) pre- and post-stimulation (20 min) with 0.5µg/ml 
unclustered ephrinB2-Fc. Data represent mean anisotropy ± SEM of n=36 and 45 cells for 
wtEphB2-mGFP in absence or presence of GRIP1-mCherry, respectively. Post-stimulation 
curves are significantly different from each other; p< 0.001, Mann-Whitney nonparametric 
test. 
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We then asked if the presence of the C-terminal SAM domain and the PDZ-
binding motif (PBM) would influence EphB2 clustering. Co-expression of GRIP1-
mcherry with an EphB2 deletion mutant lacking both SAM & PBM 
(EphB2ΔSAM/PBM) did not alter clustering response. Because SAM/PBM may 
bind other scaffolding or adaptor protein complexes that positively or negatively 
regulate clustering, we decided to repeat the experiment in the absence of GRIP1. 
Using fluorescence anisotropy, we compared the clustering propensities of 
wtEphB2-mGFP to the EphB2ΔSAM/PBM-mGFP in COS-7 cells. At steady state 
the degree of EphB2 clustering was low in both constructs (Fig. 3.15 (A), left 
panels & (B)). Upon stimulation with unclustered ephrinB2-Fc (500ng), more 
clustering was observed in cells expressing mutant EphB2ΔSAM/PBM (Fig. 3.15 
(A), right panels & (B)), suggesting that SAM/PBM negatively influence EphB2 
clustering. In line with the increased clustering, EphB2ΔSAM/PBM induced more 
cell collapse when expressed at comparable levels as wild type EphB2 (Fig. 3.14 
(C), courtesy of Marion Ponsere). Moreover, EphB2ΔSAM/PBM showed 
significantly increased autophosphorylation compared to wild type EphB2 
specifically after ephrinB2-Fc stimulation (Fig. 3.15 (D,E), courtesy of Marion 
Ponsere). Together these results indicate that the intracellular domain of EphB2 
significantly influences EphB2 clustering and that SAM domain and PBM have a 
negative impact on EphB2 clustering. 
Fig 3.15 Negative regulatory effect on EphB2 ligand-induced clustering  
(A) Steady-state FL anisotropy of ephrinB2-induced EphB2 clusters. COS-7 cells 
transiently expressing wtEphB2-mGFP or EphB2ΔSAM/PBM-mGFP were treated with 0.5 
µg/ml unclustered ephrinB2-Fc. Anisotropy values of representative cells pre (left panels) 
and 20 min post-stimulation (right panels) with ephrinB2 are shown. Deletion	  of	  SAM	  and	  PBM	  domains	   leads	   to	  a	  decrease	  of	  FL	  anisotropy. Scale bars: 10 µM. The color-coding of 
anisotropy values is shown on the right side. (B) Quantification of steady-state FL 
anisotropy plots from pre- and post-stimulation (20 min) with 0.5µg/ml unclustered 
ephrinB2-Fc. Data represent mean anisotropy ± SEM of n=35 and 46 cells for wtEphB2-
mGFP and EphB2ΔSAM/PBM-mGFP respectively. Post-stimulation curves are 
significantly different from each other; ***p< 0.001, Mann-Whitney nonparametric test. (C) 
Cell collapse assays done on HeLA cells expressing either wtEphB2 or EphB2ΔSAM/PBM 
and clustered by equal concentrations (500ng) of unclustered human-Fc fragment or 
ephrinB2-Fc. Cell assay was quantified by measuring the cell’s surface area (Mean cell area 
± SEM from n= 25 cells per condition; **** p< 0.0001, *** p< 0.001, ** p< 0.01, * p< 0.05, two-
way ANOVA with post Bonferroni test, n= 8 separate experiments). (D) Representative 
Western blots of anti-Flag immunoprecipitated wtEphB2 or EphB2ΔSAM/PBM after 
treatment with equal concentration of Fc control or ephrinB2-Fc (0.5 µg/ml, t= 20 min) 
using mouse anti-phospho tyrosine antibody (clone G410); blots were stripped and 
reblotted for total EphB2 protein levels (mouse anti-FLAG M2 antibody). (E) Quantitative 
analysis of autophosphorylation (** p< 0.01, * p< 0.05, unpaired t-test, n=7 separate 
experiments). C,D and E are data from experiments done by Marion Ponsere (submitted). 
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3.3 Spatial-temporal regulation of EphA2 activity 
3.3.1 Generation of a linker-optimized FRET based activity sensor for EphA2 	  
Activation of Ephs correlates with auto-phosphorylation of two conserved 
tyrosines (Tyr587 and Tyr593, for EphA2) embedded in a highly conserved ~10-
amino acid motif within the JMS, in addition to phosphorylation of the conserved 
TyrACT (Tyr771 in the case of EphA2)79. In the crystal structure of murine EphB2, the 
JMS in its non-phosphorylated form adopts an ordered α-helical conformation that 
hinders the kinase domain from adopting an ordered, active structure. As a whole, 
the autoinhibited EphB2 kinase domain adopts a closed conformation that 
superficially resembles an active state. Because activation of Ephs is coupled to 
conformational change that leads to release of JMS autoinhibition, we previously 
we developed a 2-component FRET based imaging approach that is sensitive to the 
distance between the EphA3-C terminus and the PM. The use of a membrane-
targeted acceptor fluorophore (FP), tkRas-RFP allowed use to measure FRET with 
EphA3-GFP as a change in GFP (donor) fluorescence lifetime, measured by time 
correlated single photon counting (TCSPC)-FLIM. Using this system, we showed 
that activation of EphA3 moves the kinase domain away from the PM 145. However, 
this approach was limited in space and time, considering the rapid endocytosis 
occurring upon stimulation, that moves the receptor away from the membrane-
restricted acceptor FP. In addition, whether the observed autoinhibited structure 
would be oriented in a certain fashion with respect to the inner surface of the 
membrane is impossible to extrapolate considering the lengthy sequence between 
the PM and the start of strand Ex1 83.  
This work formed the basis for designing a genetically encoded EphA2 
intramolecular biosensor to study the spatial regulation of the autocatalytic 
activation mechanism of Eph receptors in living cells. The EphA2 biosensor is 
designed to report on the conformational changes taking place upon full Eph 
activation by phosphorylation, as a change in distance and/or orientation of two 
FPs in frame with the receptor. Changes in FRET are then measured by TCSPC-
FLIM as a change in donor fluorescence lifetime. A stretch of (10) amino acids 
below the TM domain and away from the JMS conserved motif were chosen to 
screen for viable insertion points of the donor FP (Fig. 3.16 (A)). Insertion of the 
donor FP was optimized by using different sets of linkers that range in flexibility 
from being completely unstructured (amino acid sequence: NLSSDSSNS) 208, Beta-
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sheet forming linker (amino acid sequence: KLRTDIKVV, from accession no.: 
1A26), coiled-coil linker (amino acid sequence: LAAAYSSILSS, from accession no.: 
1FB1) or a coiled-coil linker combined with a short flexible linker (amino acid 
sequence: LAAAYSSILSSNLSSDS).  Several types of FPs were also tested for JMS 
insertion including: monomeric citrine (mCit), monomeric teal FP (mTFP) and 
circularly permuted variants of GFP (cp51, cp157 or cp173) 209 . Chimeras that were 
mislocalized inside cells, showed diminished autophorphorylation (Fig. 3.16 (B)), 
or showed a low dynamic range in FRET experiments were eliminated from 
further experiments. In all cases, the acceptor FP was appended in-frame to the 
EphA2 C-terminus. We tested two FRET pairs: mCitrine, as an acceptor for mTFP 
or mCherry, as an acceptor for mCtirine. TCSPC-FLIM was then used to identify a 
functional sensor construct with high dynamic range. From all the constructs that 
were tested, the coiled-coil + flexible linker (CCL) chimera exhibited an optimal 
localization, autophosphorylation, expression level and dynamic range and was 
therefore chosen for further experiments in living cells (Fig. 3.17 (A)). Ectopic 
expression of either the EphA2ccl mCit/mCherry FRET pair (Fig. 3.17 (A), upper 
panels), or mTFP/mCit FRET pair (Fig. 3.17 (A), lower panels) showed a basal 
FRET signal as compared to the respective donor-only samples (Fig. 3.17 (A), right 
side). As compared to a uniform distribution of fluorescence (FL) lifetime values in 
donor only samples, EphA2ccl FL lifetime (τ) decreased at points of cell-cell contact 
(Fig. 3.17 (A), white arrow) and increased towards the interior of the cell. To confirm 
that the observed drop in FL lifetime was due to FRET, an acceptor photo-
bleaching experiment was undertaken using the EphA2ccl mCit/mCherry FRET 
pair which from now onwards will be dubbed as the Linker-optimized 
Intramolecular FRET based activity sensor for EphA2 (LIFEA2). Bleaching of 
mCherry in living cells increased mCitrine FL lifetime (τ) back to donor only 
values, thereby confirming that the drop in FL lifetime was due to FRET (Fig. 3.17 
(B)). 
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Fig 3.16 Design of a genetically encoded intramolecular FRET based EphA2 biosensor  
 (A) EphA2 biosensor domain structure with mCit/mCherry FRET pair. The biosensor was 
constructed by inserting the first fluorophore (FP) on a linker in the juxtamembrane 
segment (JMS, blue). This inserted FP is always the blue-shifted donor for any FRET-pair 
used. Several optimization parameters (I, II & III, see table) were used to enhance the 
biosensor FRET efficiency, its localization inside cells and its response to stimulation. A 
control biosensor was also generated, which contained only the JMS-inserted FP (Donor 
only LIFEA2). Abbreviations: LBD, ligand binding domain; ECD, extracellular domain; 
TM: transmembrane; TKD tyrosine kinase domain (grey); SAM: sterile-alpha motif; PDB: 
PDZ-binding motif. Structural model depicting murine 2YF mutant-EphB2 kinase domain 
(grey), JMS (blue) with conserved tyrosines (cyan) (modified from PDBs: 1JPA and 1EMA) 
25. (B) Representative autophosphorylation blots of anti-GFP (left side), or anti-Eph (right 
side) immunoprecipitated EphA2-citrine, the different LIFEA2 chimeras or endogenous 
EphA2 in COS-7 cells. For blotting: mouse anti-phospho tyrosine (PY72); and goat anti-
EphA2 were used. Ratio of phosphorylated to total Eph is depicted below each condition. 
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Abbreviations: green insets (CCL, coiled-coil + flexible linker; CC, coiled-coil only; BS, 
Beta-sheet linker; UL, unstructured flexible linker; UNT, untransfected), blue insets (refers 
to the donor FP insertion point in between the two given amino acids), yellow insets (cp, 
circularly permutated; number refers to the position of the new-termini within the GFP 
sequence). Note: the lane representing untransfected COS-7 cells was contrast-optimized 
separately to facilitate display. 
 
 Fig 3.17 Characterization of LIFEA2 FRET signals inside living cells using FLIM 
 (A) Average fluorescence lifetime distribution of LIFEA2 in living cells measured by 
FLIM. Representative COS-7 cells transiently expressing EphA2ccl sensor (left panels) or 
donor only constructs (right panels). White arrows point to the lower FL lifetimes values 
detected at points of cell-cell contact and/or cell periphery. (B) Bleaching the acceptor 
returns the lifetimes of LIFEA2 to that of donor only values. Ectopic expression of LIFEA2 
in COS7 cells before (upper row) or after mCherry photo bleaching (lower row). Scale bars: 
10 µm. Lower panel shows average lifetime distribution before and after photo-bleaching.  
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3.3.2 Ligand-dependent activation of LIFEA2 	  
FLIM was used to visualize EphA2 activation in single cells following 
ephrin stimulation. Ligand stimulation of donor-only LIFEA2 showed no change 
in FL lifetime (τ) over time (Fig. 3.18), thereby excluding the possibility of 
clustering dependent photo physical artifacts. Ligand stimulation (ephrinA1-Fc (2 
µg/ml)) of ectopically expressed LIFEA2 caused a clear initial translocation of 
receptor to the PM, parallel to reduction of LIFEA2 FL lifetime (τ) (Fig. 3.19 (A)). 
The FL lifetime further decreased over time, reaching a maximum change at ~ 20 
min. We observed an expression-level dependency of FL lifetime values upon 
transient expression of LIFEA2 (Fig. 3.19, (A) compare cell 1 & 2), which affected 
the relative change in FL lifetime (τ) in response to ligand (Fig. 3.19, (B)). The FL 
lifetime distributions over time for three independent experiments showed the 
same variance prior to ligand stimulation and a consistent trend upon stimulation 
(Fig. 3.19, (C)). By calibrating microscopy settings across the various experiments, 
we determined the conformational state of LIFEA2 (τ) as a function of its 
expression level (FL intensity) for many cells (n=60), before and after 20 min of 
stimulation (Fig. 3.19, (D)). Prior to ligand addition, the amount of active LIFEA2 
conformation switched abruptly to lower values of LIFEA2 FL lifetime at intensity 
values of ~ 0.25 x106 (Fig 3.19 (D) (dashed red line)), suggesting the existence of an 
activation threshold in the system.  At much higher intensity values, a slight 
gradual drop in LIFEA2 FL lifetime (τ) might be due to molecular crowding effects. 
The relative change in FL lifetime (Δ τ) of LIFEA2 per cell upon stimulation was 
larger in cells expressing low levels of the receptor (Fig 3.19 (E)). 
 
Fig 3.18 Ligand-induced stimulation of donor-only LIFEA2 
Spatial-temporal profiling of donor-only LIFEA2 activation in living cells monitored by 
FRET-FLIM. (Upper row) show photon counts from the donor channel. (Lower row) show 
corresponding average FL lifetime (τ) maps in ns. Color-coding is shown on the right.  
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Fig 3.19 Spatial-temporal profiles of ligand-induced stimulation of LIFEA2  
(A) LIFEA2 conformational dynamics in living cells monitored by FRET-FLIM. Upper row: 
show photon counts from the donor channel. Lower row: average FL lifetime (τ) maps, 
color-coding is shown on the right. An enhanced accumulation of LIFEA2 was observed 
on endomembranes before stimulation (red arrow). (B) Spatially averaged FL lifetime over 
the whole cell is plotted for the two cells over time (mean ± S.D). (C) Average FL lifetime 
distribution over time for three independent experiments shows that stimulation with 
ephrinA1 lowers LIFEA2 FL lifetime (τ) over time. (D) Expression level dependence of 
LIFEA2 conformational activation. Individual data points represent integrated intensity 
and the mean FL lifetime (τ) of LIFEA2 for selected cells 20 min with (grey) and without 
ligand (black). (E) Ligand stimulation of LIFEA2 induced a shift in the population of 
receptor with an active state.  The relative change (Δτ) of LIFEA2 FL lifetime was larger in 
cells expressing lower levels of the receptor.  
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3.3.3 LIFEA2 reports on conformational dynamics 	  
To confirm that LIFEA2 reports changes in receptor conformational 
dynamics and not clustering, we resorted to fluorescence anisotropy. Unclustered 
ephrin-Fc can dimerize Ephs yet it does not allow for recpeptor activation, in fact it 
has been reported to act as an antagonist 46-49. Ligand-induced Eph dimers can 
undergo Förster resonance energy transfer between identical FPs (homo-FRET), 
which results in a decrease of the steady state fluorescence anisotropy of the FP 193. 
First, FLIM was used to visualize LIFEA2 active state in single cells following 
treatment with alexa647-labelled unclustered ephrinA5-Fc (500 ng/ml). (Fig. 3.20 
(A)). Despite slow ligand binding kinetics, after 40-60 minutes of ephrinA5 
addition, abundant Alexa647-ephrinA5 was bound to the cell surface with no 
apparent change in LIFEA2 average FL lifetime (τ). We also used ephrinA1-Fc (500 
ng/ml), the high affinity ligand of EphA2 to exclude the possibility that ephrinA5 
could not activate the receptor because of a reduced binding affinity and found no 
apparent change in average FL lifetime (τ) (Fig. 3.20 (C)). Second, using FL 
anisotropy imaging, we found that addition of unclustered ephrinA1-Fc (500 
ng/ml) to the cells decreased anisotropy values, pointing at the occurrence of 
homo-FRET due to the formation of dimers (Fig. 3.20 (B)). These results show that 
clustering per se does not induce a change in the FL lifetime of LIFEA2 and thereby 
demonstrates that it reports on receptor conformation. 
 
Fig 3.20 Ligand dimerization does not change LIFEA2 FL lifetime 
(A) FL lifetime distribution of ephrinA5-induced clusters of LIFEA2 in living cells 
measured with FLIM. Upper row: photon counts from the donor channel. Middle row: 
average FL lifetime (τ) maps. Lower row: Alexa-647 conjugated ephrinA5-Fc, color coding 
is shown on the right of images. (B) Steady-state FL anisotropy of ephrinA1 induced 
clusters of LIFEA2 in living cells. Anisotropy values of representative cells pre- (upper 
row) and 20 min post-clustering (lower row) with ephrinA1-Fc are shown. The coding of 
anisotropy values is shown on the right. Graph shows quantification of steady-state FL 
anisotropy plots from pre- and post- treatment (20 min) with 500 ng/ml unclustered 
ephrinA1-Fc is shown. Data represent mean anisotropy ± SEM of n=10 cells. (C) FL 
lifetime (τ) distribution of ephrinA1 induced clusters of LIFEA2 in living cells measured by 
FLIM. Representative COS-7 cells ectopically expressing LIFEA2 pre- (upper row) and 20 
min post-clustering (lower row) with ephrinA1-Fc are shown.  Scale bars: 10 µm. The 
coding of (τ) values is shown on the right. Quantification of average FL lifetime from pre- 
and post- treatment (20 min) with 500 ng/ml unclustered ephrinA1-Fc is shown.  
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3.3.4 Relating phosphorylation with conformational dynamics of LIFEA2 	  
To assess whether average FL lifetime changes of LIFEA2 correlate to its 
phosphorylation, COS-7 cells expressing LIFEA2 were fixed and stained with a 
phospho-specific antibody (Fig. 3.21 (A)). Stimulation of LIFEA2 with pre-
clustered ephrinA1-Fc shifted FL lifetime (τ) distribution to lower values in a time-
dependent manner. COS-7 cells expressing LIFEA2 were then fixed, permeabilized 
and stained for phosphorylated JMS tyrosine residues (p-JM).  The average FL 
lifetime of LIFEA2 (τ) was obtained in areas where we found p-JMS signal. From 
this it was apparent that the distribution of phosphorylated JMS coincided with 
areas inside cells where LIFEA2 FL lifetime was lower.  In addition to 
immunofluorescence of single cells, LIFEA2 autophosphorylation was tested by 
immunoblotting, which showed that LIFEA2 indeed exhibited increased 
autophosphorylation after ephrinA1-Fc stimulation (Fig. 3.21 (B)). In the previous 
section a correlation between LIFEA2 expression level and its activity as a function 
average FL lifetime (τ) was described. To confirm that LIFEA2 reports on an active 
conformation, phosphorylation of JMS as a function of LIFEA2 FL lifetime (τ) was 
determined. LIFEA2 was transiently transfected in COS-7 cells and average FL 
lifetime (τ) was calculated for many cells (n=56). Cells were fixed and stained with 
p-JM and by calibrating microscopy settings across many experiments, we could 
correlate the intensity of p-JM across all data sets to obtain a cell-to-cell 
quantification of average FL lifetime (τ) as a function of p-JM staining (Fig. 3.21 C 
(1)) and of receptor expression as a function of p-JM staining (Fig. 3.21 C (2)). 
 
Fig 3.21 Phosphorylation of LIFEA2 
(A) Fraction of active LIFEA2 maps to phosphorylated JMS. COS-7 ectopically expressing 
LIFEA2 were fixed and stained with a phospho-specific antibody (p-JM) following an 
ephrinA1 stimulation time-series. FL Lifetime values (τ) of representative cells pre- (upper 
row), 15 min (middle row) and 60 min (lower row) post ephrinA1-Fc are shown. The drop 
in lifetime values post ephrinA1 treatment correlates with an increase in p-JM staining 
indicating that LIFEA2 maps phosphorylated, activated receptor. Scale bars, 10 µm. Right 
graph shows quantification of FL lifetime (τ) values with respect to masked p-JM channel 
for n= 6 cells. Data represent mean (τ)  ± S.D. (B) Representative western blot of anti-GP 
immunoprecipitated LIFEA2, using p-JM and total-EphA2 antibodies. Blots show the time 
course of LIFE2 autophosphorylation induced by preclustered ephrinA1-Fc. (C) Single cell 
analysis correlating JMS phosphorylation level to LIFEA2 FL lifetime (τ) (1) or LIFEA2 
expression level (2). Individual data points represent integrated phospho-specific antibody 
intensity and the mean (τ) of LIFEA2 for selected cells. (2). 
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JMS phosphorylation of LIFEA2 could either be due to its intrinsic kinase 
activity or phosphorylation by other endogenous Eph receptors. To differentiate 
between these two possibilities, we assayed LIFEA2 kinase activity in-vitro. LIFEA2 
autocatlytic activity measured as ratio of tyrosine autophosphorylation to total 
receptor amount (Fig. 3.22 (B)) was measured in comparison to EphA2-citrine (Fig. 
3.22 (A)) and endogenous EphA2 in MDA-468 cells (Fig. 3.22 (C)).  In addition, we 
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measured the kinase activity of LIFEA2 using enolase as an external substrate for 
transphosphorylation (Fig. 3.22 (B)) and compared our results to C-terminally 
tagged EphA2-citrine (Fig. 3.22 (A)). Our data indicate that the active conformation 
detected by the FL lifetime of LIFEA2 is an indicator of its intrinsic kinase activity 
that phosphorylates with comparable kinetics to endogenously expressed EphA2 
in MDA-468 cells.  
  
Fig 3.22 In Vitro kinase assays of LIFEA2, EphA2-Citrine and endogenous EphA2 
Representative western blots of anti-Eph immunoprecipitated LIFEA2, EphA2citrine and 
endogenous EphA2 using anti-phospho-tyrosine (PY72) and anti-EphA2 protein levels (C-
20). Blots show the time course of EphA2 (A), LIFEA2 (B) and Endogenous EphA2 (C), 
autophosphorylation as well as transhosphorylation of enolase as an external substrate. 
 
To investigate how autophosphorylation of EphA2 temporally correlates with 
its conformational dynamics, we monitored EphA2-citrine phosphorylation in live 
cells. We have previously shown that a fluorescent Src-homology 2 (SH2) domain 
can track Eph tyrosine phosphorylation134. Therefore, COS-7 cells ectopically 
expressing EphA2-citrine were co-transfected with a dimeric SH2 domain from 
pp60src labeled with mCherry (cherry-dSH2) and FLIM was used to visualize the 
degree of EphA2 phosphorylation in single cells. Ligand-induced stimulation of 
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EphA2 led to an initial translocation of receptor to the PM, in conjunction with 
localized reduction of EphA2-citrine FL lifetime (τ). The fraction of interacting 
EphA2-citrine and cherry-dSH2 (α) was calculated according to equation 12 and 
showed a linear increase in fraction of phosphorylated EphA2 for the duration of 
the experiment (60 min) (Fig. 3.23). Compared to EphA2 conformational dynamics 
reported by LIFEA2 (refer to Fig. 3.19), the kinetics of EphA2 phosphorylation are 
slower, pointing to a temporal precedence of attaining an active kinase 
conformation over autophosphorylation. At later time points, there was still a large 
fraction of phosphorylated EphA2 on the PM, which could be due the to the high 
expression levels of dSH2 185 that masks phosphorylation sites from phosphatases. 
Because many SH2-contatining proteins are coupled to Eph receptors through 
phosphorylated JMS tyrosine residues; thereby our data highlight a possible role 
for JMS-tyrosines in the regulation of EphA2 internalization and signal 
termination. 
 
Fig 3.23 Spatial-temporal phosphorylation profiling of EphA2 measured by FLIM 
Ephrin stimulation time series monitoring SH2-domain binding to phosphorylated EphA2. 
Upper row: photon counts from the donor channel. Middle row: average FL lifetime (τ) 
maps. Lower row: Fraction of phosphorylated EphA2 (α). Color-coding is shown on the 
right. Graphs represent average FL lifetime distribution over time (left) or fraction of 
phosphorylated EphA2  (α) over time (right).   
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3.3.5 JMS conformational dynamics in the autoregulation of EphA2 activity 	  
Activation of Ephs correlates with autophosphorylation of two conserved 
tyrosines (Tyr587 and Tyr593, for EphA2) embedded in a highly conserved ~10-
amino acid motif within the JMS 79. It has been shown that mutation of the 
conserved JMS tyrosines to phenylalanine (2YF) impairs kinase activity, while 
phospho-mimetic glutamic acid substitution (2YE) preserves kinase activity 80,81. In 
the crystal structure of EphB2-KD, the JMS in its non-phosphorylatable form (2YF), 
adopts an ordered α-helical conformation that interacts with several elements in 
the KD, and prevents it from adopting an ordered, active structure 25. Despite 
knowledge gained from structural studies on autoinhibited and active Eph KD, 
crystallographic snapshots do not explain how the autocatalytic activity of the 
kinase can be suppressed by the JMS in a dynamic way to allow for robust 
activation when ligand is added in vivo.  
We therefore created 2YF- and 2YE- mutants of LIFEA2 and used FLIM to 
understand how the JMS can regulate the autocatalytic activity of EphA2. Ectopic 
expression of either 2YE-LIFEA2 or 2YF-LIFEA2 in COS-7 cells showed a distinct 
basal FRET signal for each mutant (Fig. 3.24 (A)), where the average FL lifetime (τ) 
of the 2YE mutant was higher than that of the 2YF mutant. The plots of FL lifetime 
(τ) values as a function of receptor FL intensity shows differences in the 
dependency of the FL lifetime values on the expression level between the two 
mutants (~ n= 23 cells for 2YE, n= 26 for 2YF and n= 30 for wild type) (Fig. 3.24 
(B)). One can see that the average τ distribution of 2YE-LIFEA2 was shifted 
towards higher FL intensity values as compared to 2YF-LIFEA2. The distribution 
of LIFEA2 on the other hand, covered a broad FL lifetime (τ) range, indicating a 
mixed population of inhibited and open JMS at steady state. To confirm that the 
JMS mutants reports changes in receptor conformational dynamics and not 
clustering, we resorted to fluorescence anisotropy. Ectopically expressed 2YE-, 
2YF- or wild type (wt) LIFEA2 all exhibited similar anisotropy values with no 
correlation between anisotropy and FL intensity (Fig. 3.24 (C)). This excludes 
differences in clustering as a cause for the difference in the observed FL lifetime (τ) 
of the LIFEA2 constructs. 
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Fig 3.24 Characterization of LIFEA2 JMS mutants 
Average FL lifetime (τ) distribution of LIFEA2-JMS mutants measured by FLIM. (A) 
Representative COS-7 cells ectopically expressing 2YE-LIFEA2 (upper row) or 2YF-LIFEA2 
(lower row). Color-coding is shown on the right. (B) 2D-histograms of average FL lifetime 
(τ) distribution with respect to LIFEA2 intensity. Insets represent Standard Deviation. (C) 
Steady-state FL anisotropy of (wt, 2YE, 2YF) LIFEA2 in living cells show no difference in 
anisotropy values as a function of intensity indicating the absence of clustering-dependent 
propensities. Data represent mean anisotropy ± SEM (n=8 experiments).  
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FLIM was then used to follow ephrin-induced conformational dynamics of 
ectopically expressed LIFEA2 in comparison to the 2YE- and 2YF-LIFEA2 mutants. 
Similar to LIFEA2 (Fig. 3.25 (A)), stimulation with clustered ephrinA1-Fc (2 µg/ml) 
caused an initial net translocation of the phosphomimetic 2YE-LIFEA2 construct 
towards the PM, that was paralleled by a reduction of its average FL lifetime (τ) 
(Fig. 3.25 (B)). However, the relative drop in τ was larger as compared to LIFEA2. On 
the other hand, the non-phosphorylatable 2YF-LIFEA2 construct showed slower 
and minimal changes in average τ (Fig. 3.25 (C)). The average FL lifetime of wild type 
and 2YE-LIFEA2 approached the same value after long-time ephrin stimulation, whereas 
2YF-LIFEA2 gradually shifted to even lower FL lifetime values (Fig. 3.25 (D)). We 
thereby find that the phospho-mimetic mutant of LIFEA2 (2YE) retained the ability 
to change conformation upon ligand-induced stimulation, in contrast to the non-
phosphorylatable 2YF mutant. Prior to simulation, LIFEA2 depicted a mixed 
population of “activatable” and “tight” JMS-KD interactions as revealed from the 
FL lifetime distribution that was in between that of the 2YE- and 2YF-LIFEA2 
mutants. These experiments show that the FL lifetime of the auto-inhibitied 2YF-
LIFEA2 mutant and that of the ligand activated LIFEA2 have approximately the 
same value, causing a degeneracy in the FLIM-FRET based conformation detection 
system. However, because LIFEA2 fluctuates between an open and closed 
conformation in the absence of stimulation, this system allows the detection of the 
transition to the catalytically active conformation (refer to Discussion). Therefore, 
LIFEA2 is a proper conformational activity sensor.  
 
Fig 3.25 Conformational breathing of Eph JM determines its activation barrier 
COS-7 cells ectopically expressing wild type LIFEA2 (Upper panels), 2YE mutant (middle 
panels), or 2YF mutant (lower panels) are depicted. At steady state, FL lifetime (τ) maps of 
wild type (A), 2YE (B) and 2YF-LIFEA2 (C) show that wild type LIFEA2 represents a 
mixed population of ”tight” and “activatable” JMS. Average lifetime distribution over 
time shows that the drop in lifetime values post ephrinA1 treatment correlates with Eph 
activation, with the active 2YE mutant showing the biggest relative change. (D) Average 
FL lifetime (τ) distributions of the three represented time-series over time shows that the 
2YE mutant  
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The slight change in 2YF-LIFEA2 FL lifetime possibly shows that a small 
fraction of receptors transited into an active conformation upon ligand stimulation. 
We therefore tested if the 2YF mutant exhibited any residual catalytic activity in 
comparison to wild type- and 2YE-LIFEA2 in an in-vitro kinase activity assay (Fig. 
3.26 (A)). LIFEA2 autocatalytic activity was measured as a ratio of tyrosine 
autophosphorylation to total receptor, as well as by the transphoshorylation of an 
external substrate (enolase). As compared to wild type, the 2YE mutant retained 
full catalytic activity, while the 2YF-JMS mutant’s activity was clearly impaired, 
but not completely inhibited.  In a separate experiment the activity of the JMS 
mutants was compared to a kinase dead EphA2 mutant (K645R) (Fig. 3.26 (B)), 
which demonstrated that 2YF-LIFEA2 indeed retains residual activity. 
  
Fig 3.26 In Vitro kinase assays of the different LIFEA2 mutants  
Representative western blots of anti-GFP immunoprecipitated wild type and mutant 
LIFEA2 using anti-phospho-tyrosine (PY72) and total EphA2 protein levels. (A) Blots show 
the auto- and trans- kinase activity of wild type LIFEA2 as compared to 2YF and 2YE JMS 
mutants (fixed time point, 20 min). (B) Kinase activity of JMS-mutants compared to kinase 
dead LIFEA2 (K654R). All assays were done at a fixed time point (20 min) for comparison.  
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3.3.6 Locking LIFEA2 in a specific conformation by dasatinib  	  
A kinase inhibitor that locks EphA2-KD into a specific conformation was 
used to confirm that LIFEA2 indeed reports on EphA2 conformational dynamics. 
Dasatinib is a small-molecular kinase inhibitor that is currently being used in cases 
of chronic myeloid leukemia (CML) that develop resistance to imatinib 210. Initially 
used as a selective inhibitor of BCR-Abl and Src kinaes 211, dasatinib’s spectrum of 
inhibition later expanded to include members of the Eph family 212,213. Dasatinib 
competes with ATP in a reversible manner and has been crystalized with many 
kinase domains in an active conformation.  
Dasatinib inhibition of LIFEA2 reduced basal and ligand-induced 
phosphorylation inside cells as compared to the DMSO control (Fig. 3.27 (A), right 
panel). FLIM was used to visualize LIFEA2 conformation in single cells before and 
after dasatinib inhibition. COS-7 cells ectopically expressing LIFEA2 & treated with 
200 nM dasatinib for 2 hrs exhibited reduced FL lifetimes (τ) (Fig. 3.27 (A), left 
panel). Cells that exhibit differential conformational states of LIFEA2 (due to 
differences in receptor expression level; Fig. 3.27 (B)) converge to a similar FL 
lifetime upon drug addition, indicating that dasatinib locks LIFEA2 into a unique 
conformational state. Importantly, ligand-addition after dasatinib inhibition did 
not further change the FL lifetime distribution of LIFEA2, thereby establishing that 
the sensor reports on conformational dynamics and not clustering. 
In an attempt to identify which conformation dasatinib locks EphA2 into, 
we ectopically expressed 2YF-, 2YE- and wild type-LIFEA2 and then used 
dasatinib for inhibition (Fig. 3.28 (A)). Compared to LIFEA2, the 2YE mutant 
showed a reduced relative change in average FL lifetime (τ) while the FL lifetime 
values of the 2YF mutant remained the same. These experiments suggest that 
dasatinib: (1) cannot bind the non-phosphorylatatble 2YF mutant; (2) shifts the 
equilibrium of the phospho-mimetic 2YE mutant to an active KD conformation; (3) 
inhibits EphA2 by locking the KD in an active conformation. To rule out the 
contribution of clustering to the observed differences in average FL lifetime (τ) 
before and after dasatinib inhibition, we resorted again to fluorescence anisotropy. 
Ectopic expression of 2YE-, 2YF- or wild type-LIFEA2 in COS-7 followed by 
dasatinib inhibition (200 nM) showed no differences in anisotropy values over the 
range of recorded intensity values  (Fig. 3.28 (B)), confirming that clustering does 
not contribute to the observed differences in FL lifetime.    
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Fig 3.27 Dasatinib locks the kinase domain of LIFEA2 in a specific conformation   
(A) Inhibition of EphA2 kinase activity with dasatinib locks LIFEA2 into an active state. 
Left: average FL lifetime (τ) distribution of representative COS-7 cells ectopically 
expressing LIFEA2, pre- (upper row) and 2 hr post-inhibition (lower row) with dasatinib 
(200 nM). Color-coding of FL lifetime (τ) values is shown below images. Scale bar: 10 µm. 
Right: Representative Western blots of anti-GFP immunoprecipitated LIFEA2 after 
inhibition with dasatinib (200nM) and stimulation with clustered ephrinA1-Fc (2 µg/ml), 
for the indicated time points. Blots were incubated with mouse anti-phospho tyrosine 
antibody (PY72) and goat anti-EphA2 for total Eph protein levels. Bottom: Quantitative 
analysis of receptor phosphorylation (B) Inhibition of EphA2 kinase activity with dasatinib 
hinders ligand-induced translocation and clustering. Average FL lifetime (τ) distribution of 
dasatinib-treated LIFEA2 shows that inhibition of kinase activity lowers biosensor FL 
lifetime (τ), in an activity-dependent manner. Stimulation with clustered ephrinA1-Fc (2 
µg/ml) did not affect the average FL lifetime distribution. Color-coding of FL lifetime (τ) 
values is shown on the right.  
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Fig 3.28 Dasatinib inhibition of the different LIFEA2 JMS mutants    
(A) Left: Average FL lifetime distribution of representative COS-7 cells ectopically 
expressing 2YF-LIFEA2 (upper row), 2YE-LIFEA2 (middle row) or wild type LIFEA2 
(lower row), before (left) and 2 hours post-dasatinib inhibition (right). Right: 
Representative Quantitative analysis of receptor FL lifetime (τ) distribution pre- and post-
dasatinib inhibition. Data represent mean ± SEM (B) Steady-state fluorescence (FL) 
anisotropy of (wild type, 2YE, 2YF) LIFEA2 before and after dasatinib inhibition show no 
difference in anisotropy values over a range of intensity values indicating the absence of 
clustering-dependent change. Data represent mean anisotropy ± SEM of n=8 experiments.  
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3.3.7 Spatial regulation of EphA2 conformational dynamics by PTP1B 	  
 The phosphorylation level of a given RTK at a specific place in the cell is 
given by the balance between its intrinsic kinase activity and the local protein 
tyrosine phosphatase (PTP) activity. Therefore, one cannot account for the 
signaling capacity of a given Eph receptor system inside the cell without taking 
into consideration the opposing activities of PTPs. Consistent with this idea, 
elevated PTP activity in EphA3-positivie leukaemia cells provokes adhesion to an 
ephrin-A5 surface, while PTP inhibition reverses the adhesive response to a 
repulsive one 124. Furthermore, changing the expression of PTP1B can modulate the 
duration and amplitude of EphA3 phosphorylation in response to ligand 
stimulation 127. As previously indicated in section 3.1, we found that inhibition of 
PTP1B causes increased tyrosine phosphorylation of EphA2 at points of cell-cell 
contact. In the absence of stimulus, allosteric inhibition of PTP1B (Calbiochem 
#539741) reduces the average FL lifetime (τ) of LIFEA2 specifically at sites of cell-
cell contact, indicating an autophosphorylation-stabilized active conformation (Fig. 
3.29 (D & E)). On the other hand, COS-7 cells ectopically expressing PTP1B and 
LIFEA2 showed a shift in LIFEA2 FL lifetime (τ) distribution towards higher values 
indicating reduced catalytically active states of the receptor (Fig. 3.29 (A)). This 
was corroborated by the reduced autophosphorylation level of LIFEA2 in the 
presence of PTP1B as measured by immunobloting (Fig. 3.29 (C))). 2D histograms 
of LIFEA2 FL lifetime (τ) as a function of PTP1B FL intensity showed an increase in 
LIFEA2 FL lifetime (τ) in intracellular regions with high PTP1B expression, i.e. peri-
nuclear endomembranes (n= 3) (Fig. 3.29 (B)). 
 
Fig 3.29 Regulation of LIFEA2 activity by PTP1B    
(A) PTP1B negatively regulates activity of LIFEA2. Left: COS-7 ectopically expressing 
LIFEA2 and PTP1B show a uniform average FL lifetime map and no apparent 
colocalization between EphA2 and PTP1. Color-coding of FL lifetime is on the right. Right: 
Quantitative analysis of LIFEA2 FL lifetime (τ) distribution in the absence (black trace) and 
presence of PTP1B ectopic expression (red trace), n=3 experiments. (B) 2D-histograms of 
FL lifetime (τ) distribution with respect to PTP1B intensity, n=3 separate experiments. (C) 
Representative Western blot of LIFEA2 or LIFEA2 + PTP1B after stimulation with equal 
concentration of ephrinA1-Fc (2 µg/ml) using anti-phospho JMS antibody for 
phosphorylation, anti-GFP for total LIFEA2 and anti-PTP1B for endogenous and ectopic 
PTP1B. (D) COS-7 cells transiently expressing LIFEA2, pre (upper row) or after allosteric 
inhibition of PTP1B (lower row). Color-coding of FL lifetime is on the right. (E) COS-7 cells 
ectopically expressing LIFEA2, pre (upper row) or after inhibition of PTP1B (lower row). 
Cells were fixed and stained for tyrosine phosphorylation using PY72 antibody followed 
by Alexa647-labeled secondary antibody. Color-coding of FL lifetime is on the right.  
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 Ligand-dependent activation of RTKs may be coupled to transient PTP 
inactivation in order to enhance signal efficiency. This can happen through 
increased production of H2O2 upon activation of the NADPH oxidase complex and 
the subsequent inactivation of PTPs by oxidation of the catalytic cysteine 137-141. To 
monitor the production of H2O2 in the vicinity of Eph receptors, we created a 
chimera consisting of full-length EphA2, attached via a linker to the H2O2–
biosensor Hyper. Hyper consists of a circularly permuted YFP (cpYFP) inserted 
into the regulatory domain of the H2O2–sensing protein, OxyR. Exposure of OxyR 
to H2O2 results in a dramatic conformational change of the protein translated into 
an in crease in Hyper fluorescence 214 (Fig. 3.30 (A)). Ectopic expression of EphA2-
Hyper in COS-7 cells showed enhanced EphA2-Hyper FL at point of cell-cell 
contact, on internalized vesicular structures and around the cell periphery. 
Stimulation with pre-clustered ephrinA1-Fc caused an initial increase in EphA2-
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Hyper FL, indicative of increased H2O2 production, followed by a reduction in its 
intensity (Fig. 3.30 (B)). To account for changes in the local concentration of 
EphA2-Hyper after stimulation, EphA2-mCherry was ectopically co-expressed 
with EphA2-Hyper as a normalizing factor.  Intensity curves in both channels were 
measured, and the ratiometric signal showed that the initial burst of H2O2 was 
sustained for longer duration of time (Fig. 3.30 (C)). 
 
 
 
Fig 3.30 Mapping H2O2 production by EphA2    
(A) Scheme of EPHA2-linker-Hyper chimera; circularly permuted YFP (cpYFP) is inserted 
within the H2O2 sensitive, regulatory domain of E.coli OxyR (grey). The two redox-
sensitive conserved cysteines (red) are depicted with their respective number in the amino 
acid sequence. (B) Dynamics of H2O2 production in living cells before and after stimulation 
of EphA2 with ephrinA1-Fc. Representative COS-7 cells expressing EphA2-Hyper were 
stimulated with (2 µg/ml) preclustered ephrinA1-Fc and Hyper intensity fluctuations was 
monitored over time. Plot represents normalized intensity changes of EphA2-Hyper over 
time. Scale bar 10 µm.(C) EphA2cherry was used as a normalizing factor for intensity 
changes of EphA2-Hyper. Plot represents data from n=8 experiments. Error bar = Std.  
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3.3.8 PM-recycling as a safeguard mechanism against spurious EphA2 
activation 
 
 Since the localization and activity of PTP1B is mostly perinuclear as shown 
in Fig 3.29 (A), we reasoned that at steady state, Ephs need to be transported to 
those areas for effective regulation by dephosphorylation. Indeed, we found 
EphA2 and/or LIFEA2 in the perinuclear area, but the strong PM-enrichment of 
the receptor impeded its clear detection on endomembranes. In the early endocytic 
pathway, Rab11 marks the recycling endosome (RE) 154 and is involved in recycling 
of cargo between the PM and the centrally localized RE. Ectopic expression of 
BFP/cherry-Rab11 enriched EphA2 in the perinuclear region and we observed 
substantial overlap between the spatial distribution of LIFEA2 and/or EphA2-
citrine with Rab11 (Fig. 3.31 (A) & 3.32 (A)). In the presence of BFP-Rab11, LIFEA2 
average FL lifetime (τ) distribution shifted towards higher values indicating a 
reduced catalytically active conformation (Fig. 3.31 (A)). In addition, single cell 
analysis of LIFEA2 conformational state as function of its expression level showed 
a shift in the response properties of the system in the presence of ectopically 
expressed BFP-Rab11. The ligand-independent switch-like response behavior of 
LIFEA2, as indicated in the FL lifetime versus FL intensity histograms, now 
occurred at higher receptor expression levels, indicating a higher activation 
threshold in the system as compared to LIFEA2 alone (Fig. 3.31 (B & C)). FLIM 
was also used to visualize the degree of EphA2 activation in single cells co-
expressing LIFEA2 and BFP-Rab11 following addition of ephrin. Ligand-induced 
stimulation led to an initial translocation of LIFEA2 to the PM that was paralleled 
by a reduction of its average FL lifetime (τ).  This was followed by internalization 
of receptors and increase in average FL (τ) (Fig. 3.31 (D)).  
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Fig 3.31 Recycling as a protective mechanism against spurious LIFEA2 activation   
(A) Recycling of EphA2 protects against spurious phosphorylation and activation. Left: 
average FL lifetime maps of representative COS-7 cells transiently co-expressing LIFEA2 
and Rab11. Scale bar: 10 µm. Right: Quantitative analysis of LIFEA2 FL lifetime (τ) 
distribution in the absence (black trace) and presence of Rab11 ectopic expression (red 
trace), n=3 experiments. (B) Individual data points represent integrated intensity and the 
mean FL lifetime (τ) of LIFEA2 for selected cells 20 min with (grey) and without ligand 
(black). (C) Individual data points represent integrated intensity and the mean FL lifetime 
(τ) of LIFEA2 for selected cells 20 min with (cyan) and without ligand (blue). (D) Spatial 
temporal organization of LIFEA2 active state in living cells monitored by FLIM. Upper 
row: photon counts from the donor channel. Lower row: average FL lifetime (τ) maps, 
color-coding is shown on the right. 
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To confirm that this recycling mechanism indeed protects against spuriously 
phosphorylated receptors, EphA2 autophosphorylation when Rab11 is ectopically 
expressed was investigated. COS-7 cells ectopically expressing EphA2-citrine or 
EphA2-citrine and BFP-Rab11 were fixed, permeabilized and stained with a 
phospho-tyrosine specific antibody (PY72) labeled with Cy3.5 (Fig. 3.32 (A)). 
Phosphorylation of EphA2 leads to PY72 binding and FRET between citrine-tagged 
EphA2 and Cy3.5 PY72 can be detected by the reduction in citrine FL lifetime as 
monitored by FLIM. The Rab11 marked RE that showed substantial colocalization 
with EphA2-citrine did not show significant tyrosine phosphorylation (Fig. 3.32 
(A)). Quantification of EphA2-citrine average FL lifetime (τ) in relation to EphA2-
citrine intensity, showed a lower FL lifetime (τ) at higher receptor expression levels 
indicative of its autocatalytic activation. In the presence of Rab11, a shift to higher 
average FL lifetime (τ) could be observed, indicating a lower tendency for self-
activation as compared to EphA2 alone (Fig. 3.32 (B)). The ligand-independent 
response behavior of EphA2 in the presence of an enlarged RE further strengthen 
the notion that constant receptor recycling to the PM acts as a safeguard 
mechanism against spurious receptor phosphorylation.  
We next wanted to investigate the changes in EphA2 population residing on 
the RE after ligand-induced stimulation. If EphA2 is constantly being trafficked 
between the PM and the RE to safeguard against receptor self-activation, then how 
can the ligand disrupt such an equilibrium to ensure robust activation and 
subsequent termination of signaling. To investigate this, COS-7 cells ectopically 
expressing EphA2-citrine, BFP-Rab11 and cherry-Rab7 as a marker for the late 
endosomal (LE) compartment, were imaged with confocal microscopy. Prior to 
ephrin stimulation, EphA2 colocalized with Rab11 on the RE, with no apparent 
colocalization with Rab7 (Fig. 3.32 (C)). Ligand-induced activation initially caused 
a net translocation of EphA2 towards the cell-periphery with a reduction in 
amount of colocalization between EphA2 and Rab11. This was followed by 
massive internalization of the receptor with a delayed slight enrichment of EphA2 
on the RE and more enrichment on the LE.  
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Fig 3.32 Constant recycling protects against spurious EphA2 phosphorylation.   
(A) Representative COS-7 cells expressing EphA2-citrine and Rab11-BFP were fixed and 
stained with an anti-phospho tyrosine antibody (PY72). Scale bar: 10 µM (B) 
Quantification of intermolecular FRET between EphA2 citrine and Cy3.5 labeled PY72 in 
absence (red trace) or presence (blue trace) of Rab11. Histograms are a plot of EphA2-
citrine average FL lifetime (τ) in correlation to EphA2-ctrine intensity (pixel by pixel) from 
n=40 cells. Data represent mean ± SEM. (C) The recycling endosome as a source for ligand-
induced Eph translocation to PM. Spatial-temporal profile of EphA2-citrine activation in 
living cells coexpressing BFP-Rab11 and cherry-Rab7. Scale bars: 10 µm. 
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 Quantification of EphA2/Rab11 colocalization prior to and after ephrin-
induced stimulation showed an initial loss of EphA2 from the RE, suggesting the 
trafficking of receptors towards the PM (Fig. 3.33). Ligand-induced translocation of 
Ephs towards the PM enhances its activation and initiates a massive burst of 
signaling-mediated receptor internalization into the endocytic pathway. 
 
Fig 3.33 Dynamic interactions between Rab11 and EphA2    
(A) Representative COS-7 cells expressing EphA2-citrine and cherry-Rab11 were 
stimulated with preclustered ephrinA1-Fc. Scale bar: 10 µm (B) A mask of the RE was used 
to quantify changes in EphA2 citrine FL intensity in two ROIs and show an initial loss of 
EphA2 from Rab11 +ve endosomes followed by slight reentry.  
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 Quantification of EphA2/Rab7 colocalization showed a continuous and 
slow enrichment of EphA2 onto Rab7+ve late endosomal (LE) compartments after 
ligand stimulation (Fig. 3.34). This indicates that ligand-induced signaling-
mediated receptor internalization slowly targets Ephs to the degradative pathway. 
 
Fig 3.34 Dynamic interactions between Rab7 and EphA2    
(A) Representative COS-7 cells expressing EphA2-citrine and cherry-Rab7 were stimulated 
with preclustered ephrinA1-Fc. Scale bar: 10 µm (B) Quantification of EphA2-citrine FL 
mapping to Rab7 FL on the late endosomal compartment shows continuous slow entry of 
EphA2 into Rab7 +ve endosomes. 
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 To demonstrate that EphA2 residing on the RE was continuously recycling 
to the PM, we tracked the mobility of EphA2 fused to photoactivatable GFP 
(EphA2-paGPF) in live cells 215. EphA2-paGFP, EphA2-cherry and Rab11-BFP were 
ectopically expressed in COS-7 cells. EphA2-cherry served as a marker for RE 
population of EphA2 (Fig. 3.35 (A)). Photoactivation of EphA2-paGFP (405 nm) 
specifically at the RE resulted in increased fluorescence. Continuous imaging of 
photoactivated EphA2-paGFP as compared to EphA2-mcherry, revealed an 
increase of fluorescence intensity at the PM. Using EphA2-cherry as a normalizing 
factor for changes in the photoactivated EphA2-paGFP fluorescence, we quantified 
the time constants for fluorescence loss after photoactivation at the RE and the 
complementary fluorescence gain at the PM (Fig. 3.35 (B) & (C)). 
 
Fig 3.35 Vesicular transport of Eph from the RE to the PM    
(A) COS-7 cells expressing EphA2-paGFP (upper row), EphA2-cherry (middle row) and 
Rab11-BFP (lower row) were photoactivated specifically at the RE, and the fluorescence 
intensity of EphA2-paGFP at the RE and at the PM was resolved. Scale bar: 5 µM. 
Quantification of the change in fluorescence ratio (EphA2-paGFP/EphA2-cherry) at the 
RE (B) and PM (C) was done and an average of FL decay curves was fitted with a single 
exponential equation to retrieve time constants,  (n=14 independent experiments).  
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4. DISCUSSION 	  
 Eph RTKs and their membrane-bound ephrin ligands are involved in 
controlling cell positioning during development and disease. Eph/ephrin 
interactions can decide the fate of cell-contact points by promoting either cell-cell 
adhesion or repulsion. It is currently not clear how the same Eph/ephrin 
interaction can have opposing tendencies, and this will likely depend on several 
factors, including the degree of Eph and ephrin clustering, the activity of cellular 
phosphatases and the spatial organization of Eph activity 56,124,133,144,216. In this thesis, 
the main aim was to understand how the activity of Eph RTKs, with inherent 
autocatalytic properties and intrinsic structural features that promote dimerization 
and clustering, is spatially-temporally regulated. 
 The formation of higher-order clusters is a unique feature of Eph/ephrin 
family among other RTKs 12. Using an FKBP-based dimerizing system, we find that 
the relative abundance of oligomers over dimers within a cluster population 
determines the strength of EphB2 response. Furthermore, a negative regulatory 
effect on ephrin-induced clustering by C-terminal domains of EphB2 and a positive 
effect on receptor clustering by GRIP1 protein was identified. These results suggest 
that a given Eph-ephrin interaction can either cause cell-cell repulsion or adhesion 
depending on the context of the interacting cells.  
 In addition to Ephs structural features that allow for receptor clustering and 
activation, its phosphorylation-dephosphorylation cycle is partitioned spatially 
and temporally inside the cell owing to interactions with protein tyrosine 
phosphatases (PTPs). Recent work identified EphA3 as a substrate for the ER-
anchored PTP1B 133. We report EphA2 as an additional substrate for PTP1B at 
points of cell-cell contact. Non-competitive allosteric inhibition of PTP1B creates 
EphA2 phosphorylation hot spots at points of cell-cell contact, thereby highlighting 
ER-PM interactions as an emerging new paradigm in cellular signaling. On the 
other hand, ligand-induced activation of EphA2 locally increases cellular H2O2 
levels raising the possibility of a double negative feedback-loop whereby EphA2 
negatively regulates its own inhibitory PTP in order to spread the activation signal.  
 Using a genetically encoded biosensor that monitors EphA2 conformational 
dynamics (LIFEA2), we describe the dynamics of Eph activation with precise 
spatial & temporal resolution.  Like other RTKs, Eph activity is regulated by 
reversible auto-phosphorylation of key tyrosine residues in its intracellular domain. 
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Self-amplifying systems as such have the propensity to self-activate even in the 
absence of stimulus, necessitating the need for suppressive mechanisms that yet 
allow for robust activation when needed. Suppressive mechanisms can be intrinsic 
structural features as with autoregulation of Eph kinase domain (KD) through 
intramolecular inhibitory interactions by the juxtamembrane segment (JMS), or 
cell-imposed regulatory machineries. We find that interactions between EphA2 
JMS and KD are not ON-OFF as previously suggested, but a dynamic process 
where the JMS is continuously moving between an ordered state that inhibits the 
KD and a disordered state that allows for KD activation. This dynamic process 
allows the KD to continuously sample different conformations one of which is 
stabilized by ligand-induced phosphorylation and defines the catalytically 
competent state.  
 Finally, we identify continuous receptor recycling through Rab11-positive 
endosomes as a novel cell-intrinsic safeguard mechanism against concentration 
dependent EphA2 self-activation. The recycling endosome modulates the amount 
of Eph available for activation on the plasma membrane at steady state and traffics 
the receptor through the peri-nuclear region rich in active PTP1B for efficient 
dephosphorylation.  
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4.1 Functional significance of clustering for Eph signaling 	  
The clustering propensity of Eph subfamily of RTKs raises questions about its 
role in signal transduction. It has been argued that receptor clustering confers a 
wide range of advantages including, tunable sensitivity to extracellular ligand 
217,218, enhanced specificity 219 and segregation as a means of limiting cross-talk 
between signaling systems 220,221 . How clustering translates into molecular features 
defining Eph-ephrin response is still poorly understood. We used chemical 
dimerizers to generate defined oligomeric states of EphB2 receptors in living cells 
and analyzed their biochemical and physiological properties. Four important 
observations could be conferred: (1) Small-sized EphB2 clusters produce functional 
cell responses, an unexpected finding in light of the finding that EphA2 tends to 
form large signaling arrays 42; (2) The relative abundance of active multimers 
(trimers, tetramers and oligomers) over inactive dimers determines the strength of 
EphB2 signaling, suggesting an ON-OFF activation mechanism; (3) Overexpression 
of the intracellular scaffolding protein GRIP1 can enhance ephrin-induced EphB2 
clustering, indicating that intracellular clustering can provide a means to alter the 
cell’s sensitivity towards extracellular stimuli (4) the C-terminal SAM domain and 
PDZ binding motif in the intracellular domain of EphB2 reduce EphB2 clustering 
in the presence of extracellular ephrins, an unexpected result in light of the 
inclination of SAM domains to oligomerize.  
Small sized EphB2 clusters are fully activated 
Crystal structures of whole EphA2 ectodomains bound to ephrinAs 42,43 
suggested that Eph/ephrin clusters form large two-dimensional signaling arrays. 
However, it has so far been difficult to functionally assess the different oligomeric 
states of Ephs formed in living cells, in part because of the dynamic nature of the 
process 56,144. Using different FKBP isoforms of EphB2, we generated and 
characterized defined clusters: dimers (1FKBP), mostly small-sized clusters 
(2FKBP) or larger clusters (3FKBP) (Fig 3.10 & 3.11). Fluorescence anisotropy 
imaging of physiological ephrinB/EphB interactions at cell contact sites, was then 
undertaken to determine the abundance of monomers, dimers and multimers in 
ephrin/Eph clusters (Fig 3.12). We find that ligand-free Eph receptors are 
monomeric and that clusters are heterogeneous consisting of dimers and 
multimers. Comparison of the relative phosphorylation of larger oligomers 
(trimers up to hexamers) in the two cluster populations (2FKBP and 3FKBP) did 
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not reveal significant differences (Fig. 3.13 (B)), suggesting that small-sized clusters 
(trimers/tetramers) are already fully activated and that the presence of larger 
clusters (pentamers, hexamers, etc.) serves a different purpose than enhancing 
phosphorylation of the system.  
EphB2	  follows	  an	  ON-­‐OFF	  mechanism	  
While growth factor activation of RTKs generally occurs during transition 
from monomers to dimers 7, our data shows that the activation switch of EphB2 
(and EphA4) receptors occurs during the transition from dimers to 
trimers/tetramers. The clearest difference between the two EphB2-FKBP cluster 
populations was the relative ratio of inactive states (monomers/dimers) to active 
states (≥trimers). The ratio of inactive to active states was 1:3 in cells expressing the 
2FKBP isoform, but it became 1:10 in cells expressing the 3FKBP isoform (data not 
shown). This points to the fact that the strength of the cellular response is 
determined by the relative abundance of higher-order oligomers versus 
monomers/dimers within EphB2 clusters. This can explain how a possible ON-
OFF mechanism can account for the documented Eph graded responses necessary 
for topographic mapping. Oligomerization might be important for Eph signaling 
to: (1) Relieve autoinhibition imposed on the receptor, since in bigger or more 
stable clusters the Eph intracellular domain may spend more time in the active 
conformation and produce stronger signaling output. (2) Produce a molecular 
crowding effect that limits the spatial freedom of each receptor molecule leading to 
a shift in the conformational steady state equilibrium as described by others 222,223. 
(3) Protect phosphorylated residues of receptors in the center of the cluster from 
tyrosine phosphatases and thereby produce an overall stronger activity.  
Adaptor	  proteins	  can	  precondition	  Eph	  response	  to	  extracellular	  ephrin	  
We provided direct evidence that cells may use intracellular Eph adaptors 
such as GRIP1 to precondition themselves towards extracellular ephrin (Fig 3.14). 
Because Eph/ephrin signaling is bi-directional, this raises the additional possibility 
that adaptor-induced clustering influences ephrinB reverse signaling. It has been 
shown that interaction of EphB2 with GRIP1 can regulate reverse signaling of 
ephrinB3 at specific hippocampal synapses 224. It is possible to conceive that 
endogenous GRIP enhanced EphB2 clustering in these neurons, thereby providing 
stronger trans interactions with ephrinB3 that led to stronger reverse signaling.  
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SAM/PDB	  domains	  as	  steric	  spacers	  counteracting	  ephrin-­‐induced	  EphB2	  clustering	  
Finally we report that deletion of SAM domain and PDZ binding motif (PDB) 
from EphB2 augmented EphB2 clustering and signaling. This is contrary to 
expectations considering previous work identifying the positive effect isolated 
SAM domains have on clustering and the positive effect PDZ domain interactions 
have on Eph/ephrin signaling 225,226. SAM/PDB deletion mutant showed a 
difference response to wtEphB2 only upon ephrin stimulation suggesting the 
following model: ephrinBs binding initiates EphB2 clustering and recruitment of 
cytoplasmic proteins via SAM and PDZ domain associations and that these 
interactions limit EphB2 clustering (for example: by protein modifications or steric 
hindrance). Freeing EphB2 from these interactions, as with the EphB2ΔSAM/PBM 
mutant will therefore increase receptor clustering and signaling. In line with this 
finding, a similar deletion mutant of EphA4 retained full activity in a Xenopus 
morphogenesis assay, and a conserved tyrosine residue in the SAM domain was 
proposed as a protein-protein interaction site for a negative regulator 56,227. If 
indeed SAM/PDB domain acts as a steric spacer for Ephs in vivo, then this offers a 
mechanistic explanation for a switch from repulsive to adhesive cellular responses 
as seen in cells co-expressing truncated EphA7 splice forms or ephrins 228,229.   	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4.2 Spatial organization of the phosphorylation-dephosphorylation cycle 	  
Classically, RTK-mediated signal transduction implied ligand binding for 
receptor dimerization and activation via trans-phosphorylation 230. Such a view 
however, does not take into account the conformational dynamics and flexibility of 
a kinase domain, ligand gradients and random receptor collisions on membranes, 
all of which can lead to high basal receptor activity and spurious phosphorylation. 
Cell-imposed regulatory mechanisms that act as a safeguard mechanism against 
high RTK activity are therefore essential to understand and manipulate as a 
possible method for controlling aberrant RTK activity coupled to tumorigenesis. A 
receptor-extrinsic regulatory mechanism for tyrosine phosphorylation and an 
active partner in phosphotyrosine-based signaling is the process of 
dephosphorylation undertaken by protein tyrosine phosphatases (PTPs) 3,4,231. 
Sufficient data suggests, that functions of these PTPs are controlled by changing 
their subcellular localization within the cell and/or through covalent modifications 
of their cysteine-dependent catalytic site 230,231. The invariant Cys residue found in 
the PTP superfamily signature motif  [I/V]HCXXGXXR[S/T] displays an 
unusually low pKa, which increase its susceptibility to oxidation 232. Of particular 
interest in this study is PTP1B, which contains 35 predominantly hydrophobic 
residues at its C-terminus that target the enzyme to the endoplasmic reticulum 
(ER) membrane 199. How the ER-anchored PTP1B can interact with and affect a PM 
receptor in a spatial-temporal manner is a conceptual dilemma that has been 
extensively investigated. We used quantitative cellular imaging techniques and 
mathematical modeling of protein mobility to explore how PTP1B can reach and 
interact with cell-cell contact bound substrates. The following observations could 
be conferred: (1) The ER network is in close proximity to the PM at regions of cell-
cell contact, thereby allowing the ER-anchored PTP1B to interact with substrates at 
those sites; (2) The PTP1B ER-anchor plays a pivotal role in restricting its 
interactions with cell-cell contact bound substrates; (3) Selective inhibition of 
PTP1B leads to increased tyrosine phosphorylation and activation of EphA2, more 
so at regions of cell-cell contact, thereby identifying those sites as important target 
regions for regulation by PTP1B 134; (4) Ligand induced activation of a H2O2 
sensitive EphA2 chimera led to increased production of ROS, suggesting an 
underlying bistable reaction network as a possible mechanism for spreading Eph 
activation signal. 
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The	  ER	  extends	  to	  regions	  proximal	  to	  PM	  at	  cell-­‐cell	  contacts	  
The contribution of the ER-anchored PTP1B to the regulation of 
phosphorylation of several RTKs was initially surprising considering their spatial 
segregation inside the cell. Where some studies showed that dephosphorylation by 
PTP1B takes place when endocytosed RTK transit past the ER 128,129, others 
suggested a direct contact between PTP1B and its PM and/or adhesion sites 
localized substrates 130,131, or a possible recruitment of PTP1B to the cell surface 
upon Eph-ephrin cell-cell contact 133. We show that the accumulation of the 
substrate-trapping mutant of PTP1B (D181A) 233 at points of cell-cell contact can be 
abolished by thiol-reactive compounds like pervanadate 234. Inactivation of PTP1B 
D/A by pervanadate occurred without altering its ER localization or that of the 
wild type PTP1B 134, indicating a substrate-mediated enrichment of PTP1B at points 
of cell-cell contact. However, nocodazole-based disruption of microtubules and 
hence destabilization of the ER-network 201,202, highlighted the ER’s intrinsic 
polarity and stability at points of cell-cell contact. These findings indicate that 
PTP1B-substrate interactions at points of cell-cell contact do not solely account for 
the polarity of ER towards those specialized regions. Rather, the presence of an 
intrinsic polarity of the ER towards cell contact points, directs PTP1B to those 
regions. Varying rates of endocytosis at cell-cell contact regions as compared to the 
rest of the PM is a factor that we didn’t investigate and might account for the 
differential ability of PTP1B to access cell-contact bound substrates. Varying 
amounts and types of substrates at point of cell-cell contact might also account for 
PTP1B recruitment to regions of cell-cell contact. However, uniform EGFR 
expression on the PM, still showed enhanced PTP1B (D/A)-EGFR interactions at 
regions of cell-cell contact 134. One can of course still argue, that unequal density of 
other RTKs or tight junction specific proteins such as p120 catenin at points of cell-
cell contact can dictate where PTP1B interacts with substrates.  
Regulation	  of	  Eph	  signaling	  by	  PTP1B	  
Why then is the ER-anchored PTP1B oriented towards regions of cell-cell 
contact? Allosteric inhibition of PTP1B led to increased tyrosine phosphorylation of 
EphA2, seen as increased co-localization with SH2 domain of pp60Src (Fig 3.7). 
These findings identify cell contact points as important target regions for 
regulation by PTP1B and highlight a role for PTP1B in maintaining a 
dephosphorylated EphA2 receptor prior to stimulation. Indeed overexpression of 
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PTP1B reduced basal EphA2 phosphorylation and activation indicative of negative 
regulation (Fig 3.29). Ligand-independent EphA2 phosphorylation upon allosteric 
inhibition of PTP1B may still result from the action of a heterologous kinase. This 
argument can only be disproven if inhibition of PTP1B was coupled to a kinase 
inhibitor of EphA2 or if a kinase dead variant of EphA2 (K645R) was used. 
Pending these experiments, one can argue that PTP1B inhibition modulates 
endocytosis and recycling of EphA2 from and to points of cell-cell contact. 
Changes in receptor PM residence time, can increase the chances of receptor auto-
activation at points of cell-cell contact. However, this argument would require a 
polarity of the endocytic/recycling machinery towards regions of cell-cell contact, 
a hypothesis that remains to be tested.  
Regulation	  of	  PTP	  signaling	  by	  Eph-­‐induced	  ROS	  production	  
If cell-contact points are rich in PTP1B activity, how can Eph signaling 
actively contribute to decision making at those sites? Ligand-dependent activation 
of RTKs may be coupled to transient PTP inactivation through increased 
production of H2O2 137-141. To detect H2O2, we created a chimera consisting of full-
length EphA2, attached via a linker to the H2O2–sensitive Hyper214. Ectopic 
expression of EphA2-Hyper showed enhanced H2O2 production at cell contact 
points that could be further increased upon ligand stimulation. Opposing 
gradients of Eph and PTP activities might therefore comprise a reaction cycle 
required for the establishment of a signaling threshold close to the PM & points of 
cell-cell contact. Previous work defining the coupling between EGFR activity and 
protein tyrosine phosphatases has shown that the reaction network is 
characterized by bistable response properties, which explains how high levels of 
phosphorylated EGFR can be maintained on the PM prior to ligand exposure 235. 
Production of H2O2 by EphA2 (Fig 3.30) or EphB2 (data not shown) indirectly 
points to such coupling with PTP1B. Further experiments are needed to verify the 
role of H2O2 in Eph system response. Reducing the amount of produced ROS with 
enzymatic-hydrogen-peroxide-scavenging systems such as catalase and/or with 
the NADPH oxidase inhibitor diphenyleneiodonium (DPI) 213would change the 
response of the reaction network if indeed EphA2 and PTP1B activities were 
tightly coupled.  	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4.3 Spatial organization of EphA2 activity 	  
 Similar to other RTKs, activation of Ephs follows a general framework 
beginning with, ligand binding, receptor oligomerization at the PM, activation of 
the intrinsic KD activity and consequently trans-phosphorylation of key tyrosine 
residues on the intracellular domain. Tyrosine phosphorylation affects the 
signaling properties of Ephs in at least two ways. First, phosphorylation of two 
tyrosine residues in the conserved JMS relieves JMS-mediated autoinhibition of the 
KD and creates docking sites for downstream effectors 74-77. Second, 
autophosphorylation of a key tyrosine residue within the kinase activation loop 
(AL), known as TyrACT changes the structure of the receptor and stabilizes the 
active conformation of the kinase domain. Despite knowledge gained from 
structural studies, how Eph receptor activates in living cells is still incompletely 
understood. In particular, how liganded receptor constitutes a different signaling 
entity when compared to overexpressed self-activated receptors that manage to 
evade cis-inhibiton by the JMS. To study the spatial regulation of the autocatalytic 
activation mechanism of Eph receptors, we generated a genetically encoded FRET-
based activity sensor for EphA2.  
Based on the conformational change that takes place upon full activation of 
Ephs by phosphorylation, we could confer the following observations: (1) 
Interactions between the JMS and the KD of Eph are not ON-OFF as previously 
suggested 25, but a dynamic process where the JMS is continuously switching 
between a tight (inactive KD) and a relaxed (activatable KD) conformation in the 
absence of ligand. This intra-domain “breathing” allows for autocatalytic activation 
when the local concentration of receptor is raised by ligand-induced crosslinking. 
(2) Ligand-induced clustering and activation of Ephs occurs through step-wise 
conformational transitions that involves both the JMS and AL and as such identify 
the JMS as an intrinsic safeguard mechanism against spurious receptor activity. (3) 
The ATP competitive inhibitor dasatinib, inhibits EphA2 activity by locking the KD 
in an active conformation and thereby uncouples conformational flexibility from 
ligand-induced receptor crosslinking. (4) Ligand-independent activation of EphA2 
on the PM can occur at high receptor expression levels, necessitating the need for a 
cell-intrinsic control mechanism that maintains low levels of Ephs on the PM. (5) 
Ectopic expression of the ER-anchored PTP1B or enhancement of the slow 
recycling compartment through ectopic expression of Rab11 demonstrates such a 
cell-intrinsic regulatory mechanism. Constant recycling of EphA2 through Rab11-
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positive endosomes controls its steady-state level at the PM, and traffics it through 
the peri-nuclear region rich in active PTP1B, thereby safeguarding against spurious 
receptor autoactivation. 
Design	  of	  an	  EphA2	  sensor	  for	  mapping	  receptor	  activation	  in	  space	  and	  time	  
Our current understanding of KD regulation is mostly inferred from 
biochemical experiments done on large populations of cells and/or structural 
studies. So in a way it is either information gathered from an “averaged cell”, with 
biological-relevant variance lying beyond the limits of detection 236, or information 
gathered from crystallographic snap shots that represent the most crystal favored 
conformation rather than the multiple states a full-length protein can adopt in 
living cells. Good spatial resolution of protein organization can be acquired 
through immunofluorescence experiments, but it offers poor temporal resolution 
considering that it requires fixation of cells, a strenuous process that changes the 
architecture of the cells and arrests dynamic processes. Precise spatial and 
temporal information of intracellular reaction dynamics can be attained with the 
help of functional fluorescence microscopy that exploits the photophysical 
properties of genetically encoded green-fluorescent proteins (GFPs). One of the 
photophysical phenomena regularly used in live-cell functional imaging is Förster 
Resonance Energy Transfer (FRET). FRET has proven to be an invaluable tool in 
measuring protein dynamics, as the efficiency at which Förster –type energy 
transfer occurs is steeply dependent on the distance (Equation 4) between two FPs 
(donor and acceptor) and the relative orientation of their transition dipoles 
(Equation 5) 177,179,237,238. To design a sensor that reports on the conformational 
dynamics of EphA2 in living cells, we placed the donor FP before the regulatory 
JMS and acceptor FP at the C-terminus of EphA2. Conformational changes coupled 
to EphA2 activation translated into a change in the relative distance and/or angle 
of the two FPs, which results in a change in FRET measured by FLIM as a change 
in donor fluorescence lifetime (τ). To allow for inserted FP folding (average 
distance between N and C- terminus of GFP is ~20 Å) and at the same time reduce 
the extent of disruption to EphA2 secondary structure (average distance between 
adjacent amino acids ~3.5 Å), various linkers were tested for in-frame FP insertion. 
The idea was to use linkers with different secondary structures rather than varying 
their length, ranging from a strict coiled-coil to an unstructured linker or a 
combination of both. After screening, the combination of coiled-coil (next to 
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EphA2) and flexible linker (next to the JMS-inserted FP) (Fig 4.1) was picked as the 
Linker-optimized, Intramolecular FRET-based activity sensor for EphA2 (LIFEA2). 
 
Fig 4.1 Model of donor FP insertion into EphA2 JMS via an optimized linker 
 
Expression of LIFEA2 did not cause any protein mislocalization, cytotoxicity 
or changes in cell morphology (tested in COS-7, MDCK, MCF7 and HEK293 cells). 
In addition, stimulation of LIFEA2 with pre-clustered purified ephrinA1-Fc 
showed similar phosphorylation profiles to C-terminally tagged EphA2 or 
endogenously overexpressed EphA2 in MDA-468 cells, and induced cell shrinkage 
in cultured cells. In total, LIFEA2 as a genetically encoded single-chain biosensor 
allowed us the following possibilities: (1) the choice of detecting FRET with either 
intensity-based approaches, or FLIM. The latter is advantageous since fluorescence 
lifetime is an intrinsic property of the FP that is insensitive to variations in 
instrumental setting or probe emission intensity and concentration 172. More 
importantly, FLIM measurements are robust across separate experiments and 
therefore allow for direct comparisons. 2) Visualization of steady state JMS-KD 
conformational dynamics in living cells with high spatial and temporal resolution. 
(3) Correlation of receptor expression level to its active state in the same cells 
before and after ligand stimulation. Thereby overcoming the introduction of errors 
arising from averaging different populations of cells. (4) Monitoring the effect of 
the spatially organized phosphorylation-dephosphorylation cycle on Eph activity 
and conformational dynamics. (5) The chance of increasing the complexity of cell-
culture systems to 3D vasculogenic models that can be imaged with single plane 
illumination microscopy (SPIM)-FLIM.  
EphA2
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~20  Å
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Autonomous	  activation	  of	  EphA2	  	  
 Like other RTKs, EphA2 activity is regulated by reversible auto-
phosphorylation of key tyrosine residues in its intracellular domain. Self-
amplifying systems as such have the propensity to activate even in the absence of 
stimulus, necessitating the cell to evolve suppressive mechanisms that yet allow 
for robust activation when needed. To investigate the self-activating capacity of 
EphA2, we determined the ligand-independent activity of EphA2 as a function of 
its expression level. By calibrating our microscopy settings across all experiments, 
we obtained cell-to-cell variance in LIFEA2 expression relative to its activity state 
(Fig 3.19) and JMS phosphorylation (Fig 3.21). Steady-state conformational 
dynamics of LIFEA2 that report on the receptor’s active state, exhibited a bimodal 
distribution of activated and nonactivated receptors with a switch-like response 
behavior that is sensitive to the expression levels of the receptor (Fig 3.19). 
Ultrasensitivity has been described before by Goldbeter-Koshland as an inherent 
property of reversible covalent modification schemes such as phosphorylation/ 
dephosphorylation cycles when both converting enzymes work under Michaelis-
Menten saturable kinetics with respect to the protein substrate 239. In this thesis we 
found that Eph activation generates H2O2 suggesting a reactive oxygen species 
(ROS)-mediated coupling between Ephs and phosphatases as described earlier for 
EGFR. ROS-mediated coupling between EGFR and PTPs create a bistable reaction 
network with switch-like rather than graded response properties and explain how 
high amounts of phosphorylated receptors reside on the PM prior to ligand 
stimulation 235. The ability of Ephs to abruptly switch steady state conditions points 
to the autocatalytic nature of EphA2 activation and suggest ROS as the underlying 
mechanism allowing an increase in receptor expression to shift the system from the 
“stable” to the “bistable” or even the “constitutively active” state 235,240 (Fig 4.2). 
 
Fig 4.2 Eph and PTP reaction network 
(A) Reaction network scheme showing the possible coupling of PTP inhibition through 
H2O2 (dashed line) and Eph activation. Black arrows represent a change of protein state 
grey arrows indicate catalysis. (B) Calculated fraction of phosphorylated RTK (RTKp) at 
steady states as a function of the relative maximal PTP to RTK activity (PTP/RTK). Green 
and red lines are stable steady states (resting and activated, respectively). Where the red 
and green lines coincide (blue line), the system is bistable. Depending on the parameters, 
the system can operate in one of three possible conditions: (1) a single, stable steady state 
at low receptor phosphorylation; (2) a single, stable steady state at high receptor 
phosphorylation; (3) a bistable state wherein receptor phosphorylation can either be high 
“activated” or low “resting” depending on the conditions 235.  
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 Ligand-independent activation of EGFR is already acquired during its 
maturation on the ER and Golgi apparatus 241. Opposing gradients of centrally 
active pools of PTP1B would offer the negative regulation needed to 
counterbalance this endomembrane-based RTK activity 205. However, one cannot 
entirely generalize the mechanism of ligand-independent activation between the 
different RTKs. EGFR’s basal activity for example is likely attributed to a unique 
conformation its activation loop (AL) can adopt, which mimics the 
phosphorylated-active AL of other RTKs without the need for phosphorylation 242.  
Despite an “active-like conformation” adopted by its AL, EGFR activity is sensitive 
to its surface density inside cells. Studies have shown that its autonomous 
signaling can be enhanced by phosphorylation of Tyr845 in the AL, a transition 
required for stabilizing the active conformation of the KD N-lobe 243.  
 Unlike our results with EphA2, ligand-dependent phosphorylation of EGFR 
was independent of the receptor surface density 28. This discrepancy could be 
attributed to the nature of the read-out used to define an ‘active” receptor, where 
EGFR surface-density studies were done with a phospho-specific antibody, our 
sensor in live-cells reports an “active conformation”. In addition, rather than 
average studies of different cells prior to or after ligand-induced stimulation, we 
could track the relative change in activation for individual cells. Finally, ligand-
induced clustering of EGFR and Eph is quite distinct and can be responsible for the 
difference in response properties of the system. What ligand clustering actually 
does to enhance Eph autophosphorylation is discussed with more details earlier in 
this thesis (section 4.1). As for EGFR, it has been shown that the principal function 
of ligand is to change the conformation of the extracellular domain (ECD) in a way 
that does not hinder the intrinsic ability of the JMS to activate the KD 28,244.  
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Inhibition	  of	  EphA2	  activation	  with	  the	  ATP	  competitive	  inhibitor	  dasatinib	  	  
To confirm that IFEA2 indeed reports conformational dynamics, we decided 
to use a kinase inhibitor that locks the KD into a specific conformation. Small-
molecule inhibition of aberrant RTK activity usually traps the KD in a specific 
conformation, be it the active conformation (e.g. dasatinib) 245, or an inactive one 
(e.g. imatinib) 24,246,247. Originally developed as a dual-specificity BCR-ABL & SRC-
family kinase inhibitor 211, the ATP competitive inhibitor dasatinib proved to be a 
much more promiscuous inhibitor in vitro 248 & in vivo 249 & EphA2 was later 
established as a direct target of dasatinib (IC50 = 17 nMol) 250,251.  
 By correlating LIFEA2’s autophosphorylation capacity, conformational 
dynamics and clustering propensity upon dasatinib inhibition, we could show that 
dasatinib inhibits EphA2 by locking it in an active conformation without inducing 
clustering. Ligand-induced clustering of inhibited LIFEA2 can no longer change 
the conformation of the KD due to loss of its phosphorylating activity, thereby 
confirming that our sensor detects a conformation specific signal and not 
clustering. Although we still have no direct structural proof that dasatinib locks 
the KD of LIFEA2 specifically in its active conformation, we can draw parallels 
from dasatinib inhibition of other KDs, specifically EphA4. In the crystal structure 
of EphA4-KD in complex with dasatinib, the αC-helix was in the ATP proximal 
position forming the conserved (Lys653-Glu670) salt bridge 18 and the AL in the 
“DFG-in” conformation 252, both are signatures for an active KD 78.  
The	  JMS	  acts	  as	  an	  intrinsic	  safeguard	  mechanism	  against	  spurious	  receptor	  activation	  
Tolstoy had nothing to do with the world of kinases when he wrote Anna 
Karenina, but his opening lines of the novel “paraphrased” do not fail to sum up 
our current state of knowledge about KD activation “All active kinases are alike but 
an inactive kinase is inactive after its own fashion”253. If dasatinib locks EphA2 in the 
generic active conformation, which factors contribute to the formation of the 
inactive structure and the eventual switch-like release of inhibition? Activation of 
Ephs correlates with autophosphorylation of two conserved tyrosines (Tyr587 and 
Tyr593, for EphA2) embedded in a highly conserved ~10 amino acid motif within 
the JMS and a key tyrosine residue (TyrACT) within the kinase AL 79. It has been 
shown that mutation of the conserved JM tyrosines to phenylalanine (2YF) impairs 
kinase activity, while glutamic acid substitution (2YE) preserves kinase activity 80,81. 
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In-vitro kinase assay performed on wild type (WT), 2YE and 2YF mutants of 
LIFEA2, indeed pointed to an impaired yet not completely inactive 2YF-LIFEA2. 
The presence of residual activity can be understood if one appreciates the dynamic 
character of JMS inhibition.  
By comparing the response properties of the JMS phosphomimetic mutant 
(2YE-LIFEA2), and the non-phosphorylatable mutant, (2YF-LIFEA2) to WT 
LIFEA2, we could show that interactions between JMS and KD are not ON-OFF as 
previously suggested, but a dynamic process where the KD is continuously 
switching between a tight (inactive) and relaxed (activatable) conformation in the 
absence of ligand. This points to conformational flexibility, a property of kinase 
domains that would allow it to sample for the catalytically competent 
conformation in space and time. Reducing this “breathing” tendency by for 
example the YF mutation that forces an ordered closed JMS (Fig 4.3 “O/D”), would 
prevent these activating transitions of the JMS (Fig 4.3 “D/D”) and prevent the KD 
from sampling of an active state (Fig 4.3 “D/O”).  
 
Fig 4.3 Conformational fluctuation model for EphA2 activation 
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EphA2 activating transitions therefore represent a 3-state model for the 
conformational fluctuations that occur in its intracellular domain (Fig 4.3). The 
accessibility of the active site and thereby catalysis is regulated by the 
conformation of the JMS (blue) and the activation loop in the kinase domain (pink). 
The JMS- fluctuates between an “ordered” state that tightly interacts with and 
inhibits the KD by disordering the AL (Fig 4.3 “O/D”), and a “disordered” state 
that allows for conformational breathing of the KD and AL (Fig 4.3 “D/D”). 
Autophosphorylation of the JMS tyrosines stabilizes this open JMS-kinase domain 
conformation allowing a dynamic KD and AL to sample many conformations 
compatible with catalysis. The catalytically competent KD is in turn stabilized by 
autophosphorylation of the TyrACT, a phosphorylation event that leads to ordering 
of the AL (Fig 4.3 “D/O”). 
Fluctuations of catalytic domains are affected by phosphatases that 
counterbalance the action of “active conformation”-stabilizing phosphorylation 
events 254. At steady state, phosphatases would be actively participating in the 
regulation of EphA2, by switching the JMS to an unphosphorylated ordered form 
that intrinsically inhibits EphA2 activity. EphA2-driven phosphorylation events 
would on the other hand stabilize the active conformation of JMS and AL. Beyond 
certain expression levels of EphA2, this autocatalytic system switches the 
population to an active state which is then stabilized by phosphorylation of the 
catalytic domains. Ligand-induced activation of EphA2 also makes use of this 
“breathing” of catalytic domains, as localized concentration of kinase activity 
allows for an autocatalytic initiation event that can propagate laterally42,56.  
An ordered unphosphorylated JMS can inhibit the KD, by preventing the 
AL from attaining a conformation that is compatible with catalysis. The extent to 
which the AL is ordered is commonly correlated with the phosphorylation state of 
the protein and the disordering of the JMS 25,85. In the inactive state, TyrACT blocks 
ATP binding by protruding into the active site.  Auto-phosphorylation of TyrACT 
repositions the AL and adjacent residues into a catalytically competent 
conformation (ordered), thereby freeing the active site to interact with substrates 
72,73. An ordered JMS can also inhibit Eph activity by restricting the flexibility of the 
N-terminal relative to the C-terminal kinase lobe, an inherent interlobe flexibility 
that allows the KD to adopt a range of conformations, among which lies the 
catalytically competent one 84. 
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A fourth highly unlikely conformational transition to an ordered AL despite 
of an ordered JMS can happen (Fig 4.3 “O/O”), which might explain the residual 
activity we detect in our in vitro kinase assays for the 2YF mutant. Whether WT 
Eph-KD can overcome intrinsic inhibition by a closed, ordered JMS is speculative. 
However, a symmetric transition into an active state regardless of JMS structural 
inhibition would create no protective effect against Eph receptor autoactivation and 
cannot explain the switch-like response properties of the system. Both the active 
state (Fig 4.3 “D/O”) & JMS-inhibited state (2YF) (Fig 4.3 “O/D”) exhibited a low 
fluorescence lifetime (τ), i.e. we observe degeneracy in our FRET-based system (Fig 
4.3, dashed green box). One way of explaining this, is by appreciating the fact that 
in all RTKs, the catalytically competent conformation is the one in which the two 
kinase lobes clamp together to form an interfacial nucleotide binding site and 
catalytic cleft, i.e. it is superficially a closed structure 25. In the crystal structure of 
2YF-EphB2, the autoinhibited KD adopted a closed conformation that superficially 
resembled an active state 25. In addition, the 2YF mutant used here as the “inactive” 
kinase mimic might represent a stabilization of a certain intermediate 
conformation that lacks certain aspects of catalysis such as nucleotide release and 
as such fail to faithfully translate into a conformational state that the WT is 
adopting 254.  
As for the response properties of the phosphomimetic mutant (2YE), which 
points to a ligand-activatable transition state of EphA2, we detect enhanced 
catalytic activity in our in-vitro kinase assays. This goes in accordance with 
previous studies with 2YE-EphA4, which remained sensitive to ligand-induced 
receptor activation in vivo 255. It has been suggested that JMS phosphorylation acts 
like a threshold that must be exceeded for proper receptor activation	   256,257. 
Loosing this intrinsic safeguard mechanism, as in the case of the 2YE mutant, will 
therefore not mean that the receptor is already in an active state. Indeed, structural 
and mutational studies have proposed that rather than fixing the AL or other 
elements of the KD into a catalytically competent conformation, dissociation of the 
JMS from the KD allows for more dynamic sampling of such a conformation 84. 
This notion that the intrinsic plasticity of a protein is a key feature of catalysis is 
consistent with theoretical models and experimental observations 258. 	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The	  process	  of	  recycling	  acts	  as	  a	  safeguard	  mechanism	  against	  Eph	  autoactivation	  	  
As gathered from our expression level versus activity state correlation, 
EphA2 as an RTK with intrinsic structural features that regulate its own activity 
can still bypass the JMS cis-inhibitory mechanism through its conformational 
flexibility. The cell must therefore impose another regulatory mechanism that 
maintains a low level of active Ephs at the PM. We find that ectopic expression of 
PTP1B (Fig. 3.29) as well as enhancement of the slow endosomal recycling 
compartment by ectopic expression of Rab11 (Fig. 3.31) represents a safeguard 
mechanism against ligand independent autocatalytic activation of EphA2. To 
investigate the protective effect imposed by vesicular recycling to the PM, we 
overexpressed Rab11 and determined the ligand-independent activity of LIFEA2 
as a function of its expression level. By comparing FL intensity across all 
experiments, we obtained cell-to-cell variance in EphA2 expression level relative to 
its activity state (Fig 3.31) and phosphorylation (Fig 3.32). The switch-like 
activation described earlier for the receptor in the absence of Rab11 occurred at 
higher receptor expression levels when Rab11 was ectopically expressed, 
indicating a recycling-mediated safeguard mechanism.  
The dependency of RTK self-activation on surface density has recently been 
detailed for EGFR 28. Prior to ligand activation, EGFR on the PM is under dynamic 
flow, where it is continuously internalized at a comparable rate to basal membrane 
recycling (rate constant ~ 0.02-0.05 min-1) 259. Most of internalized EGFR is recycled 
back to the PM with a constitutive recycling rate of  (≥0.2 min-1), which displays 
biphasic kinetics with a fast component (t1/2 ~ 5 min) and a more prolonged one at 
~ 20 min 260. The higher recycling rate dictates a predominant steady-state PM 
localization of EGFR and a smaller endosomal pool. It is likely that EphA2 will 
follow the same steady state conditions. A higher density of RTKs on the PM 
would increase the chances of random-collisions, increasing the chances of ligand-
independent activation. Eph recycling would therefore act as another level of 
protection against high basal KD activity. This is why we turned to Rab proteins, 
which play a pivotal role in relaying receptor signaling to the endosomal 
trafficking machinery & vice versa 157.  
Rab11 has been shown to associate with the peri-centriolar recycling 
endosome (RE) and to regulate the “slow recycling component” of transferrin 
receptor 261. Prior to ligand binding and in accordance with previous studies done 
on transferrin 261, we see less Eph on the PM and a more on the RE. By 
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photoactivating EphA2-paGFP specifically on the RE and following fluorescence 
loss from the RE and appearance on the PM over time, we could show that the 
population of EphA2 enriched on the RE is dynamic and contributes to the steady-
state localization of receptor on the PM. The fluorescence intensity (FL) decay 
curves after photoactivation point to a slow vesicular transport from the RE (t1/2 7.5 
± 5.5 min) and simultaneous slow appearance of fluorescence on the PM (t1/2 4.8 ± 
2.2 min). The specific rates of EphA2 recycling are within the range of rates 
measured for other receptors (t1/2 of 12 min for EGFR) 259. However, ligand induced 
activation of EphA2 induces a fast translocation of receptor towards the PM (~1 
min). If the slow vesicular transport contributes to this initial increase in PM-
population of receptor, it would mean the dynamics of RE-PM transport have to 
change upon addition of ligand. We plan to repeat our confocal FLAP experiments 
in the presence of ligand, to investigate whether the slow RE changes EphA2 PM-
transport kinetics upon ligand-induced activation.  
What then does trafficking through the slow RE do to Eph receptors? 
Ectopic expression of Rab11 can push more of the constitutively internalized Eph 
through the slow RE path, thereby depriving the receptor from a possible fast cycle 
back to the cell surface through Rab4-positive endosomes. In addition, considering 
the fast ligand-induced translocation of receptor towards the PM, the contribution 
of the fast RE to PM-RTK enrichment is more likely.  To explore this hypothesis, 
we are investigating the role of Rab4 in the regulation of steady state and ligand-
induced EphA2 recycling. Rab11 can also regulate incoming traffic to the RE, by 
enhancing movement of internalized cargo from the sorting endosome to the RE 
261. To address if Rab11 enhances internalization of Ephs from the PM towards the 
RE, we plan to photoactivate EphA2 (EphA2-paGFP) using total internal reflection 
fluorescence (TIRF) microscopy. TIRF restricts the excitation of EphA2-paGFP to 
the basal PM and its residence time can be derived from the loss fluorescence over 
time following photoactivation.  
Following ligand-induced translocation and enrichment of EphA2 activity 
on the PM, we observed a delayed burst of receptor-signaling-mediated 
endocytosis that depletes the activated receptors from the PM. This pool of ligand-
activated EphA2 slowly enriches on the late endosomal/lysosomal compartment. 
One of the principal determinants of ligand-induced receptor crosslinking is to 
create large clusters that are central for Eph signaling (refer to section 4.1). We 
therefore reason that this signaling-mediated switch between an active monomer 
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and oligomerized active receptor opens up a new route for internalized receptors 
(late endosome), to allow for termination of signaling. To test this hypothesis, we 
are investigating the ubiquitin-mediated molecular mechanism that regulates this 
differential endosomal sorting of ligand-activated clustered receptor versus 
monomeric active ones. It has already been shown that ligand binding causes 
EphA2 to be internalized and degraded by promoting its interaction with the 
ubiquitin ligase c-Cbl 262, an interaction that can be inhibited by dasatinib 
suggesting a dependency on kinase activity 251. Receptor signaling-mediated switch 
in endosomal trafficking could arise from tyrosine phosphorylation of a consensus 
Cbl-docking sequence (Tyrosine-XXX-Proline) and hence sort more receptor for 
degradation. Mutation of the respective tyrosine (1045) to phenylalanine in EGFR 
inhibited receptor ubiquitination and degradation 263. The corresponding residue 
on EphA2 (Tyrosine 813) is not an identified in vivo autophosphorylation site, but 
ligand induced PM-enrichment might bring EphA2 in close proximity to other 
tyrosine kinases 264-266 that bring about its phosphorylation. It is therefore 
interesting to create the Y813F EphA2 mutant and investigate its effect on PM 
recycling and/or receptor degradation.  
How then is Eph intrinsic autocatalytic activity dynamically controlled to 
prevent self-activation yet allow for robust ligand-induced activation (Fig 4.4):  
(A) Steady state level of EphA2 on the PM is maintained by constant 
trafficking and represents a sum of slow internalization and faster recycling. PM-
enriched EphA2 has a higher chance of random collision and spurious activation 
owing to its autocatalytic activity. Intrinsic structural elements of inhibition (for 
Eph, JMS) represent an initial threshold that can be surpassed. The cell must 
therefore impose additional control mechanisms that maintain low levels of active 
Eph on the PM. One of our main findings is that continuous slow recycling of 
EphA2 to the PM represents a cell intrinsic safeguard mechanism against 
autoactivated receptors by: (1) maintaining a relatively low steady-state level of 
receptor at the PM and (2) transporting the receptor past areas rich in PTP1B 
activity 205, thereby dephosphorylating spuriously activated receptors. The 
contribution of the Rab4-positive fast recycling endosome to Eph kinetics remains 
to be tested (red arrow).  
(B) Ligand induced clustering of Ephs causes a net translocation of receptors 
to the PM, ensuring robust transphosphorylation and activation. This is followed 
by a delayed burst of signaling-mediated endocytosis. Most of internalized 
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receptors end up in the late endosomal compartment for degradation (blue arrow). 
Whether ligand-activated EphA2 is at all recycled back to and enriched on the PM 
is still under investigation, but is highly unlikely. We therefore conclude that 
ligand clustering rather than the receptor’s intrinsic autocatalytic activity is what 
initiates Eph vesicular trafficking into the degradative pathway for efficient 
termination of signaling. 
 
Fig 4.4 Model depicting factors affecting the activation of EphA2 
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APPENDIX I 
 
Key:    F: forward primer   R: reverse primer 
Oligo Name Sequence Tm total 
(°C) 
Use 
EphA2-KpnI-F CAG GGT ACC ATG GAG CTC CAG 
GCA GCC C 
69.1 C-terminal FP 
introduction 
EphA2-AgeI-R CAT AC CGG TGA GAT GGG GAT CCC 
CAC AGT G 
66.0 ‘’ 
EphA2-XmaI-F TTT CCC GGG AAG TCA GAA CAA 
CTG AAG CCC  
66.6 Restriction site 
introduction 
EphA2-SpeI-R GGA CTA GTG GAG AAG TAA ACG 
TCC TCC G 
61.2 ‘’ 
EphB2-SpeI-pt-F CGG ACA AGC TGC AAC ACT ACA 
CTA GTG GCC ACA TGA CCC C 
70.0 ‘’ 
EphB2-SpeI-pt-R G GGG TCA TGT GGC CAC TAG TGT 
AGT GTT GCA GCT TGT CCG  
70.0 ‘’ 
Spe-CC1-L-PvuI-
TFP-F 
& used for Citrine 
GGACTAGTctggcggcggcgtatagcagcattctg
agcagcaacctgagcagcgatagcCGATCG 
ATGGTGAGCAAGGGCGAGGAG 
74.3 Donor 
amplification + 
linker insertion 
Xma-CC1-L-PvuI-
Cit-R 
TCCC CCC GGG GCT GCT CAG AAT 
GCT GCT ATA CGC CGC CGC CAG 
GCT ATC GCT GCT CAG GTTC GAT 
CGCTT GTA CAG CTC GTC CAT GCC  
75.8 ‘’ 
Spe-CC1-PvuI-
TFP-F 
& used for Citrine 
GGACTAGTctggcggcggcgtatagcagcattctg
agcagcCGATCG 
ATGGTGAGCAAGGGCGAGGAG 
74.4 “ 
Xma-CC1-Pvu1-
Cit-R 
TCCC CCC GGG GCT GCT CAG AAT 
GCT GCT ATA CGC CGC CGC CAG C 
GAT CGCTTGTACAGCTCGTCCATGCC 
76.8 ‘’ 
BamH-CC1-PvuI-
Cit-R 
TTCG GGATCC GCT GCT CAG AAT 
GCT GCT ATA CGC CGC CGC CAG C 
GAT CGCTTGTACAGCTCGTCCATGCC 
75.2 ‘’ 
Spe-BS1-Pvu1-TFP-
F 
GGA CTA GT A AAC TGC GCA CCG 
ATA TTA AAG TGG TG C GAT CGA 
TGG TGA GCA AGG GCG AGG AG 
71.2 “ 
Xma-BS1-PvuI-Cit-
R 
TCCC CCC GGG CAC CAC TTT AAT 
ATC GGT GCG CAG TTT C GAT CG 
CTTGTACAGCTCGTCCATGCC 
74 ‘’ 
BamH-BS1-Pvu1-
Cit-R 
TTCG GGATCC CAC CAC TTT AAT 
ATC GGT GCG CAG TTT C GAT CG 
CTTGTACAGCTCGTCCATGCC 
72.2 ‘’ 
Spe-UL1-PuvI-
TFP-F 
GGACTAGT AAC CTG AGC AGC GAT 
AGC AGC AAC AGC CGATCGA TGG 
TGA GCA AGG GCG AGG AG 
 
72.8 “ 
Xma-UL1-PvuI-
Cit-R 
TCCC CCC GGG GCT GTT GCT GCT 
ATC GCT GCT CAG GTT C GAT CG 
CTTGTACAGCTCGTCCATGCC 
75.5 ‘’ 
BamH-UL1-PvuI-
Cit-R 
TTCG GGATCC GCT GTT GCT GCT 
ATC GCT GCT CAG GTT C GAT CG 
CTTGTACAGCTCGTCCATGCC 
73.7 “ 
EphA2-2YE-F GACAGAGGTGGACCCCCACACAGAG
GAGGACCCCAACCAGGCTGTGTTG 
73.7 A2-2YE-
Mutagenesis 
EphA2-2YE-R GGGTCCTCCTCTGTGTGGGGGTCCAC
CTCTGTCTTCAGGGGCTTCAGTTG 
73.1 A2-2YE-
Mutagenesis 
EphA2-2YF-F GAAGACATTCGTGGACCCCCACACA
TTTGAGGACCCCAACCAGGCTGTG 
71.9 A2-2YF-
mutagenesis 
EphA2-2YF-R GGTCCTCAAATGTGTGGGGGTCCACG
AATGTCTTCAGGGGCTTCAGTTG 
71.4 A2-2YF-
mutagenesis 
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BamHI-calretic-
BFP-F 
TTGGGATCCATGCTGCTATCCGTGCC
GTTGCTGCTCGGCCTCCTCGGCCTGG
CCGTCGCCGACCGGTCGatgagcgagctga
ttaagg 
76 ER-BFP 
BFP-XbaI-R CCGGGCCTAGTCTAGATTACAGCTCG
TCCTTATTAAGCTTGTGCC CCA GTT 
TGC TAG 
GGAGGTCGCAGTATCTGGCCACTG 
CCA CC 
73 ER-BFP 
hephrinA1-BglII-F ACGCGTCGACTCACGGGGTTTGCAGC
AGCAGAAGTGG 
72 PCR amplify 
hephrinA1-SalI-R ACGCGTCGACCGGGGTTTGCAGCAG
CAGAAG 
71 PCR amplify 
hephrinA1-SalI-F ACGCGTCGACATGGAGTTCCTCTGGG
CCCCTCTCTTGGG 
SalI 
72.6 PCR amplify 
h-ephrinA1-Not1-
R-stop codon 
ATAAGAATGCGGCCGCTCACGGGGT
TTGCAGCAGCAGAAG 
Not1 
71.3 PCR amplify 
acceptor_AgeI_F cgcaccccgctgaacACCGGTatggtgagcaaggg
cgaggagg (AgeI) 
75 PCR amplify 
acceptor_linker_R_
1st  
CAGGCTGCCGCTGCCGCCGCTGCTctt
gtacagctcgtccatgcc 
76  
8L_B2(PBD)_Not1_
R_2nd  
ATAGTTTAgcggccgcTCAAACCTCCAC
AGACTGAATCTGGTTCATCTGGGCCA
GGCTGCCGCTGCCG (Not1) 
75  
A2_Cit_ccl_DONO
R_fix_F 
CGTTTACTTCTCCACTAGTctggccgccgcc
tatagcagcattctgagc (SpeI) 
72  
A2_Cit_ccl_DONO
R_fix_R 
caattgACCGGTGATCAGATGGGGATCC
CCACAGTGTTCACCTGGTCC 
71  
ephrinB1_BglII_F GGAAGATCT 
ATGGCTCGGCCTGGGCAGC 
67.5 Ephrin cloning 
ephrinB1_SalI_R ACGCGTCGACTCAGACCTTGTAGTAG
ATGTTCGC 
66 “ 
hephrinB2_BglII_F GGAAGATCT 
ATGGCTGTGAGAAGGGACTCC 
 “ 
hephrinB2_SalI_R ACGCGTCGACTCAGACCTTGTAGTAA
ATGTTCG 
 “ 
mTFP_AgeI_F_ 
pDisplay 
ctgaacACCGGTGTGAGCAAGGGCGAG
GAGAC 
69 “ 
mTFP_BsrG1_R_ 
pDisplay 
attcagTGTACAGCTCGTCCATGCCGTC
GGTGG 
68  
A2-D738N-F GAACTATGTGCACCGTAACCTGGCTG
CCCGCAAC 
69 Mutagenesis 
A2-D738N-R GTTGCGGGCAGCCAGGTTACGGTGC
ACATAGTTC 
69 “ 
Cp_51_A2_F GGACGTTTACTTCTCCtccgccggcAAAT
TACCTGTTCCTTGGCCAAC 
70 Circularly 
permuted GFPs 
Cp_51_A2_R CTTCAGTTGTTCTGACTTggaggcgccAC
CCGTAGTGCATATAAACTTCAG 
68.5 “ 
Cp_145_A2_F GGACGTTTACTTCTCCtccgccggcAACT
CGCATAATGTGTACATTACAG  
68.5 “ 
Cp_145_A2_R CTTCAGTTGTTCTGACTTggaggcgccGA
AATTATACTCAAGTTTATGGC 
67 “ 
Cp_157_A2_F GGACGTTTACTTCTCCtccgccggcAAGA
ACGGAATTAAAGCG 
69 “ 
Cp_157_A2_R CTTCAGTTGTTCTGACTTggaggcgccTT
GTTTGTCAGCTGTAATG 
67.5 “ 
Cp_173_A2_F GGACGTTTACTTCTCCtccgccggcGGGT
CTGTTCAACTTGC 
71 “ 
Cp_173_A2_R CTTCAGTTGTTCTGACTTggaggcgccAT 70 ‘ 
	  166	  
CTTCGACGTTGTGCC 
Cp_51_SpeI/ccl_F ggACTAGTctggccgccgcctatagcagcatcctga
gcagcaacctgagcagcgatagc 
AAATTACCTGTTCCTTGGC 
73  
 
 
 
 
 
 
 
 
 
 
To overcome 
using PvuI only 
and introduce the 
cpGFPs while 
retaining the 
linkers in 
different 
backgrounds 
 
 
 
 
 
 
 
Cp_51_XmaI/ccl_R tcccCCCGGGgctgctcaggatgctgctataggcggc
ggccaggctatcgctgctcaggtt 
ACCCGTAGTGCATATAAAC   
75 
Cp_157_SpeI/ccl_F ggACTAGTctggccgccgcctatagcagcatcctga
gcagcaacctgagcagcgatagc 
AAGAACGGAATTAAAGCG 
73 
Cp_157_XmaI/ccl_
R 
tcccCCCGGGgctgctcaggatgctgctataggcggc
ggccaggctatcgctgctcaggtt 
TTGTTTGTCAGCTGTAATG 
75 
Cp_173_SpeI/ccl_F ggACTAGTctggccgccgcctatagcagcatcctga
gcagcaacctgagcagcgatagc 
GGGTCTGTTCAACTTGC 
74 
Cp_173_XmaI/ccl_
R 
tcccCCCGGGgctgctcaggatgctgctataggcggc
ggccaggctatcgctgctcaggtt 
ATCTTCGACGTTGTGC 
76 
Cp_51_SpeI/cc_F ggACTAGTctggccgccgcctatagcagcatcctga
gcagcAAATTACCTGTTCCTTGGC 
73 
Cp_51_XmaI/cc_R tcccCCCGGGgctgctcaggatgctgctataggcggc
ggccagACCCGTAGTGCATATAAAC   
75 
Cp_157_SpeI/cc_F ggACTAGTctggccgccgcctatagcagcatcctga
gcagcAAGAACGGAATTAAAGCG 
72 
Cp_157_XmaI/cc_
R 
tcccCCCGGGgctgctcaggatgctgctataggcggc
ggccagTTGTTTGTCAGCTGTAATG 
75 
Cp_173_SpeI/cc_F ggACTAGTctggccgccgcctatagcagcatcctga
gcagcGGGTCTGTTCAACTTGC 
74 
Cp_173_XmaI/cc_
R 
tcccCCCGGGgctgctcaggatgctgctataggcggc
ggccagATCTTCGACGTTGTGC 
77 
(ED)A2-XmaI-F tttcc CCC GGG gacgtttacttctccaagtcag 66 
(ED)A2-SpeI-R GGA CTA GTctccggggactggcgggcac 70  
 
 
 
 
 
 
 
 
 
Restriction site 
introduction at 
different points 
using 
homologous 
recombination 
(DV)A2-XmaI-F tttcc CCC GGG gtttacttctccaagtcagaac 65 
(DV)A2-SpeI-R GGA CTA GTgtcctccggggactggcggg 70 
(VY)A2-XmaI-F tttcc CCC GGG tacttctccaagtcagaac 64 
(VY)A2-SpeI-R GGA CTA GTaacgtcctccggggactggc 66 
(YF)A2-XmaI-F tttcc CCC GGG ttctccaagtcagaacaac 65 
(YF)A2-SpeI-R GGA CTA GTgtaaacgtcctccggggac 63 
(FS)A2-XmaI-F tttcc CCC GGGtccaagtcagaacaactgaag 66 
(FS)A2-SpeI-R GGA CTA GTgaagtaaacgtcctccgggg 63 
(KS)A2-XmaI-F tttcc CCC GGGtcagaacaactgaagcccc 67 
(KS)A2-SpeI-R GGA CTA GT cttggagaagtaaacgtcctccg 62 
(SE)A2-XmaI-F tttcc CCC GGG gaacaactgaagcccctgaag 69 
(SE)A2-SpeI-R GGA CTA 
GTtgacttggagaagtaaacgtcctccgg 
64 
(EQ)A2-XmaI-F tttcc CCC GGGcaactgaagcccctgaagac 69 
(EQ)A2-SpeI-R GGA CTA GT 
ttctgacttggagaagtaaacgtcctccggg 
66 
(QL)A2-XmaI-F tttcc CCC GGG ctgaagcccctgaagacatac 68 
(QL)A2-SpeI-R GGA CTA GT 
ttgttctgacttggagaagtaaacgtcctccg 
65 
ccl/cc-A2(SK)-Spe-
out-F 
GGAGGACGTTTACTTCTCCACCAGCct
ggccgccgcctatagcag 
72 
ccl/cc-A2(SK)-Spe-
out-R 
GGCTTCAGTTGTTCTGACTTCCCGGGg
ctgctcaggatgctgctatag 
71 
A2-cterm-HyPer-R ccttccgcatctagattaaaccgcctgttttaaaactttatcg
aaatg 
71  
A2-intern-HyPer-F ttggACTAGTtccgccggcatggagatggcaagcca
gcag 
77  
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A2-intern-HyPer-R attaccCCCGGGggaggcgccaaccgcctgttttaaa
actttatcgaaatg  
77  
C-term Hyper-F GCCGGCatggagatggcaagccagcag 79.8 Mutagenesis 
C-term Hyper-R ctgctggcttgccatctccatGCCGGC 79.8 Quick change 
Ptp1Bwt-BspE1-F aatttctccggaggtggaggtggaggcatggag   73 Ligation/cloning 
Prp1Bwt-SalI-R taaacgcGTCGACctatgtgttgctgttgaacagg        71 “ 
A2-actYE-F ccccgaggccaccGAGaccaccagtggcgg 84 Quick Change 
A2-actYE-R ccgccactggtggtCTCggtggcctcgggg 84 Quick Change 
A2-actYF-F ccccgaggccaccTTTaccaccagtggcgg 81 Quick Change 
A2-actYF-R ccgccactggtggtAAAggtggcctcgggg 81 Quick Change 
GRIP_N_F TATATAGTCGACGCCACCATGATAGC
TGTCTCTTTTAAATGCC  
71 Ligation/cloning 
GRIP_N_R TAGTAGcccgggcATGGTGATGGTGATG
ATGACC  
73 Ligation/cloning 
GRIP_C_F TATATAGTCGACATGATAGCTGTCTC
TTTTAAATGC  
65 Ligation/cloning 
GRIP_C_R TAATAAcccgggTTAATGGTGATGGTGA
TGATGAC  
69 Ligation/cloning 
mChXmaI_F TATATAcccggggcatggtgagcaagggcgagg  75  
mChNotI_R TATATAgcggccgcCTActtgtacagctcgtcc  72  
BFP_AgeI_F CCCCCC ACCGGT 
ATGAGCGAGCTGATTAAGG AgeI 
67 Cloning 
BFP_linker_BglII_R TAATTTAGATCT 
CAGGCTGCCGCTTCCGCCGCTGCTAT
TAAGCTTGTGCCCC 
71 “ 
EBFP-AgeI-F tttaatACCGGTatggtgagcaagggcgagg  70  
EBFP-BsrG1-R tttaccttgtacagctcgtccatgccgagag   70  
EBFP-BglII-F ttttccagatctatggtgagcaagggcgagg   70  
                                                                             
